

KRISTINA MÄEMETS-ALLAS

Studies on cell growth promoting  
AKT signaling pathway – a promising  
anti-cancer drug target





**KRISTINA MÄEMETS-ALLAS**

Studies on cell growth promoting  
AKT signaling pathway – a promising  
anti-cancer drug target



Department of Cell Biology, Institute of Molecular and Cell Biology, University of Tartu, Estonia

Dissertation was accepted for the commencement of the degree of Doctor of Philosophy (in Cell Biology) on June 8, 2016 by the Council of the Institute of Molecular and Cell Biology, University of Tartu, Estonia

Supervisor: Viljar Jaks, PhD, MD  
Senior Researcher  
Department of Cell Biology  
Institute of Molecular and Cell Biology  
University of Tartu  
Estonia

Opponent: Juha Tapio Klefström, PhD  
Research Director and Vice Director  
Research Programs Unit and Translational Cancer Biology  
Medical Faculty  
University of Helsinki  
Finland

Commencement: Room No. 105, 23B Riia St., Tartu, on August 26, 2016, at 10:15 am.

The publication of this dissertation is granted by the Institute of Molecular and Cell Biology.

ISSN 1024-6479  
ISBN 978-9949-77-143-1 (print)  
ISBN 978-9949-77-144-8 (pdf)

Copyright: Kristina Mäemets-Allas, 2016

University of Tartu Press  
[www.tyk.ee](http://www.tyk.ee)

## TABLE OF CONTENTS

LIST OF ORIGINAL PUBLICATIONS .....	7
ABBREVIATIONS.....	8
INTRODUCTION.....	11
LITERATURE OVERVIEW .....	12
1. AKT kinases – classification and structure .....	12
2. AKT activation and modification.....	14
2.1. AKT1 phosphorylation at Thr308 and Ser473 .....	14
2.2. Alternative AKT modifications.....	16
3. AKT signaling pathway .....	18
3.1. AKT regulates cell survival and apoptosis.....	19
3.2. AKT regulates cell cycle progression and proliferation.....	21
3.3. AKT regulates cell growth and metabolism.....	23
3.4. AKT regulates angiogenesis.....	26
4. AKT and cancer.....	27
4.1. AKT signaling in cancer.....	27
4.2. AKT and cancer stem cells.....	28
5. Protein-protein interaction inhibitors .....	29
6. AKT inhibitors .....	31
RESULTS	
Objectives of the study.....	33
1. A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth <i>In Vivo</i> (REF I).....	33
1.1. Screening for the inhibitors of AKT1 and PDPK1 interaction.....	33
1.2. NSC156529 reduces AKT phosphorylation level and inhibits AKT1-PDPK1 endogenous interaction .....	34
1.3. AKT1-PDPK1 interaction inhibitor NSC156529 suppresses the activity of AKT downstream targets and cancer cell proliferation <i>in vitro</i> .....	35
1.4. AKT1-PDPK1 interaction inhibitor NSC156529 suppresses the cell proliferation and induces expression of differentiation markers <i>in vivo</i> .....	36
1.5. NSC156529 interacts preferentially with PDPK1 .....	37
2. The inhibition of AKT-PDPK1 interaction efficiently suppresses the growth of murine primary liver tumor cells (REF II) .....	37
2.1. Increased activity of liver tumor-associated pathways in K07074 .....	38
2.2. AKT and Notch inhibitors efficiently suppress the growth of K07074 cells .....	39

3. Activated growth factor signaling and increased phosphorylation of AKT in small blood vessels provide supportive environment for Dupuytren’s contracture pathogenesis (REF III).....	40
3.1. Blood vessels in the DC contain proliferating cells and endothelial cells with activated phenotype.....	40
3.2. The blood vessels in DC tissue contain cells with activated AKT signaling .....	41
DISCUSSION .....	42
SUMMARY .....	45
SUMMARY IN ESTONIAN .....	47
REFERENCES .....	49
ACKNOWLEDGEMENTS .....	72
PUBLICATIONS .....	73
CURRICULUM VITAE .....	128
ELULOOKIRJELDUS.....	130

## LIST OF ORIGINAL PUBLICATIONS

The current thesis is based on the following original publications, which will be referred to by their Roman numerals in the text:

- I. **Mäemets-Allas, K.**, Viil, J., Jaks, V. (2015) A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth *In Vivo*. *Mol Cancer Ther.* 14(11):2486–96
- II. **Mäemets-Allas, K.**, Belitškin, D., Jaks, V. (2016) The inhibition of AKT-PDPK1 interaction efficiently suppresses the growth of murine primary liver tumor cells. *Biochem Biophys Res Commun.* 474(1):118–125
- III. Viil, J., Maasalu, K., **Mäemets-Allas, K.**, Tamming, L., Lõhmussaar, K., Tooming, M., Ingerpuu, S., Märtson, A., Jaks, V. Laminin-rich blood vessels display activated growth factor signaling and act as the proliferation centers in Dupuytren’s contracture. (2015) *Arthritis Res Ther.* 17(1):144–153

The articles listed above have been reprinted with the permission of the copyright owners.

My contribution to these articles:

- REF I – designed and performed the experiments, analyzed the data and wrote the manuscript
- REF II – designed and performed the experiments, analyzed the data and wrote the manuscript
- REF III – designed and performed the gene expression analysis, analyzed the data, revised the manuscript

## ABBREVIATIONS

ABC	ATP binding cassette
ACK1	activated CDC42 kinase 1
ACL	ATP citrate lyase
ALDH1	aldehyde dehydrogenase 1
ALT	alanine aminotransferase
APAF-1	apoptotic protease activating factor 1
AS160	AKT substrate of 160 kDa
AST	aspartate aminotransferase
ATM	ataxia telangiectasia mutant
ATRA	all-trans-retinoic-acid
BAD	Bcl-2-associated death promoter
BCL-2	B-cell lymphoma 2
Bcl-XL	B-cell lymphoma-extra large
bFGF	basic fibroblast growth factor
BH3	Bcl-2 homology domain 3
BIM	Bcl-2-like protein 11
CC3	cleaved caspase 3
CCND	cyclinD1 gene
CDK	cyclin dependent kinase
CK	cytokeratin
CK2	casein kinase 2
cMyc	cellular myelocytomatosis oncogen
CREB	cAMP response element-binding protein
CSC	cancer stem cell
CTGF	connective tissue growth factor
DC	Dupuytren contracture
DEN	diethylnitrosamine
Deptor	DEP domain-containing mTOR-interacting protein
DMSO	dimethyl sulfoxide
DNA-DSB	DNA double strand breaks
DNA-PK	DNA-dependent protein kinase
ECM	extracellular matrix
EGF	epidermal growth factor
EGFP	enhanced green fluorescent protein
ELISA	enzyme-linked immunosorbent assay
EMT	epithelial-mesenchymal transition
eNOS	endothelial nitric oxide synthase
ERK	extracellular signal-regulated kinase
EYFP	enhanced yellow fluorescent protein
FasL	Fas ligand
FOXO	Forkhead family subclass O
FP	fluorescence polarization



FRET	fluorescence energy transfer
GADD45	growth arrest and DNA damage inducible protein 45
GFP	green fluorescent protein
GLUT	glucose transporter
GPCR	G protein-coupled receptor
GSK3	glycogen synthase kinase 3
HCC	hepatocellular carcinoma
Hek293	human embryonic kidney 293 cells
HES	hairly and enhancer of split-1
HEY	hairly/enhancer-of-split related with YRPW motif protein
HF-SC	hair follicle stem cell
HGF	hepatocyte growth factor
HIF1	hypoxia-inducible factor 1
HM	hydrophobic motif
Hnf4 $\alpha$	hepatocyte nuclear factor alpha
ICC	intrahepatic cholangiocellular carcinoma
IGF	insulin-like growth factor
I $\kappa$ B	inhibitor of nuclear factor kappa-B
IKK	I $\kappa$ B kinase
JNK	c-Jun N-terminal kinases
LSC	leukemic stem cell
MAPK	mitogen-activated protein kinase
MDM2	mouse double minute 2
mLST8	mammalian lethal with SEC13 protein 8
MMP1	matrix metalloproteinase-1
MRCK	myotonic dystrophy-related Cdc42-binding kinases
MST	microscale thermophoresis
mTORC1/C2	mechanistic/mammalian target of rapamycin complex 1/2
NF $\kappa$ B	nuclear factor kappa-light-chain-enhancer of activated B cells
NO	nitric oxide
NPF	normal palmar fascia
PCA	protein complementation assay
PCNA	proliferating cell nuclear antigen
PDE	phosphodiesterase
PDGF	platelet-derived growth factor
PDPK1	phosphoinositide-dependent protein kinase 1
PGC1 $\alpha$	peroxisome proliferator-activated receptor $\gamma$ coactivator 1
PH	pleckstrin homology
PHLPP	PH domain and leucine rich repeat protein phosphatases
PI3K	phosphatidylinositide 3-kinase
PIKfyve	FYVE-type zinc finger containing phosphoinositide kinase
PIKK	phosphatidylinositol 3-kinase-related kinases
PIP2	phosphatidylinositol (4,5)-bisphosphate
PIP3	phosphatidylinositol (3,4,5)-trisphosphate
PKA	protein kinase A

PKB	protein kinase B
PKC	protein kinase C
PKG	protein kinase G
PLA	proximity ligation assay
PLC	phospholipase C
PP2A	protein phosphatase 2A
PPI	protein-protein interaction
PRAS40	proline-rich AKT substrate of 40 kDa
PRR5	proline-rich protein 5
PTEN	phosphatase and tensin homolog
PTK6	protein tyrosine kinase 6
PUMA	p53 upregulated modulator of apoptosis
RAF	rapidly accelerated fibrosarcoma
Rheb	Ras homolog enriched in brain
Rluc	Renilla luciferase
ROCK1	Rho-associated protein kinase 1
RTK	receptor tyrosine kinase
SCF	Skp, Cullin, F-box containing complex
SGK	serum and glucocorticoid-regulated kinase
Skp2	S-phase kinase-associated protein 2
SMA	smooth muscle actin
SREBP	sterol regulatory element-binding protein
STXBP4	syntaxin binding protein 4
TGF $\beta$	transforming growth factor beta
TM	turn motif
TSC1/2	tuberous sclerosis complex 1/2
TSP-1	thrombospondin-1
TUNEL	terminal deoxynucleotidyl transferase dUTP nick end labeling
VEGF	vascular endothelial growth factor
vWF	von Willebrand's factor
XIAP	X-linked inhibitor of apoptosis protein

## INTRODUCTION

Cells are exposed to several extracellular stimuli, like hormones, cytokines and growth factors, which induce intracellular signaling pathways that ultimately regulate cell proliferation, apoptosis, differentiation, metabolism and angiogenesis. Strict balance between growth promoting and suppressing factors ensures the normal life cycle of the cell. With time the accumulating mutations and epigenetic changes can alter the signaling network, which drives the normal cell. Cancer may arise when normal cellular growth goes awry due to defects in critical signal transduction pathways. Most of the somatic mutations found in cancers, typically 40–90 per cell, are considered harmless. A smaller set of mutations occurring frequently in critical genes, like proto-oncogenes and tumor suppressors, are called “driver” mutations, which form the basis of oncogenesis. The identification of tumorigenic mutations and elucidating their impact on cell functioning has defined core signaling pathways that participate in multistep development of cancer. Protein-protein interactions (PPI) in these identified signaling cascades, which play crucial role in malignant transformation, are attractive targets for intervention with small molecular compounds. Despite of the challenges that the researchers face when designing the PPI inhibitors, the number of small molecules specifically interfering PPIs, which are crucial for the integrity of the pathway of interest, is constantly growing.

In last decades it has become apparent that PI3K/AKT signaling pathway, which has a key role in normal physiological processes, such as cell cycle progression, differentiation, survival, transcription, translation, endocytosis, motility, metabolism and autophagy, is also one of the most frequently dysregulated pathways in human tumors. Aberrantly activated AKT pathway has been commonly described in prostate, breast, liver, and colorectal carcinomas. Recently, active AKT pathway has also been linked to cancer stem cells. Moreover, the constitutive activation of the PI3K/AKT pathway confers resistance to many chemotherapeutic drugs and is a poor prognostic marker for a number of cancer types. Due to AKT involvement in critical steps of human tumor pathogenesis, targeting AKT pathway has become a promising strategy in anti-cancer therapy. Although a number of small molecule AKT kinase inhibitors have been developed, severe side effects have prevented their use in clinical trials.

The current thesis is focused on active AKT pathway in cancer cells and in Dupuytren contracture tissue. Screening, based on *Renilla* luciferase protein complementation assay (PCA), identified a small molecule compound NSC156529, that efficiently suppressed the signal transduction in PI3K/AKT pathway by interfering AKT1 and PDPK1 interaction. Since NSC156529 efficiently decreased the proliferation of different human cancer cells *in vitro* and the growth of prostate tumor xenografts *in vivo*, it could be a new promising compound for drug development to inhibit the growth of cancer cells with elevated AKT activity. We also found that the activated AKT signaling might play a role in the progression of benign hyperproliferative pathology – the Dupuytren’s contracture.

## LITERATURE OVERVIEW


### 1. AKT kinases – classification and structure

**Protein kinase B or AKT (PKB/AKT)** is a serine/threonine kinase, which belongs to AGC group of protein kinases (named after PKA, PKG and PKC), that share structural homology within their catalytic domain and have a similar mechanism of activation [1]. AKT/PKB was first described by three independent groups. Coffey *et al.* found that the catalytic domain of kinase has 65% homology with PKA and 75% homology with PKC, hence the name PKB. In addition, they demonstrated that PKB is a downstream effector of PI3K activation [2]. Jones *et al.* analyzed kinases in a similar way but named it RAC-PK (related to A and C protein kinases) [3]. Bellacosa *et al.* found PKB, or c-Akt, to be a cellular homologue of v-Akt, the gene product of AKT-8, an acute transforming retrovirus which was isolated from a rodent T cell lymphoma [4-6]. In mammals **AKT family comprises three highly homologous members** known as PKB $\alpha$  (AKT1), PKB $\beta$  (AKT2), and PKB $\gamma$  (AKT3). AKT isoforms are encoded by different genes on chromosomes 14q32, 19q13, and 1q44, respectively, and their amino acid sequences share approximately 80% similarity [7]. Despite of a close homology, the three isoforms of AKT localize in distinct sub-cellular compartments and have different functions in normal cell physiology and development [8, 9]. AKT1/PKB $\alpha$ , which is localized in the cytoplasm, is required for whole body normal growth and mammary morphogenesis [10, 11]. AKT2 colocalizes with the mitochondria and is involved in glucose metabolism, adipogenesis and  $\beta$ -cell function [12]. AKT3, which is mainly found in the nucleus and nuclear membrane, is essential for the attainment of normal brain size [13]. All three AKT isoforms are expressed in a tissue-dependent manner. AKT1 is expressed ubiquitously at high levels with exception of the kidney, spleen and liver [3, 14, 15]. AKT2 expression is elevated in insulin-sensitive tissues such as fat cells, skeletal muscle and liver [16-19]. AKT3 is relatively highly expressed in the brain and testis, with low levels in skeletal muscle and liver [20].

To assess the **functions of individual AKT isoforms**, the gene expression of each of the Akt was disrupted in the mouse germ line via homologous recombination. Mice lacking individual Akt isoforms are mostly viable. In knockout mouse experiments Akt1 $-/-$  mice have placental hypotrophy, partial neonatal mortality and reduced animal size from the embryonic stages [11, 21, 22]. The exposure to genotoxic stress decreases lifespan of Akt1 $-/-$  mice [21]. Akt1 deficiency has also been related to angiogenesis and tumor development [11]. Interestingly, Akt1 $-/-$  mutants did not have a diabetic phenotype; the mice had either normal glucose tolerance and insulin-stimulated disposal of blood glucose, or an improved insulin sensitivity and enhanced energy consumption compared to wild type animals [11, 23, 24]. Akt2  $-/-$  knockout mice have normal growth characteristics, but they have a mild to severe insulin resistance (impaired insulin action in skeletal muscle, fat and liver) [25, 26]. Akt3 $-/-$  mice

have a specific deficiency in postnatal development of the brain and 20–25% decrease in brain size, which is at least partially caused due to smaller and fewer cells [13, 27]. Akt1/Akt3 double knockout causes embryonic lethality at around embryonic days 11 and 12, with more severe developmental defects in the cardiovascular and nervous systems, apoptosis was also increased in the developing brain of double mutant embryos [28]. This indicates that Akt1 may have more important role in developing embryo than Akt3. Akt1/Akt2 double-knockout mice show severe growth deficiency and die shortly after birth. These mice display impaired skin development due to a proliferation defect, severe skeletal muscle atrophy because of a marked decrease in individual muscle cell size, and impaired bone development [29].

All AKT proteins have a similar conserved **protein structure** – an amino terminal pleckstrin homology (PH) domain, a central kinase domain and a carboxyl-terminal regulatory domain (Figure 1) [1].



**Figure 1.** Schematic structure of human AKT1 protein. AKT1 protein (length 480 amino acids) contains a pleckstrin homology domain (PH), helical region (Helix), kinase domain (Kinase) and a regulatory motif (Regulatory). The two phosphorylation sites essential for complete activation (Thr308 and Ser473) and other post-translational modifications of AKT1 are indicated in the diagram. The activation loop is encompassed by DFG and APE motifs. C: carboxyl-terminal; N: amino-terminal.

AKT pleckstrin homology (PH) domain, which comprises approximately 100 amino acids in the N-terminal region of the protein, consists of seven  $\beta$ -strands forming two antiparallel  $\beta$ -sheets capped by a C-terminal  $\alpha$ -helix. The  $\beta$ 1– $\beta$ 2,  $\beta$ 3– $\beta$ 4, and  $\beta$ 6– $\beta$ 7 loops form a positively charged pocket that can adapt the PI3K-generated phospholipids in a complementary fashion through specific hydrogen-bonding interactions. The residues Lys14, Arg25, Tyr38, Arg48, and Arg86 form the bottom of the binding pocket and specifically interact with the 3- and 4-phosphate groups of the phospholipids, while residues Thr21 and Arg23 are situated at the wall of the binding pocket and bind to the 1-phosphate group [30]. AKT PH domain interacts with membrane lipids, such as phosphatidylinositol (3,4,5)-trisphosphate (PIP3), the product of phosphatidylinositol 3-kinase (PI3-kinase, PI3K), and is believed to play significant role in recognition by upstream kinases as well as membrane translocation.

The kinase domain is located in the central region of the AKT molecule and it shares high similarity with other AGC group members, such as PKA, PKC, p70S6K and p90RSK [31]. The phosphorylation of the conserved threonine residue in the activation segment, which is required for enzymatic activation, is located in the C-lobe of the kinase domain between the DFG and APE motifs in the activation loop [31, 32].

Approximately 40 amino acid long carboxyl-terminal regulatory domain of AKT contains hydrophobic motif F-X-X-F/Y-S/T-Y/F (where X is any amino acid), which is characteristic to the AGC protein kinase family [31]. Phosphorylation of the Ser or Thr residue in this hydrophobic motif is necessary for full activation for all AGC family kinases. In mammalian AKT isoforms this motif is identical (FPQFSY) and very important, because deletion of it completely abolishes the enzymatic activity of the kinase [33]. It has been found that rat PKB $\gamma$ /AKT3 and the human PKB $\gamma$ -1 splice variant do not possess this motif, suggesting that these variants are activated by mechanisms independent of phosphorylation of the Ser/Thr residues in the hydrophobic motif [34, 35].

## 2. AKT activation and modification

### 2.1. AKT1 phosphorylation at Thr308 and Ser473

**Full activation of AKT protein** is a multistep process in which several proteins have been identified and characterized [36]. Stimulation of cells with growth factors, such as platelet derived growth factor (PDGF), insulin, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), insulin-like growth factor I (IGF-I) and vascular endothelial growth factor (VEGF), leads to the recruitment of phosphoinositide 3-kinase (PI3K) to the plasma membrane where it phosphorylates phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P<sub>2</sub>, PIP<sub>2</sub>) to generate phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P<sub>3</sub>, PIP<sub>3</sub>) [37]. The major mechanism by which PIP<sub>3</sub> exerts its physiological effect, is the interaction with proteins possessing pleckstrin homology (PH) domain [38]. AKT interaction with PIP<sub>3</sub> via PH domain leads to a conformational change so that PH domain folds back and the phosphorylation sites become available. AKT interaction with PIP<sub>3</sub> and recruitment to the membrane brings it to the close proximity to another PH domain containing serine/threonine kinase called phosphoinositide-dependent kinase 1 (PDK1 or PDK1), which phosphorylates AKT1 at the site **Thr308** (Thr 309 and 305 in AKT2 and AKT3 respectively) in the activation loop of the kinase domain.

**PDK1** is one of the most conserved protein kinases found in eukaryotes, which belongs to AGC kinase family [39]. PDK1 human gene product is a 556 amino acid long polypeptide. Folded as a globular protein, it constitutes of two domains: N-terminal serine–threonine kinase domain and a C-terminal PH domain [40]. The kinase domain can be subdivided in two lobes (a small N-terminal lobe and a large C-terminal lobe), which include two important

regulatory sites: the PIF-pocket (or PIF-binding pocket) and the activation loop (or T-loop). The phosphorylation of PDPK1 at Ser241 in T-loop is done *in trans* by another PDPK1 molecule and is essential for its kinase activity [41]. Another important structural element of the kinase domain is the  $\alpha$ C-helix which connects the PIF-pocket with the activation loop and the bound ATP [42]. PDPK1 is mainly localized in the cytoplasm. Upon increased PI3K activity, PDPK1 moves to PIP3-enriched plasma membrane regions, which has been linked to its ability to regulate cell migration [43]. In specific situations it translocates into the nucleus with the mechanism that involves the inhibition of its Nuclear Export Sequence [44, 45].

AGC kinases, such as AKT, p90RSK, p70S6K, SGK and some PKC isoforms, carry two phosphorylation sites required for the regulation of their activity, one localized in the activation loop within the kinase domain, the other in the hydrophobic motif [46]. PDPK1 phosphorylates AGC kinases on their activation loop by two different mechanisms. By the first mechanism PDPK1 phosphorylates AKT at Thr308 in the activation loop, which is essential for its activation [40]. PDPK1 and AKT both bind to PIP3 or PIP2 produced by PI3K at the plasma membrane by their PH domain [40, 47], which co-localizes the two proteins at the plasma membrane. AKT binding to these phospholipids determines a conformational change that allows the phosphorylation of Thr308 on the activation loop by PDPK1 [48]. By the second mechanism PDPK1 phosphorylates and activates other AGC kinases, such as p70S6K [49], SGK [50], p90RSK [51] and atypical PKC isoforms [52]. In this case, PDPK1 binds the phosphorylated hydrophobic motif (HM) of these AGC kinases through its PIF-pocket, which leads to their phosphorylation on the activation loop and their full activation [53]. Moreover, PDPK1 is able to bind and activate in a kinase independent manner some proteins belonging to AGC kinase family, such as ROCK1 [54] and MRCK $\alpha$  [43], or proteins not belonging to this family, such as PLC $\gamma$ 1 [55] and  $\beta$ 3 integrin [56, 57].

Since PDPK1 knock-out mice die during the embryonic development, this protein is considered to be strictly required for survival of all eukaryotes. The main role of PDPK1 is to be a signal transducer in signaling pathways activated by several growth factors and hormones. PDPK1 is involved in glucose metabolism by promoting glucose storage [58], development [59], blood vessel formation [60], and neuron differentiation [61]. Moreover, alterations of PDPK1 functions have also a relevant role in pathology such as Alzheimer's disease [62], diabetes [63] and cancer [64, 65].

For full activation, AKT needs to be phosphorylated at **Ser473** in the hydrophobic motif (Ser474 and Ser472 in AKT2 and AKT3 respectively) [66]. Phosphorylation of Ser473 is believed to be the key step in the activation of AKT because it stabilizes the active conformation state [67]. Molecular identity of the kinase phosphorylating AKT at Ser473 (referred also as „PDK2“) has been under debate for many years. Proposed candidates include PDPK1 [68], integrin-linked kinase (ILK) [69], AKT itself [70], mitogen activated protein kinase activated protein kinase 2 (MAPKAPK2) [32], protein kinase C II

(PKCII) [71] and the members of the atypical PI 3-kinase related protein kinase (PIKK) family: DNA-dependent protein kinase (DNA-PK) [72] and ataxia telangiectasia mutant (ATM) [73]. Currently it is accepted that the main candidate for this action is the mechanistic/mammalian target of rapamycin complex 2 (mTORC2).

**mTOR** is a serine/threonine kinase that mediates signals from nutrients, stress and growth factors and thereby participates in cell metabolism, proliferation, autophagy and migration regulation [74-76]. mTOR is a member of a family of protein kinases termed the PIKKs (phosphatidylinositol-3-kinase-related kinases) and functions as serine/threonine protein kinase. As the name implies, mTOR is a specific target of the natural compound rapamycin. mTOR interacts with several proteins and forms two complexes named mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The conserved components of mTORC2 are mTOR, Rictor (mAVO3), SIN1 and mLST8 (GβL). Other proteins found to be associated with mTORC2, such as PRR5/Protor, PRR5L and DEPTOR. Rictor and mSIN1 stabilize each other and are believed to create the basis for mTORC2 complex [77, 78]. mLST8 is essential to mTORC2 stability and activity [79]. Deptor is the negative regulator of mTORC2 activity [80].

mTORC2 phosphorylates AKT at Thr450 of the turn motif (TM) and Ser473 of the hydrophobic motif (HM) [66, 81]. Thr450 phosphorylation is a post-translational modification and occurs upon recruitment of AKT to the membrane via affinity of its PH domain to membrane lipids. Phosphorylation at Ser473 is induced by such stimuli as growth factors and hormones and it leads to increased activity of AKT. Ser473 phosphorylation may be related to substrate specificity, since AKT phosphorylation by mTORC2 at Ser473 has influence on Forkhead subclass O family of transcription factors (FOXO1/2) phosphorylation, but not on other substrates like GSK3 (glycogen synthase kinase 3) and TSC2 (tuberous sclerosis complex 2) [79]. Phosphorylation at Ser473 has been shown to be elevated in a number of cancers, indicating that the regulation of AKT by mTORC2 could play a significant role in cancer progression.

## 2.2. Alternative AKT modifications

Although, current evidence suggests that phosphorylation at Thr308 and Ser473 are required for full activation of AKT1 protein, there is information about other post-translational modifications, which influence AKT activity, subcellular localization, protein stability, protein folding etc. (Figure 1) [82].

**Thr92** phosphorylation indicates to proper folding of AKT protein, whereas single mutation only marginally affects expression and activation of this kinase, but double mutation of Thr92 and Thr450 residues makes AKT unstable [83]. **Ser124** high phosphorylation level has been detected in different cell lines [32]. According to one hypothesis phosphorylation of AKT at Ser124 renders the protein responsive to growth factor-induced and PI3K-dependent activation [84], but so far, there is no evidence of identified regulatory stimulus or kinase



involved with this event. **Ser129** phosphorylation *in vitro* and *in vivo* by casein kinase (CK2) is associated with an increase in the catalytic activity of AKT, which is supported by the fact that down-regulation of CK2 catalytic subunit or a mutation of the CK2 target site in AKT correlates with decreased AKT activity [85]. **Thr312** is believed to have an inhibitory effect on AKT activation. GSK3 $\alpha$  phosphorylates AKT within the substrate-binding site of the protein and this modification is considered to interfere with the interaction of AKT and its substrates preventing AKT kinase function [86]. Since mutation of **Thr450** only slightly inhibits the activation of AKT by growth factors [87], Thr450 is indicated as constitutively phosphorylated site, which controls AKT protein folding and maturation and has been proposed to be the first step in AKT activation [81, 88, 89]. In addition, constitutive phosphorylation of Thr450 inhibits co-translational ubiquitination and subsequent degradation of AKT protein [89]. Very recently it was found that AKT activity fluctuation during the cell cycle is in correlation with cyclinA2 expression pattern. Further investigation revealed cyclinA2 phosphorylation sites at the very end of the C-terminal domain of AKT protein – residues **Ser477** and **Thr479**. Phosphorylation of these two residues is proposed to trigger AKT1 activation either through enhancing its association with mTORC2 to promote phosphorylation of Ser473 or by functionally compensating the absence of pSer473 to lock Akt1 in its active conformation. In breast cancer samples as well as in breast-cancer-derived cell lines they found a positive correlation between the phosphorylation of AKT1 at Ser477/Thr479 and Ser473. These results indicate that a physiological role of cyclinA2 is to promote pro-survival and oncogenic properties of AKT1 protein [90]. Evolutionarily conserved **Tyr176** can be directly phosphorylated by non-receptor tyrosine kinase ACK1 (also known as ACK or TNK2), which causes PIP3-independent recruitment of AKT to the plasma membrane and subsequent phosphorylation of Thr308/Ser473 leading to AKT activation. In addition, activated ACK1 expression in the prostate of transgenic mice specifically induces phosphorylation of AKT at Tyr176, which promotes the development of murine prostatic intraepithelial neoplasia (mPINs). Positive correlation between activated ACK1 and Tyr176 phosphorylation in breast tumor samples was also found to be related with poor prognosis of breast cancer patient survival [91]. Chen *et al.* found that AKT is a direct substrate of Src both *in vitro* and *in vivo* and that Tyr176 phosphorylation of AKT is critical for its full activation by growth factors.

Two identified residues near the activation loop of AKT, **Tyr315** and **Tyr326**, are found to be indispensable for AKT activation. Replacing these residues with phenylalanine blocked AKT kinase activity upon growth factor stimulation [92]. Non-myristylated Src-related intracellular tyrosine kinase protein tyrosine kinase 6 (PTK6) is also capable of phosphorylating AKT at Tyr315 and Tyr326 [93]. Conus *et al.* showed that AKT activation by pervanadate or serum is associated with **Tyr474** phosphorylation on AKT. Tyr474 substitution with phenylalanine abolished its phosphorylation and resulted in up


to 55% inhibition of AKT activation, indicating that phosphorylation at Tyr474 is required for full activation of the kinase [94].

**AKT inhibition.** Among the many molecules that stimulate AKT are also these that inhibit AKT activity. Phosphatase and tensin homologue deleted chromosome 10 (**PTEN**) is a tumor suppressor, which has been frequently mutated in a variety of solid tumors [95]. This lipid phosphatase inhibits PI3K/AKT signaling indirectly by catalyzing the conversion of PIP3 into PIP2 (Figure 2) [96]. PTEN is also involved in DNA-DSB repair following genotoxic stress such as exposure to ionizing radiation [97]. Protein phosphatases such as **PHLPPs** (PH-domain leucine-rich repeat protein phosphatases) and **PP2A** (protein phosphatase 2A) have a direct effect on AKT activity. PHLPP dephosphorylates Ser473 and thereby inactivates AKT proteins. Two PHLPP isoforms have distinct impact on AKT proteins: PHLPP2 dephosphorylates AKT1 and PHLPP1 dephosphorylates AKT2 and AKT3 [98]. Indicated as tumor suppressor, PHLPP expression is commonly lost in human cancers [99]. PP2A preferentially dephosphorylates AKT at Thr308 [100].

### 3. AKT signaling pathway

PI3K/AKT pathway is initiated by various growth factors, hormones and cytokines, such as insulin, insulin like growth factor (IGF), epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF). These factors bind to receptor tyrosine kinases (RTKs), cytokine receptors or GPCRs and trigger the activation of the lipid kinase PI3K. Activated PI3K phosphorylates PIP2 to produce PIP3, which recruits AKT to the cell membrane where it is phosphorylated at Thr308 and Ser473. Once activated, AKT migrates to the cytosol, mitochondria and nucleus, phosphorylates numerous substrates throughout the cell and thereby regulates multiple cellular events and processes like cell growth, survival, differentiation and metabolism (Figure 2) [101, 102].

Up to now, more than 100 proteins have been identified as potential AKT targets, including caspase-9, p27<sup>Kip1</sup>, p21<sup>Cip1/WAF1</sup>, glycogen synthase kinase 3 (GSK3) cAMP response element-binding protein (CREB), murine double minute 2 (MDM2), BAD, proline-rich AKT substrate 40 (PRAS40), Forkhead family subclass O (FOXO) transcription factors etc. [54, 101, 102]. Most of the AKT substrates contain the minimal consensus sequence RxRxx(S/T), where x is any amino acid and S/T is the Ser/Thr phosphorylation site [103]. Many targets of the pathway modulated by AKT are also subjects for regulation by other pathways, further highlighting the extreme complexity of AKT signaling regulation [104–106].



**Figure 2.** Schematic representation of the PI3K/AKT pathway. Growth factor receptor activated PI3K phosphorylates PIP2 and produces PIP3, which recruits AKT to the cell membrane where it is phosphorylated by PDK1 and mTORC2. Phosphorylated AKT regulates a plethora of downstream cellular processes from cell survival, angiogenesis, proliferation, translation and metabolism. AKT is dephosphorylated by PHLPP and PP2A.


**AKT signaling specificity.** There is a large body of evidence about the diverse functions of AKT isoforms, but the mechanisms by which AKT isoform-specificity is conferred are largely unknown. Selectivity might at least in part be reached through tissue-specific expression, spatial segregation at distinct subcellular locations and phosphorylation of isoform-specific substrates [103]. Since the subcellular localization of AKT isoforms in cancer cells is different [104], the current model of AKT activation by PI3K/PDK1/mTORC2 might only be applicable to AKT1.

### 3.1. AKT regulates cell survival and apoptosis

AKT promotes cell survival by inhibiting the functions of pro-apoptotic proteins and apoptosis related processes, or activates transcription factors, which regulate the expression of genes with anti-apoptotic activity (Figure 3).

AKT inhibits the functions or expression of several Bcl-2 homology domain 3 (BH3)-only proteins, which exert their proapoptotic effects by binding to and inactivating prosurvival Bcl-2 family members. AKT can directly phosphorylate

pro-apoptotic Bcl-2-antagonist of death (**BAD**), BAX and BIM [105-108]. Unphosphorylated BAD interacts with Bcl-XL, which leads to a release of cytochrome c from the mitochondrial compartment into the cytoplasm where it binds to Apaf1 thereby activating apoptotic proteases called caspases [109]. Phospho-serine residues Ser112 (phosphorylated by Raf1) and Ser136 (phosphorylated by AKT) on BAD form high-affinity binding sites for cytoplasmic 14-3-3 molecules, which prevent BAD binding with BclXL [110, 111]. Ser112 and Ser136 residues on BAD can also be phosphorylated by p21-activated kinase 1 (Pak) [112]. Pak activation is triggered by oncogenic Ras stimulation and subsequent AKT activation, which means that AKT can regulate BAD also indirectly [113].



**Figure 3.** The substrates of AKT involved in blocking apoptosis and promoting cell survival.

AKT regulates positively some transcription factors to allow expression of pro-survival genes. Cell survival promoting cAMP response element binding protein (**CREB**) is phosphorylated by AKT at Ser133, which stimulates recruitment of CREB-binding protein (CBP) to the promoter of target genes, such as Bcl-2 [114]. AKT can phosphorylate and activate the IκB kinase IKKα at Thr23, causing degradation of IκB and nuclear translocation of **NF-κB** where it promotes expression of caspase inhibitors, c-Myb and Bcl-XL [115]. AKT also inhibits the expression of BH3-only proteins through effects on **FOXO** transcription factors [116]. AKT phosphorylates FOXO1 at Thr24, Ser256, Ser319 and FOXO3a and FOXO4 at three equivalent sites in the nucleus [117]. Phosphorylation of FOXO proteins by AKT triggers the rapid relocalization of FOXOs from the nucleus to the cytoplasm. Phosphorylated Thr24 and Ser256 are binding sites for 14-3-3 proteins, which masks FOXO nuclear localization signal (NLS) and causes FOXO transcription factor translocation to the cytoplasm [118]. By this mechanism AKT blocks FOXO-mediated transcription of target genes that promote apoptosis, cell-cycle arrest, and metabolic processes, such as BIM [119] and proapoptotic cytokine Fas ligand (FasL) [120]. Down-


stream of cytochrome c release AKT can phosphorylate **caspase 9** at Ser196 in human cells, which leads to an inhibition of caspase activity through an unknown mechanism [121]. AKT can interact and phosphorylate X-linked inhibitor of apoptosis protein (**XIAP**) at residue Ser87 *in vitro* and *in vivo*. Phosphorylation of XIAP by AKT prevents XIAP ubiquitination and degradation in response to cisplatin and also XIAP autoubiquitination [122]. By stabilizing XIAP, AKT promotes cell survival.

### 3.2. AKT regulates cell cycle progression and proliferation

AKT kinase modulates the activity, localization and functions of several substrates related to cell cycle progression at the G1/S and G2/M transitions, either by directly phosphorylating the target proteins or indirectly regulating their expression levels (Figure 4). Growth-factor-mediated AKT activation causes cells to exit G0 via directly increasing the transcription of proto-oncogene **c-Myc** (cellular myelocytomatosis oncogen), which executes its multiple activities mostly through transcriptional regulation of the target genes [123]. c-Myc induces the expression of D-type cyclins (cyclinD) and inhibits the expression of negative cell cycle regulators such as p21<sup>Cip1/WAF1</sup>, p27<sup>Kip1</sup> and p15<sup>INK4b</sup> [124-126]. Indirectly AKT controls the stability of c-Myc and cyclinD1 via its downstream substrate GSK3 $\beta$ . c-Myc phosphorylation at Thr58 and cyclinD1 phosphorylation at Thr286 by GSK3 $\beta$  is required for ubiquitin-dependent proteolysis of these proteins [127, 128].

p21<sup>Cip1/WAF1</sup> is a critical regulator of cell cycle progression and cell survival. p21<sup>Cip1/WAF1</sup> inhibits the kinase activity of the cyclin-dependent kinases (CDKs), leading to cell growth arrest at specific stages in the cell cycle. p21<sup>Cip1/WAF1</sup> binding to proliferating cell nuclear antigen (**PCNA**) interferes PCNA-dependent DNA polymerase activity and thereby inhibits DNA replication and modulates various PCNA-dependent DNA repair processes [129]. Elevated p21<sup>Cip1/WAF1</sup> protein levels have been observed in various aggressive tumors and it has been linked to enhanced survival and chemoresistance [27]. p21<sup>Cip1/WAF1</sup> is reported to be a direct substrate of AKT [130]. AKT phosphorylation of p21<sup>Cip1/WAF1</sup> at Thr145 in the nuclear-localization signal (NLS) leads to the cytoplasmic localization and suppression of the inhibitory effect of p21<sup>Cip1/WAF1</sup> on cell cycle progression [130]. In addition, AKT-dependent phosphorylation of p21<sup>Cip1/WAF1</sup> at Thr145 prevents the formation of DNA replication inhibiting complex between p21<sup>Cip1/WAF1</sup> and PCNA, and decreases the binding of the cyclin-dependent kinases CDK2 and CDK4 to p21<sup>Cip1/WAF1</sup> [131]. Alternatively, it has been found that AKT phosphorylation of p21<sup>Cip1/WAF1</sup> at Ser146 significantly increases p21<sup>Cip1/WAF1</sup> protein stability and thereby modulates p21<sup>Cip1/WAF1</sup> protein level [132]. AKT induced p21<sup>Cip1/WAF1</sup> protein can promote the assembly and activation of cyclinD1-CDK4 complex, which controls G1 to S phase progression and enhances cell cycling [132]. These data suggest that p21<sup>Cip1/WAF1</sup>

protein stabilization is an additional mechanism, by which AKT regulates tumor cell survival and/or proliferation.



**Figure 4.** AKT role in cell cycle progression. Activated AKT kinase regulates the function of numerous proteins involved in cell cycle progression, either by direct phosphorylation of the target proteins or indirectly, by controlling protein expression levels.

AKT controls the expression, localization, and protein stability of another major cyclin/CDK inhibitor - **p27<sup>Kip1</sup>**. AKT directly binds to and phosphorylates p27<sup>Kip1</sup> at several residues, such as Ser10, Thr157, Thr187 and Thr198 [133-137]. Thr157 phosphorylation within the nuclear localization sequence (NLS) leads to cytoplasmic accumulation of p27<sup>Kip1</sup>. In the cytoplasm p27<sup>Kip1</sup> is not able to bind and inhibit nuclear cyclinE/CDK2 kinase activity and thus halting cell cycle progression. p27<sup>Kip1</sup> phosphorylation by AKT at Thr198 promotes 14-3-3 binding and cytoplasmic localization [138]. Cytoplasmic localization of p27<sup>Kip1</sup> has been observed in various human tumors [139, 140]. In up to 40% of primary human breast cancers, cytoplasmic p27<sup>Kip1</sup> correlates with AKT activation, indicating that AKT-mediated cytoplasmic mislocalization of p27<sup>Kip1</sup> may be critical in the development of human cancers. In addition, AKT can downregulate p27<sup>Kip1</sup> transcription by phosphorylation-dependent inhibition of the FOXO transcription factors [141]. Protein stability of p27<sup>Kip1</sup> is controlled by AKT-dependent phosphorylation of S-phase kinase-associated protein 2 (**Skp2**) [142, 143]. Skp2 is a key component of SCF (Skp1/Cul-1/F-box) E3 ubiquitin ligase, which binds to p27<sup>Kip1</sup> and targets it for ubiquitination and degradation [144, 145].

The tumor suppressor p53 binds to DNA and up-regulates the expression of several genes involved in cell cycle control, DNA repair, senescence, angiogenesis, and apoptosis [146-148]. In normal cells p53 is maintained at low levels by **MDM2**, which targets p53 for ubiquitination, translocation from the nucleus to the cytoplasm and proteolysis [149, 150]. By growth factor stimulation activated AKT binds to and phosphorylates MDM2 at Ser166 and Ser186, which is necessary for the translocation of MDM2 from the cytoplasm to the nucleus, to enhance protein stability and facilitate the function of MDM2 to promote p53 ubiquitination [151, 152]. MDMX, which is a MDM2 homologue, has also been shown to be an AKT target. MDMX alone does not have E3 ubiquitin ligase activity, but it binds to and stabilizes MDM2 thereby promoting p53 ubiquitination [153]. AKT phosphorylation of MDMX at Ser367 generates a 14-3-3 binding site and leads to the stabilization of the MDM2-MDMX complex [154]. Through MDM2 phosphorylation and activation AKT has impact also on transcriptional targets of p53, like BH3-only proteins PUMA (p53 upregulated modulator of apoptosis) and Noxa, which appear to be essential for p53-induced apoptosis [155].

AKT regulates the phosphorylation of cyclin-dependent kinase 2 (**CDK2**), which is a key regulator of G1-S cell cycle progression [156]. AKT phosphorylation of CDK2 at Thr39 in the nucleus causes temporary localization of cyclinA/CDK2 complex into the cytoplasm, which is required for cell cycle progression from S to G2/M phase [157]. Alternatively, AKT-mediated phosphorylation and cytoplasmic translocation of CDK2 is also important for stress induced apoptosis [158]. Phosphatase Cdc25B has an essential role in control of cyclinB/CDK1 activity [159]. The function of Cdc25B is tightly linked to its intracellular localization [160, 161]. AKT-mediated Ser353 phosphorylation causes the cytoplasmic accumulation and inactivation of Cdc25B by avoiding the access to its substrates [162]. WeeHu, a CDK1 inhibitor, is also an AKT target. AKT phosphorylates WeeHu at Ser642, which does not affect its kinase activity, however, it promotes the interaction of WeeHu with 14-3-3 protein and translocation into the cytoplasm [163].

### **3.3. AKT regulates cell growth and metabolism**


In response to growth factors, AKT also regulates nutrient uptake and cell metabolism. One of the most important physiological functions of AKT is to regulate the glucose uptake in response to insulin. AKT activity increases the transcription of the glucose transporters **GLUT1** and the translocation of **GLUT4** to the plasma membrane in muscle and fat cells, which increases the uptake of glucose into cells [164, 165]. Other AKT substrates that may regulate cell metabolism by mediating the regulation of GLUT4 translocation include AKT substrate of 160 kDa (**AS160**), phosphoinositide kinase for five position containing a Fyve finger (**PIKfyve**) and syntaxin binding protein 4 (**STXBP4/synip**) [166-168]. After entering into the cell, glucose is converted

by hexokinase to glucose-6-phosphate. AKT stimulates the association of hexokinase with mitochondria, where it can access its glucose substrate more readily, but the direct target of AKT is currently unknown [169, 170]. Next, glucose 6-phosphate is stored by conversion to glycogen or catabolized to produce cellular energy through glycolysis. AKT regulates glycogen synthesis and suppression of glycogenolysis through the AKT-dependent phosphorylation and inactivation of **GSK3**. Nonphosphorylated GSK3 is catalytically active and inhibits the activity of glycogen synthase [171]. Activated AKT phosphorylates and inhibits GSK3 and prevents GSK3 from phosphorylating and inhibiting glycogen synthase, thereby stimulating glycogen synthesis. AKT can regulate glucose homeostasis also by phosphorylation and inhibition of **FOXO1**, as FOXO1 promotes hepatic glucose production and regulates the differentiation of cells involved in metabolic control [172]. In hepatocytes, AKT can inhibit gluconeogenesis and fatty acid oxidation through direct phosphorylation of peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) coactivator 1  $\alpha$  (**PGC-1 $\alpha$** ) at Ser570, which is a coactivator that can regulate genes with FOXO1 and other transcription factors [173]. AKT activation also increases the rate of glycolysis, which is common event seen in tumor cells [174]. AKT ability to enhance the rate of glycolysis is at least partly related to its ability to promote the expression of glycolytic enzymes through hypoxia-inducible factor 1- $\alpha$  (**HIF1 $\alpha$** ) [175, 176]. AKT-dependent phosphorylation and inhibition of GSK3 also regulates lipid metabolism. Phosphorylation of substrates by GSK3 often targets them for proteasomal degradation. GSK3 has been shown to promote degradation of the sterol regulatory element-binding proteins (**SREBPs**), which are transcription factors that turn on the expression of genes involved in cholesterol and fatty acid biosynthesis. AKT-mediated inhibition of GSK3 promotes SREBP stability and enhances lipid production [177]. AKT can also phosphorylate Ser454 on **ATP citrate lyase (ACL)**, indicating a potential role in regulating ACL activity and fatty acid synthesis [178]. In addition, AKT activates the 3B isoform of cyclic nucleotide phosphodiesterase (**PDE**) via phosphorylation at Ser273, resulting in reduced cyclic-AMP levels and inhibition of lipolysis [179].

Promoting the cell growth (including an increase in cell mass) is one of the conserved functions of AKT. The predominant mechanism of AKT-dependent cell growth involves **mTORC1** (mTOR complex 1 or the mTOR-raptor complex), which is activated by nutrients or growth factors. mTORC1 has a critical role in cell growth control, translation initiation and ribosome biogenesis [180]. mTORC1 is composed of mTOR, raptor (regulatory associated protein of mTOR), mLST8 (also called G-protein-subunit-like protein, GL), PRAS40 and deptor (death domain containing mTOR interacting protein) (Figure 5) [181]. mTORC1 regulates translation by phosphorylating its various downstream effectors from which the best characterized are p70 ribosomal protein S6 kinase 1 (p70S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (EIF4E-BP1). Ras homolog enriched in brain (Rheb) GTPase directly binds to the catalytic domain of mTOR and acts as a positive regulator of mTORC1 kinase activity [182]. TSC1 and TSC2 proteins form *in vivo* a complex, which



negatively regulates mTORC1 by acting as Rheb GAP (GTPase activation protein) that converts Rheb into an inactive GDP bound form [183]. In response to growth factors, AKT directly phosphorylates TSC2 on several distinct residues (Ser939 and Thr1462), which prevents the formation of TSC1-TSC2 complex, thus allowing GTPase Rheb to convert back into the GTP-bound active state leading to mTORC1 activation (Figure 5) [184].



**Figure 5.** PI3K–AKT signaling activates mTOR complex 1 (mTORC1) through the phosphorylation of TSC2 at position Ser1462. This phosphorylation event results in the dissociation of the TSC1–TSC2 complex and thus prevents TSC2 from stimulating the intrinsic GTPase activity of the small G protein RHEB, resulting in the accumulation of GTP-bound RHEB, which is a positive regulator of mTORC1. AKT also phosphorylates 40 kDa proline-rich AKT1 substrate PRAS40 at position Thr246, resulting in its dissociation from mTOR and thus blocking PRAS40-mediated mTORC1 inhibition. mTOR complex 2 (mTORC2) phosphorylates AKT at Ser473 and Thr450.

Thus PI3K/AKT signaling pathway regulates mTORC1 by phosphorylation and inhibition of TSC2 which impairs its ability to inhibit Rheb, thereby resulting in the subsequent activation of Rheb and mTORC1. AKT activation by growth factors can stimulate mTORC1 also in a TSC1/2-independent manner through proline-rich AKT substrate 40 kDa (PRAS40). Unphosphorylated PRAS40 binds raptor and inhibits mTOR kinase activity. PRAS40 phosphorylation by AKT at Thr246 promotes the dissociation of PRAS40 from mTORC1 and subsequent mTORC1 activation [182, 185].

### 3.4. AKT regulates angiogenesis

Angiogenesis is essential in many normal physiological processes, including embryogenesis, wound healing, tissue repair and organ regeneration, but it also contributes to several pathological conditions, like rheumatoid arthritis, tumor progression and metastasis. AKT participates in both physiological and pathological angiogenesis through promoting angiogenic signal production and regulating the response of endothelial cells to these stimuli. Under physiological conditions, angiogenesis is tightly regulated through a local balance between angiogenic stimulators, such as growth factors VEGF, bFGF, TGF $\beta$  and PDGF, and angiogenic inhibitors like thrombospondin-1 (TSP-1), tissue inhibitor of matrix metalloproteinase-1 (MMP-1), angiostatin and endostatin. The formation of new blood vessels in pathological disorders is often due to either a decrease in levels of inhibitors, an increase in levels of stimulators or a combination of both [186].

In endothelial cells PI3K/AKT pathway is activated by vascular endothelial growth factor (VEGF), which thereby promotes the survival, growth and proliferation of these cells [187]. One of the major stimuli for increased VEGF production by tumor cells is hypoxia, which is characteristic to advanced solid tumors. Hypoxia leads to the induction of hypoxia-inducible factor 1 (HIF-1) [188]. HIF-1 is a heterodimeric transcriptional factor, which is composed of HIF-1 $\alpha$  and HIF-1 $\beta$  subunits. Under hypoxic conditions the ubiquitin-mediated degradation of HIF-1 $\alpha$  is inhibited and stabilized  $\alpha$  subunit binds to the  $\beta$  subunit, which is constitutively present. Composed heterodimer binds to numerous promoters containing hypoxia response elements (HREs), leading to the transcription of multiple target genes including VEGF [189]. In addition, HIF-1 $\alpha$  production and VEGF expression can be increased by the activation of EGFR/PI3K/AKT/mTOR pathway and PTEN mutation [190]. HIF-1 $\alpha$  activation in endothelial and other surrounding cells leads to elevated expression and secretion of VEGF, which therefore stimulates angiogenesis through autocrine and paracrine manner.

AKT regulates angiogenesis through the activation of endothelial nitric oxide synthase (eNOS), which catalyzes nitric oxide (NO) synthesis in endothelial cells. AKT phosphorylates eNOS at Ser1177, by leading to a persistent, calcium-independent eNOS activation [191]. The activity of eNOS is also regulated by subcellular localization and protein-protein interactions. eNOS can be localized in a specific domain of plasma membrane called caveolae, where it interacts with caveolin-1 through caveolin-1 scaffolding domain, which inhibits eNOS activity. Stimulation with VEGF or stress induces eNOS to interact with heat shock protein 90 (Hsp90), and this interaction enhances eNOS activity. Remarkably, on stimulation, AKT can also interact with Hsp90 and this interaction enhances AKT enzymatic activity, which suggests that Hsp90 may serve as a scaffold protein for the efficient phosphorylation of eNOS by AKT at caveolae [192].

Elevated levels of VEGF and subsequent eNOS activity can lead to vascular permeability, leaky vessels, slow blood flow, and elevated interstitial pressure.

Constitutive activation of the ERK/MAPK pathway could induce angiogenesis but not vascular permeability, while activation of PI3K/AKT was required for both angiogenesis and vascular permeability [193]. In animal studies overexpression of constitutively active AKT in the vascular endothelium increased resting diameter and blood flow, whereas transduction of dominant-negative AKT attenuated endothelium-dependent vasodilation induced by acetylcholine, suggesting that AKT regulates the vasomotor tone in vivo [194].

## 4. AKT and cancer

### 4.1. AKT signaling in cancer

Since AKT kinases control essential cellular processes, it is inevitable that the dysregulation of AKT signaling pathway leads to the loss of the strict balance between AKT-regulated tumor suppressor factor activities and proto-oncogenes, which yields severe consequences. Less active or defective AKT-dependent pathway does not provide an efficient protection from apoptotic signals, which may contribute to the pathogenesis and/or progression of several human disorders, such as type-2 diabetes, neurodegenerative diseases or illnesses of the cardiovascular system [195-200]. The overexpression and/or constitutively increased activity of the AKT-regulated pathway has been observed in a wide variety of human cancers, including carcinomas, *glioblastoma multiforme* and various hematological malignancies [201, 202]. Elevated AKT activity is usually not a result of any single event, but rather a consequence of multiple causes, which lead to AKT-dependent suppression of apoptosis, differentiation and to uncontrolled cell cycle progression. The AKT activity may be caused of increased amounts of extracellular factors that stimulate AKT signaling, altered number of receptors, which mediate these signals, constitutively activating mutations in these receptors as well as deregulation of intracellular AKT-activating mediators, like Ras or PI3K and their regulators [203]. The control mechanisms that regulate AKT activity can be downregulated or deleted; for example, tumor suppressor protein PTEN has been found mutated or deleted in many advanced cancers [204, 205]. The elevated expression of AKT isoforms has been described in some cancer types, like pancreatic, prostate and mammary cancer [20, 206-208]. Amplification of AKT1 is rather rare, but amplification of AKT2, found in several cancer types, is more common [206, 209, 210]. AKT3 amplification has recently been reported to promote DNA repair and glioma progression [211]. Carpten *et al.* described a transforming point-mutation E17K (lysine substituted with glutamic acid at position 17) within the PH domain of AKT1 in human breast, ovarian and colorectal cancer, which increases the plasma membrane recruitment and confers to the constitutively active state of the protein [212]. Analogous point-mutation in the AKT3 has been found in human melanoma [213]. AKT hyperactivation has frequently been found in less differentiated tumors, which are more invasive, grow faster and do not respond

to treatment. In addition, hyperactivated AKT in primary tumors is considered as poor prognostic marker for disease outcome [214].

Considering the central role in cell signaling and frequent aberrant regulation in human cancers, AKT has become an attractive target in anti-cancer drug design. A better understanding of upstream regulators and downstream targets is necessary to control and regulate activity of AKT-related pathway in human malignancies. However, it has to be remembered that AKT signaling pathway is not only multifaceted and complicated but it is a part of a more complex and integrated network. To date, direct or indirect communication of AKT pathway with RAF-MEK1/2-ERK1/2, NF $\kappa$ B, JNK, p38, Wnt, p53 and NOTCH pathways has been described, which means that activation or inhibition of one of these pathways may have a strong impact on other signaling pathways as well [152, 215-219].

## **4.2. AKT and cancer stem cells**

Since PI3K/AKT/mTOR pathway is implicated in resistance mechanisms to antineoplastic therapies, it is rapidly emerging as a signaling network important for cancer stem cell (CSC) survival. CSC have suggested to be immortal tumor-initiating cells that have self-renewal and pluripotent capacity [220]. CSCs have been identified in multiple malignancies, including leukemia and various solid cancers, such as lung cancer, colon cancer, prostate cancer, ovarian cancer, brain cancer and melanoma. CSCs are thought to be responsible for tumor initiation, development, metastasis and recurrence, and to be resistant to conventional anti-tumor treatment, like polychemotherapy, which only acts on more mature cells. The reason could be the different regulation of gene expression and some signaling pathways compared to other tumor cells, like the elevated expression of ATP-binding cassette (ABC) family membrane transporters [221], or the fact that CSCs have low proliferation rate [222, 223]. Cell surface proteins CD133, CD24 and CD44 are considered as putative markers for cancer stem cell populations, associated with aggressive cancer types and poor prognosis. However, distribution of these markers differs between patients and cell lines [224]. In contrast, tumor initiating cells from head-and-neck and breast cancer have been shown to be CD24-negative [225].

Probably due to different experimental models and methods, the published findings regarding the role of AKT in promoting cancer stem-cells are controversial. AKT co-expression with CD133 has been shown to provide the cells resistance to chemotherapeutics [226]. Whereas AKT activation has been found both negatively as well as positively correlated with CD44 expression [227, 228]. Radiation itself can increase the expression of AKT, CD133, and reduce the expression of CD44 in colorectal cancer cells [229]. The study with colon cancer cell lines showed that cells highly expressing CD133/CD44 have elevated expression of AKT and these cells are more resistant to radiation. In addition, AKT isoforms had different influence on CD44 and CD133 expres-

sion. Knocking down AKT1 but not AKT2 in colon cancer cell line, reduced CD133 expression. CD44 expression was increased in both knockdown variants [230]. Gargini *et al.* demonstrated a close relationship between maintenance of the CSC-like phenotype and the survival of tumor initiating cells [231]. Inhibiting PI3K activity or AKT1 activity was not only related to increased apoptosis but also reduced significantly stem cell/mesenchymal phenotype and recovery of epithelial-like markers. They also revealed that maintenance of stem cell-like phenotype and survival of these cells is linked to AKT-FOXO-Bim pathway [231]. Studies with hair follicle stem cells (HF-SCs) showed that the expression of permanently active form of AKT leads to HF-SC activation and increases the response to proliferative stimuli, at the same time maintaining their stem-cell identity and functionality. In addition, active AKT signaling increased tumor development and malignancy [232]. Recently it was found that cells over-expressing Twist, a key transcriptional factor of epithelial mesenchymal transition (EMT), had cancer stem cell-like properties, such as tumorsphere formation and significantly elevated expression of ALDH1 (aldehyde dehydrogenase 1) and CD44. In addition, activation of  $\beta$ -catenin and AKT pathways correlated with the expression of CD44 in these cells and knockdown of  $\beta$ -catenin expression and inhibition of the AKT pathway substantially suppressed the expression of CD44 [233]. Recent study claims that the EMT and stem cell renewal programs are influenced by imbalance between AKT1 and AKT2, which dysregulates the microRNAs that control these processes, rather than overall activity of AKT [234]. It has been noted that inactivation or deletion of tumor suppressor PTEN, the negative regulator of PI3K/AKT/mTOR signaling cascade, is important in conferring CSC properties in several types of solid tumors, like glioblastoma, hepatocellular carcinoma, prostate carcinoma, lung adenocarcinoma and breast carcinoma [235-240]. In glioblastomas, AKT activation correlated with stemness, invasivity, and increased tumorigenicity, whereas ERK activation correlated with tumor cell proliferation [241]. PTEN gene down-regulation was also detected when leukemic stem cells (LSCs) from chronic myelogenous leukemia (CML) patients were analyzed and compared with healthy hematopoietic stem cells (HSCs) [242].

Although the present information about AKT kinase relationship with CSCs is controversial and needs further research, it is still obvious that AKT signaling can have an important role in preserving CSC characteristics, like tumor initiation, self-renewal and pluripotency.

## 5. Protein-protein interaction inhibitors

**Protein-protein interactions (PPI)** have a central role in cellular biological processes, like extracellular signaling, protein translation, DNA-synthesis, protein degradation, programmed cell death etc. There are roughly 30 000 protein sequences in human genome, an estimated number of PPIs in human body reaches up to  $\approx$ 400 000, and therefore PPIs are a large and important class of

highly promising targets for human therapeutics [243]. In cancer cells, PPIs are responsible for transmitting signals along molecular networks, by promoting tumorigenesis, invasion and metastasis. Large number of PPIs have a role in signaling networks that allow the acquisition and maintenance of cancer hallmarks. PPIs promote oncogenic signals by cell proliferation stimulation, for example by aberrantly activated epidermal growth factor receptor (EGFR) and its downstream target Ras protein [244]. Cell survival signaling is activated by proteins like insulin-like growth factor 1 (IGF-1) and PI3K, which enables cells to resist apoptosis through several different ways. Transcription-dependent mechanism uses AKT-FOXO3a-14-3-3 axis and transcription-independent antiapoptotic mechanism AKT-BAD-14-3-3 pathway [105, 116]. In addition, by regulating mTOR complex, AKT promotes translation of growth promoting genes, like c-Myc [245]. Disruption of PPIs, which are critical for cancer progression and that cancer cells rely on for survival, offers a potential effective, although challenging strategy for development of anticancer treatment. The challenges to discover compounds that could inhibit PPIs are for example the lack of good starting points for drug design and the difficulty to distinguish the real interaction from false/artefactual binding. The concerning properties of PPIs include large PPI interface areas, lack of deep pockets, where small molecule can dock, lack of noncontiguous binding sites and general lack of natural ligands. Protein-protein complexes are typically hydrophobic and have different amino acid residue composition than small-molecule binding sites [246]. The presence of hot spots (small subsets of amino acid residues that contribute the most of the free binding energy), post-translational modifications and natural ligands simplifies defining of targeting suitable interfaces.

Current approaches to design PPI modulators include structure based design and different small-molecule screening methods [246]. Structural analysis helps to identify specific amino acid or peptide fragments, which are critical for protein-protein interactions. These methods include computational design of peptides and peptide engineering [247], design of small molecules based on  $\alpha$ -helix and  $\beta$ -sheet scaffolds [248], protein design strategies to stabilize  $\alpha$ -helical motif [249]. Small-molecule screening allows the identification of PPI modulators when structural information is lacking or limited. Most widely used high throughput screening techniques in such cases include fluorescence energy transfer (FRET) and fluorescence polarization (FP) method [250], ELISA, flow cytometry, surface plasma resonance, label free methods [251], cell-based reporter assays, which are also able to identify cell-permeable compounds [252] and fragment based screening [253]. The screening method and structure based approach used in combination helps to find modulators with better pharmacological and physicochemical properties.

Natural compounds like taxanes for tubulin and rapamycin for mTOR, which were discovered in the late 90s as potent stabilizers of PPIs, show the potential of PPI modulation as therapeutic target. Despite of challenges in PPI modulator design, more than 15 years after the mentioned discoveries novel small molecules targeting specific PPIs have entered clinical trials, and in some cases

already resulted in new therapeutics or optimized treatments. Probably one of the most studied PPI in cell-cycle pathway is MDM2-p53 interaction. MDM2 interacts with a hydrophobic surface groove with three key hydrophobic residues Phe19, Trp23 and Leu26 on p53. These residues make up the “hot spot” which was targeted to identify molecules that can interrupt this specific interaction [254]. For now, seven MDM2-p53 inhibitors have progressed to clinical trials with promising results [243]. The inhibitors of apoptosis proteins (IAPs) are overexpressed or constitutively activated in tumor cells, resulting in evasion of programmed cell death. The XIAP (X-linked IAP) is the most potent caspase inhibitor among the IAP protein family, with the natural inhibitor SMAC [255]. After discovery of the SMAC protein in 2000, a number of SMAC mimetics have been designed, from which seven have reached clinical trials and five molecules are in clinical development [256]. The antiapoptotic Bcl2 members of the protein family, which protect the cells against apoptosis, by inhibiting the actions of the proapoptotic members, are in some cancer types overexpressed. Bcl-2 specific inhibitor ABT-199 (RG7601) is in phase 1 trials for chronic lymphocytic lymphoma or small lymphocytic lymphoma. Another Bcl2 inhibitor Obatoclax (GX015-070) is currently assessed in multiple phase 2 clinical trials offers the opportunity to treat many forms of cancer both as a single agent and in combination with current treatments [243]. The inhibition of Hsp90 chaperone protein, which regulates the activity and stability of numerous targets, is able to shut down multiple oncogenic pathways [257]. Hsp90 inhibitors not only elicit potent anti-cancer effects, but also render tumor cells susceptible to chemotherapy and/or radiation therapy [258].

Novel small molecules targeting PPIs, which have entered to clinical trials and already resulted in optimized treatments or new therapeutics, clearly demonstrate the potential of PPIs in drug development.

## 6. AKT inhibitors

Although AKT has been targeted by several small-molecule inhibitors, the development of an AKT-specific inhibitor is challenging due to its high sequence and structural homology to other kinases and proteins containing PH domains. Despite of that, a plethora of AKT inhibitors is under pre-clinical and clinical trials.

AKT inhibitors can be divided into six major classes based on their mechanisms of action [259]. The first class contains ATP competitive inhibitors, which bind to enzyme active site and display ATP-competitive behavior, like AKT2 inhibitor CCT128930 [260], AKT1 inhibitor GDC-0068 [261], which has entered to Phase II trials, the pan-AKT kinase inhibitors such as GSK2110183 (afuresertib) [262], which has entered Phase II trials, and AT7867 [263], which is still in pre-clinical phase. The second class contains phospholipid-like molecules, which prevent the generation of PIP3 by PI3K, thereby avoiding AKT translocation to the cell membrane and its subsequent activation.

This mechanism is utilized by phosphatidylinositol analogs such as Calbiochem AKT Inhibitors I, II and III (category no. 124005, 124008, 124009 respectively) [264] or other PI3K inhibitors such as PX-866 [265]. This category also includes compounds such as Perifosine that entered phase III trials for colorectal cancer and multiple myeloma, but failed in 2012 [266]. The third class contains a group of compounds called pseudosubstrate and substrate-mimetic inhibitors, which include compounds like AKTide-2 T and FOXO3 hybrid [267]. These peptides are potent selective inhibitors of AKT, that bind to substrate binding site and inhibit AKT1 enzyme activity. Unfortunately, their size makes them poor leads for small molecule inhibitor development. The fourth class consists of allosteric inhibitors of AKT kinase domain, like MK-2206. MK-2206 is an orally bioavailable allosteric inhibitor of AKT, which binds to and inhibits the activity of AKT in a non-ATP competitive manner by inducing a conformational change of AKT to the closed cytoplasmic conformation [268]. MK-2206 is currently widely examined in several clinical trials in phase II status in combination with other targeted drugs and chemotherapy. The fifth class consists of antibodies and include entities such as GST-anti-AKT1-MTS [269]. The last class comprises of compounds that interact with the PH domain of AKT, and include compounds such as Triciribine and PX-316 [270]. Triciribine is a cell-permeable tricyclic nucleoside that inhibits the phosphorylation, activation, and signaling of all three family members of AKT [271]. RX-0201 (Archexin) is an antisense oligonucleotide directed toward AKT1 mRNA, which significantly downregulated the expression of AKT1 at both mRNA and protein level [272].

Although, various drug trials have been initiated for AKT inhibitors, only miltefosine has been recently approved by FDA for treatment of leishmaniasis, which is a disease caused by an intracellular protozoan parasite (*genus Leishmania*) transmitted by the bite of a female phlebotomine sandfly.



## RESULTS

### Objectives of the study

The main objectives of present work were as follows:

- to identify AKT pathway inhibitors with principally novel mechanism of action, by targeting the crucial step in the AKT pathway – the interaction of PDPK1 and AKT1 proteins, which leads to AKT phosphorylation and subsequent activation of AKT-related pathways (REF I).
- to use DEN-phenobarbital induced mouse liver tumor tissue derived primary mouse liver tumor cell line K07074 as a model system for testing the effect of chemotherapeutic agents that could target the pathways deregulated in liver tumors (REF II).
- to study the specific areas in Dupuytren's contracture (DC), which sustain active cell proliferation, to describe the potential molecular factors that could promote the DC pathogenesis (REF III).

### 1. A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth *In Vivo* (REF I)

Ser/Thr kinase AKT has a central role in regulating survival and proliferation of normal and cancerous cells [201, 273]. Since inadequately regulated AKT pathway has been found in several human malignancies [274], it has become an attractive target for treatment of different types of cancer. Although a number of small molecule AKT kinase inhibitors have been developed, only a few are suitable for clinical trials due to severe side effects, which have prevented their further use. To find inhibitors of AKT1 signaling with principally novel mechanism of action, we carried out a live cell-based screen for small molecule inhibitors of physical interaction between AKT1 and its primary activator PDPK1.

#### 1.1. Screening for the inhibitors of AKT1 and PDPK1 interaction

Small-chemical library screen was carried out in live cells by using the NCI Diversity Set I. The screening method, protein complementation assay (PCA), is based on *Renilla reniformis* luciferase (Rluc) fragments (F1 and F2) that are fused to the proteins of interest [275]. When the proteins of interest interact, the *Renilla* fragments are brought in close proximity, which results in reconstitution of the enzyme activity (Figure 1 in REF I), and vice versa, the inhibition of protein-protein interaction unfolds the functional enzyme and destroys the Rluc activity. To assess the quality of the screen setup, Z-factor was measured using the constructs encoding p53-F1 and HDM2-F2 fusion proteins and the inhibitor of p53-HDM2 interaction – Nutlin-3. The value of the Z-factor for this assay

was 0.5, demonstrating its suitability for detecting the inhibition of the protein-protein interactions.

For screening experiments, H1299 cells, which harbor an active AKT signaling pathway and are well-suited for DNA transfection experiments, were used [276] (**Figure 1B in REF I**). To exclude unspecific readouts of luciferase modulation, a number of controls were included in the screen setup (**Table S4 in REF I**). Well-to-well variations were eliminated by normalizing the luciferase read values to cell viability counts. The viability counts were also used to identify and exclude toxic compounds. Baseline values were set according to DMSO (vehicle) treated cells. As controls, each experiment assay included cells that were transfected with p53-F1 and HDM2-F2 fusions and treated with Nutlin-3 or vehicle. At least 2-fold reduction in luciferase activity upon Nutlin-3 addition was considered as successful experiment. To eliminate the chemicals, which directly inhibited the Rluc activity, cells transfected with plasmids encoding full-length Rluc were treated with the chemical library in parallel. Taken together the selection criteria for compounds were set as follows: 1) at least 2-fold reduction of normalized Rluc activity representing the disruption of AKT1-PDPK1 interaction; 2) 25% or less reduction in cell viability counts when compared to the average of untreated controls; 3) less than 10% reduction in the normalized luciferase signal in cells transfected with full-length Rluc when compared to the average reading of untreated cells (**Figure 1C in REF I**).

The screen was performed in two major steps. First, 74 chemicals out of 2,000 were identified, as inhibitors of AKT1-F1-PDPK1-F2 interaction that reduced the luciferase signal at least to 50% or less. In the second step, the selected 74 chemicals were retested for AKT1-PDPK1 PCA inhibition and the inhibition of full-length Rluc and cell toxicity were evaluated. From 74 chemicals that inhibited the AKT1-PDPK1 PCA, 29 chemicals also inhibited the activity of full-length Rluc, and 13 chemicals were toxic for cells. Nine more chemicals from remaining 45 were excluded from further analysis due to toxicity as these reduced the viability counts more than 25%. Consequently, 36 chemicals were selected for the next evaluation step.

## **1.2. NSC156529 reduces AKT phosphorylation level and inhibits AKT1-PDPK1 endogenous interaction**

Since the hallmark of AKT1 activation by PDPK1 is the phosphorylation of AKT1 at Thr308 [32, 33, 84, 277], we evaluated the ability of the chosen chemicals to inhibit the phosphorylation of AKT protein at Thr308. H1299 cells were treated with 36 chemicals selected in the previous step (**Figure 2A in REF I**). GSK2334470, a direct inhibitor of PDPK1, was used as a positive control. By using Western blot method and pAKT(T308) specific antibody, we identified 12 compounds from 36, which inhibited AKT1 protein phosphorylation to a various degree. The cell cultures treated with these compounds were carefully examined for signs of toxicity and 4 chemicals of 12, which did not cause

notable changes in cell density and morphology were chosen for further analysis (**Figure 2A, 2B, Figure S1A-S1D in REF I**).

To find out, whether the selected chemicals were able to inhibit the interaction of endogenous AKT1 and PDPK1 proteins, we used *in situ* proximity ligation assay (*in situ* PLA), which allows specific and sensitive detection of protein-protein interactions in their native conditions. PLA is based on the immunodetection of the interaction partners with specific primary and oligonucleotide-tagged secondary antibodies. When the proteins of interest interact, the *in situ* PCR generates specific DNA sequence, which is detected by the hybridization with fluorescently-labelled DNA oligonucleotides [278]. PLA experiment was performed using PC-3 prostate cancer cells, which harbor an activated AKT signaling pathway [279]. PC-3 cells were seeded to glass slides and incubated with the 4 chemicals selected in the previous step. The number of AKT1-PDPK1 interaction sites detected in the cells treated with the NSC156529 was significantly decreased when compared to PC-3 cells treated with DMSO (**Figure 2C in REF I**). The number of AKT1-PDPK1 interaction sites in cells treated with other three chemicals (**Figure S2A-S2G in REF I**) remained at the same level as in control cells. Remarkably, NSC156529 had no significant effect on AKT2-PDPK1 and AKT3-PDPK1 interactions, indicating to the specific effect of NSC156529 to AKT1-PDPK1 interaction.

### **1.3. AKT1-PDPK1 interaction inhibitor NSC156529 suppresses the activity of AKT downstream targets and cancer cell proliferation *in vitro***

To promote cell-cycle progression and proliferation, active AKT1 protein phosphorylates and thereby inactivates a large number of downstream targets [102]. Therefore, we next sought to find out, whether the disruption of AKT1-PDPK1 interaction and reduction of AKT phosphorylation by NSC156529 influences the phosphorylation of AKT1 downstream targets, such as GSK3 $\beta$ , FOXO3a, BAD and procaspase 9 [121, 280-283]. We found that in PC-3 cells incubated with NSC156529 the phosphorylation of the studied AKT1 target proteins was significantly decreased when compared to control cells incubated with DMSO (**Figure 3B in REF I**). PDPK1 inhibitor was used as a positive control. The basal level of these proteins did not change, with the exception of FOXO3a, the overall protein level of which was also reduced. These results indicated that NSC156529 treatment inhibited the key biochemical activities of the AKT signaling pathway.

The main goal of anticancer drugs is to suppress the growth of cancerous cells. Therefore, we incubated a selection of immortalized and tumor cell lines (Hek293, PC-3, H1299, K07074, and Hep3B) with NSC156529 to verify whether this compound is able to inhibit the proliferation of these cells. As a result, 96-hour treatment with NSC156529 strongly inhibited the growth of selected cell lines, in addition, NSC156529 was more efficient compared to

PDPK1 inhibitor which was used as an assay control (**Figure S4A-S4D in REF I**). Importantly, NSC156529 inhibited the growth of PC-3 cells to a larger extent than that of primary human fibroblasts, and osteoblasts (**Figure 3C in REF I**).

#### **1.4. AKT1-PDPK1 interaction inhibitor NSC156529 suppresses the cell proliferation and induces expression of differentiation markers *in vivo***

To examine whether NSC156529 has an effect on tumor growth *in vivo*, we used a tumor xenograft model (**Figure 4A in REF I**). Nude mice were injected subcutaneously with PC-3 prostate cancer cells, which constitutively expressed EGFP.

The mice bearing a tumor with the median size of 29–32 mm<sup>3</sup> were injected subcutaneously 3 times a week with NSC156529 at concentrations 1 mg/kg, 5 mg/kg, 10 mg/kg, or with vehicle only. Tumor size was measured externally by using a caliper, and additionally the number of tumor cells was monitored by using an *in vivo* imaging device. The reason for using fluorescent imaging was to measure the pure amount of human GFP-expressing xenografts. As the human GFP-expressing xenografts are gradually infiltrated by mouse stromal cells the caliper measurements might have yielded incorrect results. Tumor growth was monitored during the 28-day treatment period. Measurements obtained with external caliper were consistent with GFP measurements and showed clearly that all used NSC156529 concentrations reduced the tumor growth *in vivo* (**Figure 4B and 4C in REF I**). Since no adverse side effects, such as weight loss, ulcerations, or decline in general health conditions of the animals, were observed, and the ALT and AST levels, the biomarkers of liver health, stayed within the normal values, it was concluded that in our experimental system NSC156529 did not exert hepatotoxicity (**Figure S5 in REF I**).

NSC156529 inhibited AKT pathway in tumor xenografts, as the number of cells positive for the pAKT(T308) and the phosphorylated form of BAD protein were notably reduced in NSC156529-treated PC-3-GFP xenografts compared to control xenografts (**Figure 5A and 5B in REF I**). The mitotic activity, which was detected by the number of pH3-positive cell nuclei, was decreased in NSC156529-treated xenografts, indicating that at least in part the inhibition of tumor growth was caused by the inhibition of cell proliferation (**Figure 5C and 5D in REF I**). The presence of cells, which spontaneously undergo apoptosis, is a characteristic feature of malignant neoplasms. To study the role of apoptosis in NSC156529-induced tumor growth suppression, we used terminal deoxynucleotidyl transferase nick end labelling (TUNEL) assay, and measured the amount of apoptosis markers – fragmented DNA and cleaved caspase-3 (CC3) – in tumor xenograft cryosections. The treatment with NSC156529 did not significantly increase the number of cells positive for TUNEL nor CC3, which indicates that apoptosis did not have a significant role in the growth reduction of

mouse tumor xenografts induced by NSC156529 (**Figure S6A and S6B in REF I**). Interestingly, we found that the expression of cytokeratins 15 and 17 (CK15/17) (**Figure 6A, C, D in REF I**) and cytokeratins 8 and 18 (CK8/18) (**Figure 6B, E, F in REF I**) was increased in NSC156529-treated PC-3-GFP xenografts. CK15/CK17 label the human prostate basal epithelial cells and CK8/CK18 expression characterizes the differentiated luminal cells [284]. Since PC-3 cells display properties of poorly differentiated prostate cancer [285], increased levels of CK15/CK17 and CK8/CK18 indicate that NSC156529 could limit the tumor growth at least in part by directing the cancer cells to differentiate.

### **1.5. NSC156529 interacts preferentially with PDPK1**

Interaction inhibition between AKT1 and PDPK1 might be caused by direct interaction of NSC156529 either with AKT1 or PDPK1. To study the potential interaction between NSC156529 and EYFP-tagged AKT1 or PDPK1 in cell lysates we used microscale thermophoresis method (MST). For MST analysis, H1299 cells were transfected with either EYFP-tagged AKT1 or PDPK1 (AKT1–EYFP; PDPK1–EYFP) expressing vectors. Cell lysates containing fluorescently labeled proteins were incubated with serially diluted unlabeled NSC156529 and analyzed using a dedicated MST instrument. While NSC156529 stable binding to AKT1–EYFP could not be detected (**Figure S3A in REF I**), the binding event with the  $K_d$  of  $981 \pm 131$  nmol/L was determined for the NSC156529 and PDPK1–EYFP interaction (**Figure S3B in REF I**). These data suggested that NSC156529 binds directly to PDPK1. The PDPK1 protein has two well-defined docking sites, which are required for the phosphorylation of selected PDPK1 targets: ATP pocket and PIF pocket [286]. The potential of NSC156529 to bind to these sites was evaluated by docking calculations using Glide (Glide, v6.2, Schrodinger, LLC, 2014) and with standard settings performed by the previously published PDPK1 crystal structure (PDB ID–1H1W, [287]). Since the results of the calculations demonstrated no reliable binding of NSC156529 to these two sites, NSC156529 most likely interacts with PDPK1 at other less structured locations (U. Maran and A.T. Garcia-Sosa; personal communication).

## **2. The inhibition of AKT-PDPK1 interaction efficiently suppresses the growth of murine primary liver tumor cells (REF II)**

Most frequently upregulated pathways in liver cancer are related to hyper-activated growth-factor signaling, such as epidermal growth factor (EGF), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF), which lead to signal transduction

involving cytoplasmic tyrosine kinases like RAS/MAPK, AKT/PI3K/mTOR and ERK1/2 pathways [288, 289]. AKT signaling in liver cancer progression and the level of AKT activation has been found to correlate with increased hepatocellular carcinoma (HCC) recurrence risk [290]. By using a primary mouse liver tumor cell line K07074 as a model system, we tested the effect of novel chemotherapeutic agents on pathways deregulated in liver tumors.

## 2.1. Increased activity of liver tumor-associated pathways in K07074

K07074 is a primary cancer cell line derived from DEN-phenobarbital induced mouse liver tumor tissue. The origin of K07074 cells is not clear. Expression of CK19 is characteristic to cholangiocytes, though, the polygonal shape and low expression of *Hnf4a* in K07074 cells might also indicate to hepatocyte origin (**Figure 1A and 1B in REF II**).

Based on previously published data about active signaling cascades in HCC and intrahepatic cholangiocellular carcinoma (ICC) [291, 292], we evaluated the gene and protein expression of Wnt, Hedgehog, p53, Notch and AKT1 targets. Significantly higher gene expression level of Notch pathway target genes *Hes1*, *Hey1*, *Notch3*, *Trib1*, *Ccnd1* and the Hedgehog pathway target genes *Gli1* and *Gli2* in K07074 cells compared to cultivated hepatocytes (**Figure 3A-G in REF II**) indicates to elevated activity of these pathways. Although the protein level of *Axin2*, a Wnt signaling pathway target gene, was higher in K07074 cells (**Figure 3H and 3I in REF II**), the expression of *Axin2*, was not significantly different from that in the control cells (**Figure S1 in REF II**), suggesting that stability of this protein is regulated post-transcriptionally. Immunofluorescence analysis showed that in hepatocytes  $\beta$ -catenin localized primarily near cell membrane and in cytosol. In the K07074 cells perimembraneous  $\beta$ -catenin content was decreased and the signal was mainly detected in the nucleus (**Figure 3J in REF II**), which indicated to activated Wnt pathway in K07074 cells. The p53 protein level (**Figure 3H and 3I in REF II**) and the expression of p53 target genes *p21*, *CyclinG1* and *Gadd45* (**Figure S1 in REF II**) was moderately increased in K07074 cells, though, the expression of p53 target and its negative regulator *Mdm2* and the proapoptotic gene *Puma* were not significantly different from those of control cells. Since sequencing of the *trp53* gene in K07074 cells revealed no p53 mutations, it is assumed that p53 transcriptional activity is partially inactivated in K07074 cells.

Flow cytometry analysis of AKT1 protein expression and phosphorylation revealed an increased AKT phosphorylation at its activation sites Thr308 and Ser473 in K07074 cells when compared to normal hepatocytes (**Figure 3H and 3I in REF II**). In K07074 cells treated with AKT1-PDPK1 interaction inhibitor NSC156529 and PDPK1 inhibitor GSK2334470 the phosphorylation of AKT at Thr308 but not at Ser473 was decreased (**Figure 4A in REF II**).

Next, the phosphorylation status of AKT target proteins was analyzed by Flow cytometry to examine, whether inhibition of Thr308 phosphorylation is sufficient to downregulate the AKT pathway activity (**Figure 4B in REF II**). Although Bad protein expression and the level of Bad phosphorylation at Ser136 were downregulated in NSC156529 treated cells, the change in phosphorylated Bad signal was proportional to the change in Bad protein level. Decreased phosphorylation of Gsk $\beta$  at Ser9 and Foxo at Thr32 indicated to downregulated AKT pathway activity in K07074 cells after incubation with NSC156529 and GSK2334470. Since studied phosphorylation sites are also modified by other Ser/Thr kinases, like serum- and glucocorticoid-inducible kinases (SGKs) [217, 293], the treatment with AKT pathway inhibitor NSC156529 did not completely abolish the phosphorylation of these sites.

## **2.2. AKT and Notch inhibitors efficiently suppress the growth of K07074 cells**

Previous results indicated to increased activity of several liver tumor associated pathways in K07074 cells, therefore, these cells were treated with Nutlin-3 (Trp53-Mdm2 interaction inhibitor) [294], Gant61 (Hedgehog pathway inhibitor at the level of Gli transcription factors) [26], PNU74654 (Wnt inhibitor) [295], GSK2334470 (PDPK1 inhibitor) [296], LY3039478 (Notch inhibitor) [297] and NSC156529 (AKT1-PDPK1 interaction inhibitor) [298] to study the potential effect of these modulators on K07074 cell growth. PNU74654 and Gant61 had no significant impact on K07074 cell growth, and Nutlin-3 and GSK2334470 had only a modest impact on cell viability of these cells. The moderate effect of Nutlin3 on K07074 growth may be explained by the fact that the expression of a subset of p53 target genes, including Mdm2, was not activated. On the contrary, Notch inhibitor LY3039478 and AKT1-PDPK1 interaction inhibitor NSC156529 incubation decreased the number of K07074 cells notably during 96-hour treatment (**Figure 4C in REF II**).

Since the antitumor efficacies of current therapies are limited, most likely because of the high degree of cancer clonal heterogeneity, intratumor genetic heterogeneity and cell signal complexity, a shutdown of a single target does not necessarily eradicate the cancer and it has been proposed that combined therapies should be used. Therefore, we tested the combined treatment of K07074 cells with NSC156529 and Hedgehog, Notch or Wnt pathway inhibitors. While co-treatment of the cells with a reduced amount (5 $\mu$ M) of NSC156529 and working concentrations of Gli and Wnt and Notch inhibitors had no significant additive effect (**Figure 4D in REF II**), the lower NSC156529 concentration (3 $\mu$ M) in conjunction with LY3039478 reduced the cell number more effectively than either inhibitor alone (**Figure 4E in REF II**). Conclusively, AKT pathway inhibitor NSC156529 is potentially powerful antitumor agent in liver cancer treatment and a combination therapy with Notch inhibitors may be considered when using suboptimal doses of NSC156529.

### **3. Activated growth factor signaling and increased phosphorylation of AKT in small blood vessels provide supportive environment for Dupuytren's contracture pathogenesis (REF III)**

Dupuytren's contracture (DC) is a chronic and progressive transformation of connective tissue beneath the palm skin. When the disease progresses, palmar fascia within the hand becomes abnormally thick, which severely impairs the hand functioning. DC is non-malignant, but it invades locally and has progressive and irreversible nature [299, 300]. Fibrotic lesions in DC of the palmar fascia include two distinct structures, the nodule and the cord. Histologically the Dupuytren's nodule is a vascular tissue which comprises numerous myofibroblasts (alpha smooth muscle actin expressing fibroblasts). The Dupuytren's cord has a rich connective tissue matrix containing a low density of elongated spindle-shaped fibroblasts. Although widely studied, exact pathogenic process of the disease is largely unknown. The aim of the study was to shed light into the mechanisms and potential molecular targets related to DC pathogenesis.

#### **3.1. Blood vessels in the DC contain proliferating cells and endothelial cells with activated phenotype**

It is widely accepted that uncontrolled proliferation of atypical fibroblasts and their differentiation into myofibroblasts forms the cellular basis of DC [301]. The distribution of proliferative cells in the DC tissue and in normal palmar fascia (NPF) samples was visualized by antibodies recognizing proliferation marker Ki67 and the myofibroblast marker smooth muscle actin (SMA). While the NPF samples were Ki-67-negative (**Figure S1A in Additional file 2 in REF III**), numerous Ki67-positive proliferating cells were concentrated in the surrounding area and inside of the SMA-expressing blood vessels in the DC tissue (**Figure 1A in REF III**). Co-staining of DC samples with the SMA and endothelial marker von Willebrand's factor (vWF) verified SMA-positive structures as blood vessels (**Figure S1B in Additional file 2 in REF III**). Additional co-staining with antibodies recognizing vWF, pericyte marker desmin and Ki67 revealed that vast majority of proliferating cells were located in SMA-positive muscular layer of the blood vessels (**Figure 1B and 1D in REF III**), small part of the proliferative cells was located in vWF-expressing endothelial compartment (**Figure 1C in REF III**) and no proliferative desmin-positive pericytes could be identified (**Figure 1E in REF III**). Increased number of proliferating cells near the blood vessels in the DC tissue may indicate to activated growth factor signaling in the DC-associated blood vessels. The expression of CD90 (Thy-1) and CD105 (endoglin) has been associated with the activated state of the endothelial cells in response to growth factor signaling [302, 303]. Tissue sample staining revealed that rare small blood vessels found in NPF did not contain CD105-expressing cells (**Figure S1g in Additional file**



**2 in REF III**), however, a number of CD105/CD90 double-positive cell clusters were present in DC tissue (**Figure 2A, Figure S1E in Additional file 2 in REF III**). As CD105 expression coincided with the vWF-positive endothelial cells (**Figure 2B, Figure S1f in Additional file 2 in REF III**) and SMA-expressing CD90 negative myofibroblasts surrounded the CD90-expressing endothelial compartment (**Figure 2E, Figure S1H in Additional file 2 in REF III**) we concluded that endothelium displays an activated phenotype in DC.

### **3.2. The blood vessels in DC tissue contain cells with activated AKT signaling**

Previous studies, which described protein expression profile in the diseased palmar fasciae of DC patients indicated the presence of activated AKT pathway [304]. While AKT has an essential role in cell proliferation regulation we hypothesized that AKT may contribute to the cell division in vascular/perivascular compartment of DC. Since phosphorylated AKT (pAKT) protein is the hallmark of activated AKT pathway, DC samples were stained with pAKT(Thr308) recognizing antibody to evaluate activation status of AKT protein. pAKT was present in all layers of SMA-positive blood vessels and their surrounding structures (**Figure 3A in REF III**). High level of pAKT was also detected in the acini and ducts of sweat glands (**Figure 3B in REF III**), which were surrounded by small blood vessels. AKT kinase is activated by growth factors like CTGF, bFGF and IGF-2, which have also been linked to DC pathogenesis [305-307]. Analysis of CTGF, bFGF and IGF-2 mRNA expression in NPF and DC samples revealed that the level of all three growth factors was increased in the DC samples compared to NPF (**Figure 3D-F in REF III**). DC tissue section staining with anti-CTGF antibody detected a strong signal in the K15-positive acini of the sweat glands (**Figure 3G in REF III**), while in other parts of the DC tissue, including K15-negative sweat gland ducts and blood vessels, CTGF was not expressed (**Figure 3H in REF III**). Although activated AKT was found in the acini and ducts, the cells secreting CTGF in acini were not proliferatively active (**Figure 3I in REF III**). IGF-2 expression was distributed all over the DC tissue without any preference in respect of small blood vessels (**Figure 3J-L in REF III**). Only the expression of bFGF was confined to the endothelium of the small blood vessels (**Figure 3M and 3N in REF III**) correlating with the increased number of proliferative cells in and near the blood vessels.

Since the composition of the ECM plays a critical role in the regulation of cell fate and regenerative potential [32], the presence of specific components of the ECM in the areas of DC tissue with increased proliferation was studied. Laminin subunits  $\alpha 4$ ,  $\alpha 5$ ,  $\beta 1$ ,  $\beta 2$ , and  $\gamma 1$ , which correspond to laminins 411/421 and 511/521, were enriched in the DC tissue by localizing in the myoepithelial compartment of the blood vessel wall (**Figure S2A-E in Additional file 3, Figure 4 in REF III**). These laminins are normal components of the endothelial basement membrane [22] and the high laminin content of the DC nodule was likely caused by the increased vascularization.

## DISCUSSION

Extensive biological and clinical studies during the last decades have identified signaling cascades responsible for cancer progression, maintenance and metastasis. AKT signaling pathway, which has important role in cell growth, survival and proliferation, has been found to be hyperactivated in many human cancers. In addition, activated AKT is an indicator of poor prognosis and resistance to cancer therapy. Since protein-protein interactions are responsible for transmitting oncogenic signals in pro-oncogenic pathways they have become promising therapeutic targets in cancer drug design. Thereof, specific small molecule compounds that could block protein-protein interactions in tumors possessing aberrantly activated AKT signaling pathway, would be promising tools for cancer treatment.

The purpose of the first study (REF I) was to discover small-molecule compounds with principally novel mechanism of action that would target the critical step in the AKT cascade – the interaction between AKT1 and PDPK1. We took advantage of the reversible protein complementation assay, which utilized two *Renilla* luciferase fragments and enabled to detect the interaction between two proteins in live cells [275]. The screening and following experiments identified one chemical – NSC156529 – which reduced the interaction of ectopically expressed and endogenous AKT1 and PDPK1 proteins, decreased AKT1 phosphorylation and inhibited tumor cell growth *in vitro* and *in vivo* in a tumor xenograft model. The detailed molecular mechanism of inactivation by NSC156529 is unknown, but based on our data NSC156529 interferes AKT1–PDPK1 interaction by the direct binding of the compound to PDPK1. NSC156529-treated xenografts expressed increased levels of differentiation markers, suggesting that inhibiting activity of AKT pathway at the level of AKT1–PDPK1 interaction, may possibly open up an alternative way for tumor treatment via stimulation of cell differentiation. Since poor differentiation is an important hallmark of cancer cells, novel substances that could promote tumor cells to differentiate rather than induce cell death is a promising way for cancer treatment. To date, the only successful clinical application of differentiation-based tumor therapy is used in the acute promyelocytic leukemia (APML) treatment scheme. All-trans-retinoic acid (ATRA)-based therapy induces granulocytic differentiation of APML leukemic blasts, which dramatically improves patient survival [308]. Since limited therapeutic effectiveness of conventional chemotherapy is often associated with the development of drug resistance and systemic toxicity [309], the combined therapy scheme, which consists in addition a tumor cell differentiation inducing component, could offer a possibility to reduce a drug dosage, limit the occurrence of side effects, and decrease the incidence of drug resistance [310, 311]. *In vitro* cell growth analysis confirmed that NSC156529 inhibits the proliferation of the cell lines of variable origin. Since hyperactivated AKT pathway has been found in many human tumor types [201], the potential use of this chemical should not be limited with one cancer type only. In fact, tumor xenograft assays conducted by NCI within the frame-

work of Developmental Therapeutics Program confirm, that NSC156529 inhibits also the growth of B16 melanoma cells and leukemia cell lines L1210 and P388 [312]. Although NSC156529 inhibited also the growth of normal human fibroblasts and osteoblasts *in vitro*, the cancer cell proliferation seems to be more sensitive to NSC156529 inhibition. *In vivo* subcutaneous administration of the compound was well-tolerated by the animals, since severe symptoms of irritation at the injection sites of the skin were not seen. Intraperitoneal administration of the compound caused severe irritation indicating to potential local toxicity on mucous membranes and endothelium. Because systemic administration of this compound to the blood stream was not tested, the relatively low general toxicity observed during our studies might be caused by a reduced exposure of NSC156529 to the host organism. Further toxicity studies are required to assess and resolve drug administration issues.

The potential anti-tumor effects of NSC156529 were further elaborated in **REF II**, where primary mouse liver tumor cell line K07074, which was derived from DEN-phenobarbital induced mouse liver tumor tissue, was used as a model system to test the tumor-suppressive effects of NSC156529 and other novel antitumor agents that target cancer-related pathways. Analysis of gene and protein expression demonstrated an increased activity of Notch, Hedgehog and AKT pathways in these cells. Activation of AKT and Notch pathways, has been shown to convert the hepatocytes to cholangiocyte-like cells that act as precursors of rapidly progressing ICC [313, 314]. The nuclear localization of  $\beta$ -catenin found in K07074 cells, commonly refers to the Wnt pathway activation. Nevertheless, we were unable to detect an increase in *Axin2* mRNA and found only a modest increase in Axin2 protein level. Therefore in our model system  $\beta$ -catenin nuclear localization may appear as a consequence of constitutive AKT signaling activity, which phosphorylates and deactivates GSK $\beta$ , the kinase responsible for  $\beta$ -catenin phosphorylation, cytoplasmic localization and degradation [315]. This could also be the explanation why Wnt pathway inhibitor did not have any effect on the growth of K07074 cells. p53 tumor suppressor gene inactivation or mutation is a frequent event in tumorigenesis. Accumulation of a stable mutant p53 protein is regarded as a hallmark of cancer cells [316]. In K07074 cells *trp53* gene was not mutated, but the expression of a subset of p53 target genes including Mdm2 was not activated. This could be the reason why in our experiments the inhibitor of p53-Mdm2 interaction – Nutlin3 – was not efficient on K07074 cell growth inhibition.

While the gene and protein expression analysis showed an increased activity of several pathways, only AKT and Notch inhibitors efficiently decreased the growth of K07074 cells. At higher concentrations, AKT-PDPK inhibitor NSC156529 alone was sufficient to inhibit the cancer cell growth, but at suboptimal concentrations LY3039478 and NSC156529 co-treatment was more effective than either compound alone. These results confirm the effective antitumor properties of NSC156529 as demonstrated previously by its ability to suppress the growth of human tumor cell-line xenografts in nude mice (**REF I**).

Taken together, the small molecular compound NSC156529 is a potent inhibitor of AKT1 pathway in tumor cells. NSC156529 reduces AKT activity, inhibits the activation of AKT target proteins that are involved in regulating cell survival, proliferation, and metabolism, and inhibits the growth of different tumor cells *in vitro* and *in vivo*. Since treatment with NSC156529 increased the differentiation status of cancer cells in *in vivo* xenograft treatment, this compound presents a promising lead for the development of a novel class of tumor therapeutics.

AKT signaling is not only involved in the appearance of malignancies but it may also play a role in formation of benign pathologies. Dupuytren's contracture (DC) is a chronic, progressive fibroproliferative disease of the hand, which is non-malignant but invades locally and has progressive and irreversible nature [317]. Although, uncontrolled proliferation and accumulation of contractile myofibroblasts is believed to have the central role in DC pathogenesis [301], the exact molecular mechanism of the disease is still unclear. The analysis of proliferative cell distribution in the DC tissue (**REF III**) revealed that these were concentrated in the small blood vessels or in their surrounding area, primarily in the myofibroblast layer of the blood vessel walls. Previously it has been shown that small blood vessels can act as stem cell niches in normal and malignant brain tissue [318], therefore, small blood vessels in DC might provide a favorable microenvironment for sustaining myofibroblast proliferation. In addition, proteomic studies have implicated the proliferation promoting AKT pathway in DC pathogenesis [304]. In correlation with these studies, elevated levels of phosphorylated AKT, a hallmark of activated AKT signaling, was detected in the blood vessels and sweat glands of the DC tissue. The potential AKT activating growth factors, including basic fibroblast growth factor (bFGF) in the endothelium of the blood vessels, insulin-like growth factor 2 (IGF-2) uniformly throughout the nodular tissue and connective tissue growth factor (CTGF) in sweat glands near the nodule, were also highly upregulated in DC tissue. These observations are supported by previous studies, which suggest that IGF-2 has a role in regulating cellular contractility and proliferation in DC [307] and that CTGF, a TGF- $\beta$  target gene and a potent activator of the AKT signaling pathway is implicated in the pathogenesis of fibrotic diseases including DC [304]. Li *et al.* reported that in response to FGF signaling, constitutively active AKT induces the transcription of laminin  $\beta$ 1 and collagen IV  $\alpha$ 1 isoforms and causes their translocation to the basement membrane [319]. Since in our study we found active AKT and laminin subunits  $\alpha$ 4,  $\alpha$ 5,  $\beta$ 1,  $\beta$ 2, and  $\gamma$ 1 expressed in the DC tissue, it provides additional support to the hypothesis of AKT role in DC pathogenesis. Conclusively, we proposed that small blood vessels, which contain increased expression of growth factors and favorable extracellular matrix components, form a microenvironment that supports the activation of AKT pathway and sustains the persistent myofibroblast proliferation promoting thereby the progression of DC.

## SUMMARY

Extensive biological and clinical studies during the last decades have identified signaling cascades responsible for cancer progression, maintenance and metastasis. AKT-related signaling pathway, which has important role in cell growth, survival and proliferation, has been found hyperactivated in many human cancers. In addition, activated AKT has been linked also to poor prognosis and resistance to cancer therapy. Since protein-protein interactions in tumorigenesis promoting pathways are responsible for transmitting oncogenic signals, they have become promising therapeutic targets in cancer drug design. Thereof, specific small molecule compounds that could target protein-protein interactions in tumors possessing aberrantly activated signaling pathways, would be promising tools in cancer treatment.

Small molecule library screen utilizing a *Renilla* luciferase protein complementation assay (PCA)-based approach, which was aimed to discover AKT1 and PDPK1 interaction inhibitors, identified one compound – NSC156529 – that interacted preferentially with PDPK1, inhibited AKT1 phosphorylation and suppressed AKT-mediated signal transduction to several AKT1 substrates. The discovered compound efficiently decreased the proliferation of human cancer cells *in vitro* and inhibited tumor growth in a prostate tumor xenograft model *in vivo*. In addition to the reduction in the mitotic activity in NSC156529-treated tumors, the tumor cells exhibited a significant increase in the expression of prostate differentiation markers, suggesting that the inhibition of tumor growth was achieved at least in part through enhanced differentiation of tumor cells toward prostate epithelium. In the study with primary mouse liver tumor cell line, the AKT-PDPK interaction inhibitor NSC156529 and the Notch pathway inhibitor LY3039478, significantly reduced the growth of K07074 cells. Although gene and protein expression analysis suggested the presence of activated Hedgehog, Wnt and p53-related pathways, the inhibitors targeting these pathways had little or no effect on K07074 cell growth. In addition, no additive effect to NSC156529 could be seen when the cells were co-treated with the pathway inhibitors suggesting that the disruption of AKT-PDPK interaction is sufficient to inhibit the growth of primary liver tumor cells.

Dupuytren contracture sample analysis showed that proliferative cells in DC nodules localized in the vicinity of small blood vessels, predominantly in the myofibroblast layer. The small blood vessels also contained increased levels of phosphorylated AKT, which is a hallmark of activated growth factor signaling. Respectively, expression of potential activators of AKT signaling, such as bFGF, IGF and CTGF, was detected in DC samples. bFGF was expressed in the endothelium of the small blood vessels, IGF-2 was present uniformly in the DC tissue, and CTGF expressed in the DC-associated sweat gland acini. The blood vessels in DC nodules contained also increased amounts of laminins 511 and 521, which have been previously shown to promote the proliferation and stem cell properties of different cell types. Conclusively, DC-associated small blood

vessels, with the presence of growth factors and subsequent AKT activation in combination with extracellular matrix components, provide a supportive environment for myofibroblast proliferation and play an important role in DC pathogenesis.

Taken together, the results presented in current thesis demonstrate that targeting AKT related signaling pathway in cancer cells is effective way to suppress the growth of cancerous cells. The small molecular compound NSC156529 is a potent inhibitor of AKT1 signaling pathway, which reduces AKT activity, inhibits the activation of AKT target proteins that are involved in regulating cell survival, proliferation, and metabolism, and inhibits the growth of tumor cells *in vitro* and *in vivo*. NSC156529 is powerful antitumor agent in monotherapy, which can also be used at lower doses in combined therapy. Since the treatment with NSC156529 increases the differentiation status of cancer cells, this compound has an advantage for the development of a novel class of tumor therapeutics. In addition, we found that the activated AKT signaling might promote the progression of benign hyperproliferative pathology – the Dupuytren’s contracture.

## SUMMARY IN ESTONIAN

### Rakkude paljunemist soodustav AKT signaalirada kui potentsiaalne kasvavastase ravi sihtmärk

Rakud võtavad väliskeskkonnast vastu mitmesuguseid signaale, näiteks hormoonide, kasvufaktorite ja tsütokiinide vahendusel, mis antakse edasi mööda signaaliülekanne radasid, mõjutades seeläbi nende rakkude paljunemist, eluiga ja metabolismiga seotud protsesse ning diferentseerumist. Rakkude jagunemine ja suremine on rangelt kontrollitud sündmused, millega tagatakse organismi normaalne funktsioneerimine ja kahjustatud rakkude asendamine uutega. Aja jooksul, rakkude vananedes või kokkupuutel kahjulike ühenditega võivad raku DNAsse tekkida mutatsioonid, mis omakorda põhjustavad muutusi raku normaalsel elutsükli toetavates olulistel signaaliradades. Kasvajarakkude piiramatul kasvul on väga sageli seotud mutatsioonidega just onkogeenides, mis tekitab nende liigset aktiivsust, ja tuumor-supressor valkudes, mis tingib nende geenide väljalülitumise. Vähhkasvaja areng on mitmeastmeline protsess, milles põhiroll on valk-valk interaktsioonidel kindlates signaaliradades. Seetõttu on kriitilise tähtsusega signaaliülekanne kaskaadides olevad valk-valk interaktsioonid perspektiivikaks sihtmärgiks potentsiaalsete kasvavastaste terapeutiliste vahendite väljatöötamisel.

AKT kinaas on seriin/treoniinkinaas, mida kirjeldati esmakordselt umbes 25 aastat tagasi. Praeguseks on selge, et AKT kinaasiga seotud signaalirajal on keskne roll normaalsel rakkude füsioloogilistel protsessidel nagu näiteks rakkude elulemus, rakutsükli edenemine, metabolism, transkriptsioon, valgusüntees, rakkude liikuvus jne. Samal ajal on kontrollimatult aktiivset PI3K/AKT signaalirada kirjeldatud väga paljudes inimese tuumorites nagu näiteks maksa-, aju-, rinna-, soole ja eesnäärme kasvavastates. Lisaks sellele on leitud, et AKT signaalirada on seotud ka kemoterapia käigus tekkivate resistentsusmehhanismidega ja üldiselt peetakse AKT aktiivsust mõnede kasvavastaste puhul halva prognoosi markeriks. AKT kinaasi keskse rolli tõttu olulistel raku elutsükli protsessides ja tema liigse aktiivsuse tõttu kasvavastates peetakse AKT valguga seotud signaalirada heaks märklauaks kasvavastaste terapeutiliste vahendite väljatöötamisel. Praeguseks on avastatud ja kliinilistesse katsetustesse võetud juba mitmeid AKT signaaliraja inhibiitoreid, kuid paraku on tugevad mittespetsiifilised kõrvaltoimed ja toksilisus takistanud nende edasise kasutamise raviskeemides.

Käesoleva doktoritöö esimese osa põhieesmärk oli leida AKT signaaliraja aktiivsust pärssivaid inhibiitoreid, mida võiks kasutada potentsiaalsete kasvavastaste ravimitena. Otsitavate inhibiitorite täpsem märklaud oli AKT1 ja PDPK1 valkude omavaheline interaktsioon, mille käigus PDPK1 fosforüleerib AKT1 valgusünteesi – esimene etapp, mis on vajalik AKT1 aktiveerimiseks. Väikesemolekulaarsete ainete skriinimiseks kasutati *Renilla* lutsiferaasi valgusünteesi komplementaarsusel põhinevat lähenemisviisi. Skriinimine ning sellele järgnenud erinevatest meetoditest koosnenud valideerimisprotsess tuvastas ühe kemikaali – NSC156529 – mis pidurdas erinevat päritolu kasvavastaste paljunemist nii koekultuuri

tingimustes kui *in vivo* hiire kasvjamudel. Tuumorirakkude töötlemine NSC156529 kemikaaliga mõjutas lisaks AKT kinaasi enda aktiivsusele ka AKT signaalirajas allpool asuvate märklaudvalkude aktiivsust, viidates sellele, et antud kemikaal mõjutab AKT toimet laiemalt. *In vivo* kasvjamudelitest eraldatud tuumorite analüüsimisel tuvastati, et NSC156529 kemikaaliga töödeldud kasvajatel oli suurenenud rakkude diferentseerumisele viitavate markerite (tsütokeratiin 8 ja 18) ekspressioon, millest järeldub, et lisaks suudab NSC156529 tuumorirakkude paljunemist pärssida neid diferentseeruma suunates. Käesoleva töö teises osas testiti NSC156529 ühendit koos teiste potentsiaalsete kasvajaspetsiifilisi signaale pärssivate kemikaalidega hiire primaarse maksakasvaja rakuliinis K07074. See mudelsüsteem peegeldab paremini kui püsirakuliinid maksakasvajatel esinevaid signaaliradade aktiivsuse muutusi. Kuigi geeni- ja valguekspressiooni analüüs viitas ka selliste signaaliradade nagu Notch, Wnt, Hedgehog ja p53 aktiivsusele, leiti et NSC156529 on üksinda piisavalt efektiivne kasvajarakkude proliferatsiooni inhibeerimisel. Ainult tingimustes, kus NSC156529 inhibiitorit kasutati madalates kontsentratsioonides, andis Notch inhibiitori ja NSC156529 koos kasutamine rakkude kasvu pidurdamisele tugevama efekti.

Dupuytreni kontraktuur (DK) on pihukilekõõluse (palmaaraponeuroosi) paksenemisega kaasnev sõrme liikuvuse piiratus. Koe tasandil iseloomustab seda haigust atüüpiliste müofibroblastide kontrollimatu proliferatsioon. Kuna praeguseni on DK täpne molekulaarne mehhanism ebaselge, siis oli käesoleva töö kolmanda osa eesmärk kirjeldada täpsemalt paljunevate rakkude asukohta DK koes ja selgitada võimalikke selle haiguse tekkimise mehhanisme. DK koe analüüsimisel leiti, et aktiivselt jagunevad rakud on koondunud veresoonte lähedusse, peaaegalt neid ümbritsevasse silelihaskihti. Samal ajal oli võrreldes normaalse koega DK koe veresoontes ja higinäärmetes suurenenud fosforüleeritud AKT valgu hulk, mis võis olla tingitud sellest, et DK koes oli suurenenud ka potentsiaalsete AKT signaalirada aktiveerivate kasvufaktorite nagu bFGF, IGF ja CTGF tase. Lisaks sisaldasid DK koe veresooned suuremal hulgal laminiine 511 ja 521, mida on varasemalt seostatud rakkude tõusnud proliferatsiooniga ja tüvirakuliste omadustega. Varasemalt on näidatud, et vastuseks FGF stimulatsioonile indutseerib aktiivne AKT kinaas laminiin  $\beta 1$  ja kollageen IV  $\alpha 1$  isotüüpide transkriptsiooni. Seega viitavad antud töö tulemused sellele, et DK väikesed veresooned koos suurenenud kasvufaktorite ekspressiooni ja aktiivse AKT valgu tasemega loovad soodsa keskkonna müofibroblastide paljunemiseks ning DK haiguse edenemiseks.

Kokkuvõtvalt, antud töös esitatud tulemused kinnitavad, et AKT kinaasiga seotud signaalirada on oluline märklaud kasvajakasvatuste ravimite väljatöötamisel. Kuna leitud AKT1-PDPK1 interaktsiooni inhibiitor NSC156529 on efektiivne kasvajarakkude kasvu pärssimisel nii *in vitro* koekultuuri tingimustes kui *in vivo* hiire tuumori mudelis ning lisaks on NSC156529 kemikaalil rakkude diferentseerumist soodustav toime, siis võiks antud ühendit kasutada potentsiaalse vähi-vastase ravimi väljatöötamisel. Lisaks näitasime, et aktiveeritud AKT signaalirada osaleb healoomulise hüperproliferatiivse patoloogia – Dupuytreni kontraktuuri – arengus.



## REFERENCES

- [1] M. Hanada, J. Feng, B.A. Hemmings, Structure, regulation and function of PKB/AKT – a major therapeutic target, *Biochimica et Biophysica Acta (BBA) – Proteins and Proteomics*, 1697 (2004) 3–16.
- [2] P.J. Coffey, J.R. Woodgett, Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families, *European journal of biochemistry / FEBS*, 201 (1991) 475–481.
- [3] P.F. Jones, T. Jakubowicz, B.A. Hemmings, Molecular cloning of a second form of rac protein kinase, *Cell Regulation*, 2 (1991) 1001–1009.
- [4] S.P. Staal, Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma, *Proc Natl Acad Sci U S A*, 84 (1987).
- [5] S.P. Staal, J.W. Hartley, W.P. Rowe, Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma, *Proc Natl Acad Sci U S A*, 74 (1977) 3065–3067.
- [6] A. Bellacosa, J.R. Testa, S.P. Staal, P.N. Tsichlis, A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region, *Science (New York, N.Y.)*, 254 (1991) 274–277.
- [7] S.S. Murthy, A. Tosolini, T. Taguchi, J.R. Testa, Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization, *Cytogenetics and cell genetics*, 88 (2000) 38–40.
- [8] B. Dummler, B.A. Hemmings, Physiological roles of PKB/Akt isoforms in development and disease, *Biochem Soc Trans*, 35 (2007) 231–235.
- [9] S.A. Santi, A.C. Douglas, H. Lee, The Akt isoforms, their unique functions and potential as anticancer therapeutic targets, *Biomolecular concepts*, 1 (2010) 389–401.
- [10] J. LaRocca, J. Pietruska, M. Hixon, Akt1 is essential for postnatal mammary gland development, function, and the expression of Btn1a1, *PLoS One*, 6 (2011) e24432.
- [11] H. Cho, J.L. Thorvaldsen, Q. Chu, F. Feng, M.J. Birnbaum, Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice, *The Journal of biological chemistry*, 276 (2001) 38349–38352.
- [12] P. Fischer-Posovszky, D. Tews, S. Horenburg, K.M. Debatin, M. Wabitsch, Differential function of Akt1 and Akt2 in human adipocytes, *Molecular and cellular endocrinology*, 358 (2012) 135–143.
- [13] R.M. Easton, H. Cho, K. Roovers, D.W. Shineman, M. Mizrahi, M.S. Forman, V.M. Lee, M. Szabolcs, R. de Jong, T. Oltersdorf, T. Ludwig, A. Efstratiadis, M.J. Birnbaum, Role for Akt3/protein kinase Bgamma in attainment of normal brain size, *Molecular and cellular biology*, 25 (2005) 1869–1878.
- [14] P.J. Coffey, J.R. Woodgett, Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families, *European journal of biochemistry / FEBS*, 205 (1992) 1217.
- [15] A. Bellacosa, T.F. Franke, M.E. Gonzalez-Portal, K. Datta, T. Taguchi, J. Gardner, J.Q. Cheng, J.R. Testa, P.N. Tsichlis, Structure, expression and chromosomal mapping of c-akt: relationship to v-akt and its implications, *Oncogene*, 8 (1993) 745–754.

- [16] M.R. Calera, C. Martinez, H. Liu, A.K. Jack, M.J. Birnbaum, P.F. Pilch, Insulin increases the association of Akt-2 with Glut4-containing vesicles, *The Journal of biological chemistry*, 273 (1998) 7201–7204.
- [17] M.R. Calera, P.F. Pilch, Induction of Akt-2 correlates with differentiation in Sol8 muscle cells, *Biochemical and biophysical research communications*, 251 (1998) 835–841.
- [18] M.M. Hill, S.F. Clark, D.F. Tucker, M.J. Birnbaum, D.E. James, S.L. Macaulay, A role for protein kinase Bbeta/Akt2 in insulin-stimulated GLUT4 translocation in adipocytes, *Molecular and cellular biology*, 19 (1999) 7771–7781.
- [19] S.A. Summers, V.P. Yin, E.L. Whiteman, L.A. Garza, H. Cho, R.L. Tuttle, M.J. Birnbaum, Signaling pathways mediating insulin-stimulated glucose transport, *Annals of the New York Academy of Sciences*, 892 (1999) 169–186.
- [20] K. Nakatani, D.A. Thompson, A. Barthel, H. Sakaue, W. Liu, R.J. Weigel, R.A. Roth, Up-regulation of Akt3 in estrogen receptor-deficient breast cancers and androgen-independent prostate cancer lines, *The Journal of biological chemistry*, 274 (1999).
- [21] W.S. Chen, P.Z. Xu, K. Gottlob, M.L. Chen, K. Sokol, T. Shiyanova, I. Roninson, W. Weng, R. Suzuki, K. Tobe, T. Kadowaki, N. Hay, Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene, *Genes & development*, 15 (2001) 2203–2208.
- [22] Z.Z. Yang, O. Tschopp, M. Hemmings-Mieszczak, J. Feng, D. Brodbeck, E. Perentes, B.A. Hemmings, Protein kinase B alpha/Akt1 regulates placental development and fetal growth, *The Journal of biological chemistry*, 278 (2003) 32124–32131.
- [23] F. Buzzi, L. Xu, R.A. Zuellig, S.B. Boller, G.A. Spinaz, D. Hynx, Z. Chang, Z. Yang, B.A. Hemmings, O. Tschopp, M. Niessen, Differential effects of protein kinase B/Akt isoforms on glucose homeostasis and islet mass, *Molecular and cellular biology*, 30 (2010) 601–612.
- [24] M. Wan, R.M. Easton, C.E. Gleason, B.R. Monks, K. Ueki, C.R. Kahn, M.J. Birnbaum, Loss of Akt1 in mice increases energy expenditure and protects against diet-induced obesity, *Molecular and cellular biology*, 32 (2012) 96–106.
- [25] H. Cho, J. Mu, J.K. Kim, J.L. Thorvaldsen, Q. Chu, E.B. Crenshaw, 3rd, K.H. Kaestner, M.S. Bartolomei, G.I. Shulman, M.J. Birnbaum, Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta), *Science (New York, N.Y.)*, 292 (2001) 1728–1731.
- [26] R.S. Garofalo, S.J. Orena, K. Rafidi, A.J. Torchia, J.L. Stock, A.L. Hildebrandt, T. Coskran, S.C. Black, D.J. Brees, J.R. Wicks, Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta, *J Clin Invest*, 112 (2003).
- [27] O. Tschopp, Z.Z. Yang, D. Brodbeck, B.A. Dummmler, M. Hemmings-Mieszczak, T. Watanabe, T. Michaelis, J. Frahm, B.A. Hemmings, Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis, *Development (Cambridge, England)*, 132 (2005) 2943–2954.
- [28] Z.Z. Yang, O. Tschopp, N. Di-Poi, E. Bruder, A. Baudry, B. Dummmler, W. Wahli, B.A. Hemmings, Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice, *Molecular and cellular biology*, 25 (2005) 10407–10418.

- [29] X.D. Peng, P.Z. Xu, M.L. Chen, A. Hahn-Windgassen, J. Skeen, J. Jacobs, D. Sundararajan, W.S. Chen, S.E. Crawford, K.G. Coleman, N. Hay, Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2, *Genes & development*, 17 (2003) 1352–1365.
- [30] T.F. Franke, D.R. Kaplan, L.C. Cantley, A. Toker, Direct Regulation of the Akt Proto-Oncogene Product by Phosphatidylinositol-3,4-bisphosphate, *Science* (New York, N.Y.), 275 (1997) 665–668.
- [31] R.T. Peterson, S.L. Schreiber, Kinase phosphorylation: Keeping it all in the family, *Current biology : CB*, 9 (1999) R521–524.
- [32] D.R. Alessi, M. Andjelkovic, B. Caudwell, P. Cron, N. Morrice, P. Cohen, B.A. Hemmings, Mechanism of activation of protein kinase B by insulin and IGF-1, *The EMBO journal*, 15 (1996) 6541–6551.
- [33] M. Andjelkovic, D.R. Alessi, R. Meier, A. Fernandez, N.J. Lamb, M. Frech, P. Cron, P. Cohen, J.M. Lucocq, B.A. Hemmings, Role of translocation in the activation and function of protein kinase B, *The Journal of biological chemistry*, 272 (1997) 31515–31524.
- [34] D. Brodbeck, M.M. Hill, B.A. Hemmings, Two splice variants of protein kinase B gamma have different regulatory capacity depending on the presence or absence of the regulatory phosphorylation site serine 472 in the carboxyl-terminal hydrophobic domain, *The Journal of biological chemistry*, 276 (2001) 29550–29558.
- [35] H. Konishi, S. Kuroda, M. Tanaka, H. Matsuzaki, Y. Ono, K. Kameyama, T. Haga, U. Kikkawa, Molecular cloning and characterization of a new member of the RAC protein kinase family: association of the pleckstrin homology domain of three types of RAC protein kinase with protein kinase C subspecies and beta gamma subunits of G proteins, *Biochemical and biophysical research communications*, 216 (1995) 526–534.
- [36] D.P. Brazil, B.A. Hemmings, Ten years of protein kinase B signalling: a hard Akt to follow, *Trends Biochem Sci*, 26 (2001) 657–664.
- [37] B. Vanhaesebroeck, S.J. Leever, K. Ahmadi, J. Timms, R. Katso, P.C. Driscoll, R. Woscholski, P.J. Parker, M.D. Waterfield, Synthesis and function of 3-phosphorylated inositol lipids, *Annual review of biochemistry*, 70 (2001) 535–602.
- [38] M.A. Lemmon, K.M. Ferguson, Signal-dependent membrane targeting by pleckstrin homology (PH) domains, *The Biochemical journal*, 350 Pt 1 (2000) 1–18.
- [39] A.C. Dittrich, T.P. Devarenne, Perspectives in PDK1 evolution: insights from photosynthetic and non-photosynthetic organisms, *Plant signaling & behavior*, 7 (2012) 642–649.
- [40] D.R. Alessi, M. Deak, A. Casamayor, F.B. Caudwell, N. Morrice, D.G. Norman, P. Gaffney, C.B. Reese, C.N. MacDougall, D. Harbison, A. Ashworth, M. Bownes, 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the *Drosophila* DSTPK61 kinase, *Current biology : CB*, 7 (1997) 776–789.
- [41] A. Casamayor, N.A. Morrice, D.R. Alessi, Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo, *The Biochemical journal*, 342 ( Pt 2) (1999) 287–292.

- [42] R.M. Biondi, A. Kieloch, R.A. Currie, M. Deak, D.R. Alessi, The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB, *The EMBO journal*, 20 (2001) 4380–4390.
- [43] P.A. Gagliardi, L. di Blasio, A. Puliafito, G. Seano, R. Sessa, F. Chianale, T. Leung, F. Bussolino, L. Primo, PDK1-mediated activation of MRCK $\alpha$  regulates directional cell migration and lamellipodia retraction, *The Journal of cell biology*, 206 (2014) 415–434.
- [44] M.A. Lim, C.K. Kikani, M.J. Wick, L.Q. Dong, Nuclear translocation of 3'-phosphoinositide-dependent protein kinase 1 (PDK-1): a potential regulatory mechanism for PDK-1 function, *Proc Natl Acad Sci U S A*, 100 (2003) 14006–14011.
- [45] M.P. Scheid, M. Parsons, J.R. Woodgett, Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation, *Molecular and cellular biology*, 25 (2005) 2347–2363.
- [46] L.R. Pearce, D. Komander, D.R. Alessi, The nuts and bolts of AGC protein kinases, *Nature reviews. Molecular cell biology*, 11 (2010) 9–22.
- [47] S.R. James, C.P. Downes, R. Gigg, S.J. Grove, A.B. Holmes, D.R. Alessi, Specific binding of the Akt-1 protein kinase to phosphatidylinositol 3,4,5-trisphosphate without subsequent activation, *The Biochemical journal*, 315 ( Pt 3) (1996) 709–713.
- [48] V. Calleja, D. Alcor, M. Laguerre, J. Park, B. Vojnovic, B.A. Hemmings, J. Downward, P.J. Parker, B. Larijani, Intramolecular and intermolecular interactions of protein kinase B define its activation in vivo, *PLoS biology*, 5 (2007) e95.
- [49] P.B. Dennis, N. Pullen, R.B. Pearson, S.C. Kozma, G. Thomas, Phosphorylation sites in the autoinhibitory domain participate in p70(s6k) activation loop phosphorylation, *The Journal of biological chemistry*, 273 (1998) 14845–14852.
- [50] T. Kobayashi, P. Cohen, Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2, *The Biochemical journal*, 339 ( Pt 2) (1999) 319–328.
- [51] C.J. Jensen, M.B. Buch, T.O. Krag, B.A. Hemmings, S. Gammeltoft, M. Frodin, 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1, *The Journal of biological chemistry*, 274 (1999) 27168–27176.
- [52] J.A. Le Good, W.H. Ziegler, D.B. Parekh, D.R. Alessi, P. Cohen, P.J. Parker, Protein kinase C isoforms controlled by phosphoinositide 3-kinase through the protein kinase PDK1, *Science (New York, N.Y.)*, 281 (1998) 2042–2045.
- [53] R.M. Biondi, A. Kieloch, R.A. Currie, M. Deak, D.R. Alessi, The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB, *The EMBO journal*, 20 (2001) 4380–4390.
- [54] S. Pinner, E. Sahai, PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE, *Nature cell biology*, 10 (2008) 127–137.
- [55] C. Raimondi, A. Chikh, A.P. Wheeler, T. Maffucci, M. Falasca, A novel regulatory mechanism links PLC $\gamma$ 1 to PDK1, *J Cell Sci*, 125 (2012) 3153–3163.
- [56] R.I. Kirk, M.R. Sanderson, K.M. Lerea, Threonine phosphorylation of the  $\beta$ 3 integrin cytoplasmic tail, at a site recognized by PDK1 and Akt/PKB in vitro, regulates Shc binding, *The Journal of biological chemistry*, 275 (2000) 30901–30906.

- [57] L. di Blasio, P.A. Gagliardi, A. Puliafito, R. Sessa, G. Seano, F. Bussolino, L. Primo, PDK1 regulates focal adhesion disassembly by modulating endocytosis of alphavbeta3 integrin, *J Cell Sci*, 128 (2015) 863–877.
- [58] T. Yamada, H. Katagiri, T. Asano, M. Tsuru, K. Inukai, H. Ono, T. Kodama, M. Kikuchi, Y. Oka, Role of PDK1 in insulin-signaling pathway for glucose metabolism in 3T3-L1 adipocytes, *American journal of physiology. Endocrinology and metabolism*, 282 (2002) E1385–1394.
- [59] M.A. Lawlor, A. Mora, P.R. Ashby, M.R. Williams, V. Murray-Tait, L. Malone, A.R. Prescott, J.M. Lucocq, D.R. Alessi, Essential role of PDK1 in regulating cell size and development in mice, *The EMBO journal*, 21 (2002) 3728–3738.
- [60] Q. Feng, R. Di, F. Tao, Z. Chang, S. Lu, W. Fan, C. Shan, X. Li, Z. Yang, PDK1 regulates vascular remodeling and promotes epithelial-mesenchymal transition in cardiac development, *Molecular and cellular biology*, 30 (2010) 3711–3721.
- [61] T. Zurashvili, L. Cordon-Barris, G. Ruiz-Babot, X. Zhou, J.M. Lizcano, N. Gomez, L. Gimenez-Llort, J.R. Bayascas, Interaction of PDK1 with phosphoinositides is essential for neuronal differentiation but dispensable for neuronal survival, *Molecular and cellular biology*, 33 (2013) 1027–1040.
- [62] M. Pietri, C. Dakowski, S. Hannaoui, A. Alleaume-Butaux, J. Hernandez-Rapp, A. Ragagnin, S. Mouillet-Richard, S. Haik, Y. Bailly, J.M. Peyrin, J.M. Launay, O. Kellermann, B. Schneider, PDK1 decreases TACE-mediated alpha-secretase activity and promotes disease progression in prion and Alzheimer’s diseases, *Nat Med*, 19 (2013) 1124–1131.
- [63] N. Hashimoto, Y. Kido, T. Uchida, S. Asahara, Y. Shigeyama, T. Matsuda, A. Takeda, D. Tsuchihashi, A. Nishizawa, W. Ogawa, Y. Fujimoto, H. Okamura, K.C. Arden, P.L. Herrera, T. Noda, M. Kasuga, Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass, *Nature genetics*, 38 (2006) 589–593.
- [64] M. Maurer, T. Su, L.H. Saal, S. Koujak, B.D. Hopkins, C.R. Barkley, J. Wu, S. Nandula, B. Dutta, Y. Xie, Y.R. Chin, D.I. Kim, J.S. Ferris, S.K. Gruberger-Saal, M. Laakso, X. Wang, L. Memeo, A. Rojzman, T. Matos, J.S. Yu, C. Cordon-Cardo, J. Isola, M.B. Terry, A. Toker, G.B. Mills, J.J. Zhao, V.V. Murty, H. Hibshoosh, R. Parsons, 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma, *Cancer research*, 69 (2009) 6299–6306.
- [65] K.A. Choucair, K.P. Guerard, J. Ejdelman, S. Chevalier, M. Yoshimoto, E. Scarlata, L. Fazli, K. Sircar, J.A. Squire, F. Brimo, I.W. Cunha, A. Aprikian, M. Gleave, J. Lapointe, The 16p13.3 (PDPK1) Genomic Gain in Prostate Cancer: A Potential Role in Disease Progression, *Translational oncology*, 5 (2012) 453–460.
- [66] D.D. Sarbassov, D.A. Guertin, S.M. Ali, D.M. Sabatini, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex, *Science (New York, N.Y.)*, 307 (2005) 1098–1101.
- [67] J. Yang, P. Cron, V. Thompson, V.M. Good, D. Hess, B.A. Hemmings, D. Barford, Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation, *Molecular cell*, 9 (2002) 1227–1240.
- [68] A. Balendran, R. Currie, C.G. Armstrong, J. Avruch, D.R. Alessi, Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252, *The Journal of biological chemistry*, 274 (1999) 37400–37406.

- [69] S. Persad, S. Attwell, V. Gray, N. Mawji, J.T. Deng, D. Leung, J. Yan, J. Sanghera, M.P. Walsh, S. Dedhar, Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343, *The Journal of biological chemistry*, 276 (2001) 27462–27469.
- [70] A. Toker, A.C. Newton, Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site, *The Journal of biological chemistry*, 275 (2000) 8271–8274.
- [71] Y. Kawakami, H. Nishimoto, J. Kitaura, M. Maeda-Yamamoto, R.M. Kato, D.R. Littman, M. Leitges, D.J. Rawlings, T. Kawakami, Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion, *The Journal of biological chemistry*, 279 (2004) 47720–47725.
- [72] J. Feng, J. Park, P. Cron, D. Hess, B.A. Hemmings, Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase, *The Journal of biological chemistry*, 279 (2004) 41189–41196.
- [73] J.G. Viniegra, N. Martinez, P. Modirassari, J. Hernandez Losa, C. Parada Cobo, V.J. Sanchez-Arevalo Lobo, C.I. Aceves Luquero, L. Alvarez-Vallina, S. Ramon y Cajal, J.M. Rojas, R. Sanchez-Prieto, Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM, *The Journal of biological chemistry*, 280 (2005) 4029–4036.
- [74] E.K. Kim, S.J. Yun, J.M. Ha, Y.W. Kim, I.H. Jin, J. Yun, H.K. Shin, S.H. Song, J.H. Kim, J.S. Lee, C.D. Kim, S.S. Bae, Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis, *Oncogene*, 30 (2011) 2954–2963.
- [75] M. Laplante, D.M. Sabatini, mTOR signaling in growth control and disease, *Cell*, 149 (2012) 274–293.
- [76] M. Laplante, D.M. Sabatini, mTOR Signaling, *Cold Spring Harbor perspectives in biology*, 4 (2012).
- [77] M.A. Frias, C.C. Thoreen, J.D. Jaffe, W. Schroder, T. Sculley, S.A. Carr, D.M. Sabatini, mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s, *Current biology : CB*, 16 (2006) 1865–1870.
- [78] E. Jacinto, V. Facchinetti, D. Liu, N. Soto, S. Wei, S.Y. Jung, Q. Huang, J. Qin, B. Su, SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity, *Cell*, 127 (2006) 125–137.
- [79] D.A. Guertin, D.M. Stevens, C.C. Thoreen, A.A. Burds, N.Y. Kalaany, J. Moffat, M. Brown, K.J. Fitzgerald, D.M. Sabatini, Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1, *Developmental cell*, 11 (2006) 859–871.
- [80] T.R. Peterson, M. Laplante, C.C. Thoreen, Y. Sancak, S.A. Kang, W.M. Kuehl, N.S. Gray, D.M. Sabatini, DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival, *Cell*, 137 (2009) 873–886.
- [81] T. Ikenoue, K. Inoki, Q. Yang, X. Zhou, K.L. Guan, Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling, *The EMBO journal*, 27 (2008) 1919–1931.
- [82] G. Risso, M. Blaustein, B. Pozzi, P. Mammi, A. Srebrow, Akt/PKB: one kinase, many modifications, *The Biochemical journal*, 468 (2015) 203–214.

- [83] Y. Liao, M.C. Hung, Physiological regulation of Akt activity and stability, *American journal of translational research*, 2 (2010) 19–42.
- [84] A. Bellacosa, T.O. Chan, N.N. Ahmed, K. Datta, S. Malstrom, D. Stokoe, F. McCormick, J. Feng, P. Tsichlis, Akt activation by growth factors is a multiple-step process: the role of the PH domain, *Oncogene*, 17 (1998) 313–325.
- [85] G. Di Maira, M. Salvi, G. Arrighoni, O. Marin, S. Sarno, F. Brustolon, L.A. Pinna, M. Ruzzene, Protein kinase CK2 phosphorylates and upregulates Akt/PKB, *Cell death and differentiation*, 12 (2005) 668–677.
- [86] M.F. Gulen, K. Bulek, H. Xiao, M. Yu, J. Gao, L. Sun, E. Beurel, O. Kaidanovich-Beilin, P.L. Fox, P.E. DiCorleto, J.A. Wang, J. Qin, D.N. Wald, J.R. Woodgett, R.S. Jope, J. Carman, A. Dongre, X. Li, Inactivation of the enzyme GSK3 $\alpha$  by the kinase IKK $\beta$  promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenance, *Immunity*, 37 (2012) 800–812.
- [87] D.R. Alessi, L.R. Pearce, J.M. Garcia-Martinez, New insights into mTOR signaling: mTORC2 and beyond, *Science signaling*, 2 (2009) pe27.
- [88] T.O. Chan, P.N. Tsichlis, PDK2: a complex tail in one Akt, *Science's STKE : signal transduction knowledge environment*, 2001 (2001) pe1.
- [89] V. Facchinetti, W. Ouyang, H. Wei, N. Soto, A. Lazorchak, C. Gould, C. Lowry, A.C. Newton, Y. Mao, R.Q. Miao, W.C. Sessa, J. Qin, P. Zhang, B. Su, E. Jacinto, The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C, *The EMBO journal*, 27 (2008) 1932–1943.
- [90] P. Liu, M. Begley, W. Michowski, H. Inuzuka, M. Ginzberg, D. Gao, P. Tsou, W. Gan, A. Papa, B.M. Kim, L. Wan, A. Singh, B. Zhai, M. Yuan, Z. Wang, S.P. Gygi, T.H. Lee, K.P. Lu, A. Toker, P.P. Pandolfi, J.M. Asara, M.W. Kirschner, P. Sicinski, L. Cantley, W. Wei, Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus, *Nature*, 508 (2014) 541–545.
- [91] K. Mahajan, D. Coppola, S. Challa, B. Fang, Y.A. Chen, W. Zhu, A.S. Lopez, J. Koomen, R.W. Engelman, C. Rivera, R.S. Muraoka-Cook, J.Q. Cheng, E. Schonbrunn, S.M. Sebt, H.S. Earp, N.P. Mahajan, Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation, *PLoS One*, 5 (2010) e9646.
- [92] R. Chen, O. Kim, J. Yang, K. Sato, K.M. Eisenmann, J. McCarthy, H. Chen, Y. Qiu, Regulation of Akt/PKB activation by tyrosine phosphorylation, *The Journal of biological chemistry*, 276 (2001) 31858–31862.
- [93] Y. Zheng, M. Peng, Z. Wang, J.M. Asara, A.L. Tyner, Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor, *Molecular and cellular biology*, 30 (2010) 4280–4292.
- [94] N.M. Conus, K.M. Hannan, B.E. Cristiano, B.A. Hemmings, R.B. Pearson, Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase, *The Journal of biological chemistry*, 277 (2002) 38021–38028.
- [95] L.C. Cantley, B.G. Neel, New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway, *Proc Natl Acad Sci U S A*, 96 (1999) 4240–4245.
- [96] T. Maehama, J.E. Dixon, The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate, *The Journal of biological chemistry*, 273 (1998) 13375–13378.

- [97] C. Bassi, J. Ho, T. Srikumar, R.J. Dowling, C. Gorrini, S.J. Miller, T.W. Mak, B.G. Neel, B. Raught, V. Stambolic, Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress, *Science (New York, N.Y.)*, 341 (2013) 395–399.
- [98] J. Brognard, E. Sierrecki, T. Gao, A.C. Newton, PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms, *Molecular cell*, 25 (2007) 917–931.
- [99] M. Chen, C.P. Pratt, M.E. Zeeman, N. Schultz, B.S. Taylor, A. O’Neill, M. Castillo-Martin, D.G. Nowak, A. Naguib, D.M. Grace, J. Murn, N. Navin, G.S. Atwal, C. Sander, W.L. Gerald, C. Cordon-Cardo, A.C. Newton, B.S. Carver, L.C. Trotman, Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression, *Cancer cell*, 20 (2011) 173–186.
- [100] R. Meier, M. Thelen, B.A. Hemmings, Inactivation and dephosphorylation of protein kinase B $\alpha$  (PKB $\alpha$ ) promoted by hyperosmotic stress, *The EMBO journal*, 17 (1998) 7294–7303.
- [101] D.P. Brazil, Z.Z. Yang, B.A. Hemmings, Advances in protein kinase B signalling: AKTion on multiple fronts, *Trends Biochem Sci*, 29 (2004) 233–242.
- [102] B.D. Manning, L.C. Cantley, AKT/PKB signaling: navigating downstream, *Cell*, 129 (2007) 1261–1274.
- [103] A. Toker, S. Marmiroli, Signaling specificity in the Akt pathway in biology and disease, *Advances in biological regulation*, 55 (2014) 28–38.
- [104] S.A. Santi, H. Lee, The Akt isoforms are present at distinct subcellular locations, *American journal of physiology. Cell physiology*, 298 (2010) C580–591.
- [105] S.R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, M.E. Greenberg, Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery, *Cell*, 91 (1997) 231–241.
- [106] L. del Peso, M. Gonzalez-Garcia, C. Page, R. Herrera, G. Nunez, Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt, *Science (New York, N.Y.)*, 278 (1997) 687–689.
- [107] S.J. Gardai, D.A. Hildeman, S.K. Frankel, B.B. Whitlock, S.C. Frasch, N. Borregaard, P. Marrack, D.L. Bratton, P.M. Henson, Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils, *The Journal of biological chemistry*, 279 (2004) 21085–21095.
- [108] X.J. Qi, G.M. Wildey, P.H. Howe, Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function, *The Journal of biological chemistry*, 281 (2006) 813–823.
- [109] H. Zou, Y. Li, X. Liu, X. Wang, An APAF-1/cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9, *The Journal of biological chemistry*, 274 (1999) 11549–11556.
- [110] J. Downward, How BAD phosphorylation is good for survival, *Nature cell biology*, 1 (1999) E33–35.
- [111] J. Hayakawa, M. Ohmichi, H. Kurachi, Y. Kanda, K. Hisamoto, Y. Nishio, K. Adachi, K. Tasaka, T. Kanzaki, Y. Murata, Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin, *Cancer research*, 60 (2000) 5988–5994.
- [112] A. Schurmann, A.F. Mooney, L.C. Sanders, M.A. Sells, H.G. Wang, J.C. Reed, G.M. Bokoch, p21-activated kinase 1 phosphorylates the death agonist bad and



- protects cells from apoptosis, *Molecular and cellular biology*, 20 (2000) 453–461.
- [113] Y. Tang, H. Zhou, A. Chen, R.N. Pittman, J. Field, The Akt proto-oncogene links Ras to Pak and cell survival signals, *The Journal of biological chemistry*, 275 (2000) 9106–9109.
- [114] K. Du, M. Montminy, CREB is a regulatory target for the protein kinase Akt/PKB, *The Journal of biological chemistry*, 273 (1998) 32377–32379.
- [115] O.N. Ozes, L.D. Mayo, J.A. Gustin, S.R. Pfeffer, L.M. Pfeffer, D.B. Donner, NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase, *Nature*, 401 (1999) 82–85.
- [116] X. Zhang, N. Tang, T.J. Hadden, A.K. Rishi, Akt, FoxO and regulation of apoptosis, *Biochimica et Biophysica Acta (BBA) – Molecular Cell Research*, 1813 (2011) 1978–1986.
- [117] H. Tran, A. Brunet, E.C. Griffith, M.E. Greenberg, The many forks in FOXO's road, *Science's STKE : signal transduction knowledge environment*, 2003 (2003) Re5.
- [118] X. Zhang, L. Gan, H. Pan, S. Guo, X. He, S.T. Olson, A. Mesecar, S. Adam, T.G. Unterman, Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding, *The Journal of biological chemistry*, 277 (2002) 45276–45284.
- [119] M. Stahl, P.F. Dijkers, G.J. Kops, S.M. Lens, P.J. Coffey, B.M. Burgering, R.H. Medema, The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2, *Journal of immunology (Baltimore, Md. : 1950)*, 168 (2002) 5024–5031.
- [120] A. Brunet, A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. Anderson, K.C. Arden, J. Blenis, M.E. Greenberg, Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor, *Cell*, 96 (1999) 857–868.
- [121] M.H. Cardone, N. Roy, H.R. Stennicke, G.S. Salvesen, T.F. Franke, E. Stanbridge, S. Frisch, J.C. Reed, Regulation of cell death protease caspase-9 by phosphorylation, *Science (New York, N.Y.)*, 282 (1998) 1318–1321.
- [122] H.C. Dan, M. Sun, S. Kaneko, R.I. Feldman, S.V. Nicosia, H.G. Wang, B.K. Tsang, J.Q. Cheng, Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP), *The Journal of biological chemistry*, 279 (2004) 5405–5412.
- [123] A.L. Gartel, K. Shchors, Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes, *Experimental cell research*, 283 (2003) 17–21.
- [124] A.L. Gartel, X. Ye, E. Goufman, P. Shianov, N. Hay, F. Najmabadi, A.L. Tyner, Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3, *Proc Natl Acad Sci U S A*, 98 (2001) 4510–4515.
- [125] W. Yang, J. Shen, M. Wu, M. Arsur, M. FitzGerald, Z. Suldan, D.W. Kim, C.S. Hofmann, S. Pianetti, R. Romieu-Mourez, L.P. Freedman, G.E. Sonenshein, Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc, *Oncogene*, 20 (2001) 1688–1702.
- [126] P. Staller, K. Peukert, A. Kiermaier, J. Seoane, J. Lukas, H. Karsunky, T. Moroy, J. Bartek, J. Massague, F. Hanel, M. Eilers, Repression of p15INK4b expression by Myc through association with Miz-1, *Nature cell biology*, 3 (2001) 392–399.

- [127] J.A. Diehl, M. Cheng, M.F. Roussel, C.J. Sherr, Glycogen synthase kinase-3 $\beta$  regulates cyclin D1 proteolysis and subcellular localization, *Genes & development*, 12 (1998) 3499–3511.
- [128] R. Sears, F. Nuckolls, E. Haura, Y. Taya, K. Tamai, J.R. Nevins, Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability, *Genes & development*, 14 (2000) 2501–2514.
- [129] T. Abbas, A. Dutta, p21 in cancer: intricate networks and multiple activities, *Nature reviews. Cancer*, 9 (2009) 400–414.
- [130] B.P. Zhou, Y. Liao, W. Xia, B. Spohn, M.H. Lee, M.C. Hung, Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells, *Nature cell biology*, 3 (2001) 245–252.
- [131] L. Rossig, A.S. Jadidi, C. Urbich, C. Badorff, A.M. Zeiher, S. Dimmeler, Akt-dependent phosphorylation of p21(Cip1) regulates PCNA binding and proliferation of endothelial cells, *Molecular and cellular biology*, 21 (2001) 5644–5657.
- [132] Y. Li, D. Dowbenko, L.A. Lasky, AKT/PKB phosphorylation of p21Cip1/WAF1 enhances protein stability of p21Cip1/WAF1 and promotes cell survival, *The Journal of biological chemistry*, 277 (2002) 11352–11361.
- [133] G. Viglietto, M.L. Motti, P. Bruni, R.M. Melillo, A. D’Alessio, D. Califano, F. Vinci, G. Chiappetta, P. Tschlis, A. Bellacosa, A. Fusco, M. Santoro, Cytoplasmic relocation and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer, *Nat Med*, 8 (2002) 1136–1144.
- [134] G. Viglietto, M.L. Motti, A. Fusco, Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization, *Cell Cycle*, 1 (2002) 394–400.
- [135] I. Shin, F.M. Yakes, F. Rojo, N.Y. Shin, A.V. Bakin, J. Baselga, C.L. Arteaga, PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization, *Nat Med*, 8 (2002) 1145–1152.
- [136] J. Liang, J. Zubovitz, T. Petrocelli, R. Kotchetkov, M.K. Connor, K. Han, J.H. Lee, S. Ciarallo, C. Catzavelos, R. Beniston, E. Franssen, J.M. Slingerland, PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest, *Nat Med*, 8 (2002) 1153–1160.
- [137] N. Fujita, S. Sato, T. Tsuruo, Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization, *The Journal of biological chemistry*, 278 (2003) 49254–49260.
- [138] N. Fujita, S. Sato, K. Katayama, T. Tsuruo, Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization, *The Journal of biological chemistry*, 277 (2002) 28706–28713.
- [139] M. Ciaparrone, H. Yamamoto, Y. Yao, A. Sgambato, G. Cattoretti, N. Tomita, T. Monden, H. Rotterdam, I.B. Weinstein, Localization and expression of p27KIP1 in multistage colorectal carcinogenesis, *Cancer research*, 58 (1998) 114–122.
- [140] S.P. Singh, J. Lipman, H. Goldman, F.H. Ellis, Jr., L. Aizenman, M.G. Cangi, S. Signoretti, D.S. Chiaur, M. Pagano, M. Loda, Loss or altered subcellular localization of p27 in Barrett’s associated adenocarcinoma, *Cancer research*, 58 (1998) 1730–1735.
- [141] P.F. Dijkers, R.H. Medema, C. Pals, L. Banerji, N.S. Thomas, E.W. Lam, B.M. Burgering, J.A. Raaijmakers, J.W. Lammers, L. Koenderman, P.J. Coffey, Forkhead transcription factor FKHR-L1 modulates cytokine-dependent tran-

- scriptional regulation of p27(KIP1), *Molecular and cellular biology*, 20 (2000) 9138–9148.
- [142] H.K. Lin, G. Wang, Z. Chen, J. Teruya-Feldstein, Y. Liu, C.H. Chan, W.L. Yang, H. Erdjument-Bromage, K.I. Nakayama, S. Nimer, P. Tempst, P.P. Pandolfi, Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB, *Nature cell biology*, 11 (2009) 420–432.
- [143] D. Gao, H. Inuzuka, A. Tseng, R.Y. Chin, A. Toker, W. Wei, Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCdh1-mediated Skp2 destruction, *Nature cell biology*, 11 (2009) 397–408.
- [144] D. Ganoth, G. Bornstein, T.K. Ko, B. Larsen, M. Tyers, M. Pagano, A. Hershko, The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27, *Nature cell biology*, 3 (2001) 321–324.
- [145] C. Spruck, H. Strohmaier, M. Watson, A.P. Smith, A. Ryan, T.W. Krek, S.I. Reed, A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1, *Molecular cell*, 7 (2001) 639–650.
- [146] A.J. Levine, p53, the cellular gatekeeper for growth and division, *Cell*, 88 (1997) 323–331.
- [147] S. Bates, E.S. Hickman, K.H. Vousden, Reversal of p53-induced cell-cycle arrest, *Molecular carcinogenesis*, 24 (1999) 7–14.
- [148] S. Bates, K.H. Vousden, Mechanisms of p53-mediated apoptosis, *Cellular and molecular life sciences : CMLS*, 55 (1999) 28–37.
- [149] M.H. Kubbutat, S.N. Jones, K.H. Vousden, Regulation of p53 stability by Mdm2, *Nature*, 387 (1997) 299–303.
- [150] Y. Haupt, R. Maya, A. Kazaz, M. Oren, Mdm2 promotes the rapid degradation of p53, *Nature*, 387 (1997) 296–299.
- [151] M. Ashcroft, R.L. Ludwig, D.B. Woods, T.D. Copeland, H.O. Weber, E.J. MacRae, K.H. Vousden, Phosphorylation of HDM2 by Akt, *Oncogene*, 21 (2002) 1955–1962.
- [152] Y. Ogawara, S. Kishishita, T. Obata, Y. Isazawa, T. Suzuki, K. Tanaka, N. Masuyama, Y. Gotoh, Akt enhances Mdm2-mediated ubiquitination and degradation of p53, *The Journal of biological chemistry*, 277 (2002) 21843–21850.
- [153] L.K. Linares, A. Hengstermann, A. Ciechanover, S. Muller, M. Scheffner, HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53, *Proc Natl Acad Sci U S A*, 100 (2003) 12009–12014.
- [154] V. Lopez-Pajares, M.M. Kim, Z.M. Yuan, Phosphorylation of MDMX mediated by Akt leads to stabilization and induces 14-3-3 binding, *The Journal of biological chemistry*, 283 (2008) 13707–13713.
- [155] A. Villunger, E.M. Michalak, L. Coultas, F. Mullauer, G. Bock, M.J. Ausserlechner, J.M. Adams, A. Strasser, p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa, *Science (New York, N.Y.)*, 302 (2003) 1036–1038.
- [156] J. Rosenblatt, Y. Gu, D.O. Morgan, Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A, *Proceedings of the National Academy of Sciences*, 89 (1992) 2824–2828.
- [157] E. Okumura, T. Fukuhara, H. Yoshida, S. Hanada Si, R. Kozutsumi, M. Mori, K. Tachibana, T. Kishimoto, Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition, *Nature cell biology*, 4 (2002) 111–116.

- [158] S. Maddika, S.R. Ande, E. Wiechec, L.L. Hansen, S. Wesselborg, M. Los, Akt-mediated phosphorylation of CDK2 regulates its dual role in cell cycle progression and apoptosis, *Journal of Cell Science*, 121 (2008) 979–988.
- [159] I. Nilsson, I. Hoffmann, Cell cycle regulation by the Cdc25 phosphatase family, *Progress in cell cycle research*, 4 (2000) 107–114.
- [160] N. Davezac, V. Baldin, B. Gabrielli, A. Forrest, N. Theis-Febvre, M. Yashida, B. Ducommun, Regulation of CDC25B phosphatases subcellular localization, *Oncogene*, 19 (2000) 2179–2185.
- [161] N. Davezac, B. Ducommun, V. Baldin, [Role of CDC25 phosphatases in the control of proliferation], *Pathologie-biologie*, 48 (2000) 182–189.
- [162] V. Baldin, N. Theis-Febvre, C. Benne, C. Froment, M. Cazales, O. Burlet-Schiltz, B. Ducommun, PKB/Akt phosphorylates the CDC25B phosphatase and regulates its intracellular localisation, *Biology of the cell / under the auspices of the European Cell Biology Organization*, 95 (2003) 547–554.
- [163] K. Katayama, N. Fujita, T. Tsuruo, Akt/protein kinase B-dependent phosphorylation and inactivation of WEE1Hu promote cell cycle progression at G2/M transition, *Molecular and cellular biology*, 25 (2005) 5725–5737.
- [164] A. Barthel, S.T. Okino, J. Liao, K. Nakatani, J. Li, J.P. Whitlock, Jr., R.A. Roth, Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1, *The Journal of biological chemistry*, 274 (1999) 20281–20286.
- [165] A.D. Kohn, S.A. Summers, M.J. Birnbaum, R.A. Roth, Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation, *The Journal of biological chemistry*, 271 (1996) 31372–31378.
- [166] S. Okada, K. Ohshima, Y. Uehara, H. Shimizu, K. Hashimoto, M. Yamada, M. Mori, Synip phosphorylation is required for insulin-stimulated Glut4 translocation, *Biochemical and biophysical research communications*, 356 (2007) 102–106.
- [167] D.C. Berwick, G.C. Dell, G.I. Welsh, K.J. Heesom, I. Hers, L.M. Fletcher, F.T. Cooke, J.M. Tavare, Protein kinase B phosphorylation of PIKfyve regulates the trafficking of GLUT4 vesicles, *J Cell Sci*, 117 (2004) 5985–5993.
- [168] H. Sano, S. Kane, E. Sano, C.P. Miinea, J.M. Asara, W.S. Lane, C.W. Garner, G.E. Lienhard, Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation, *The Journal of biological chemistry*, 278 (2003) 14599–14602.
- [169] K. Gottlob, N. Majewski, S. Kennedy, E. Kandel, R.B. Robey, N. Hay, Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase, *Genes & development*, 15 (2001) 1406–1418.
- [170] R.B. Robey, N. Hay, Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt, *Oncogene*, 25 (2006) 4683–4696.
- [171] S.K. Moule, G.I. Welsh, N.J. Edgell, E.J. Foulstone, C.G. Proud, R.M. Denton, Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta-adrenergic agonists in rat epididymal fat cells. Activation of protein kinase B by wortmannin-sensitive and -insensitive mechanisms, *The Journal of biological chemistry*, 272 (1997) 7713–7719.
- [172] D. Accili, K.C. Arden, FoxOs at the crossroads of cellular metabolism, differentiation, and transformation, *Cell*, 117 (2004) 421–426.

- [173] X. Li, B. Monks, Q. Ge, M.J. Birnbaum, Akt/PKB regulates hepatic metabolism by directly inhibiting PGC-1 $\alpha$  transcription coactivator, *Nature*, 447 (2007) 1012–1016.
- [174] R.L. Elstrom, D.E. Bauer, M. Buzzai, R. Karnauskas, M.H. Harris, D.R. Plas, H. Zhuang, R.M. Cinalli, A. Alavi, C.M. Rudin, C.B. Thompson, Akt stimulates aerobic glycolysis in cancer cells, *Cancer research*, 64 (2004) 3892–3899.
- [175] P.K. Majumder, W.R. Sellers, Akt-regulated pathways in prostate cancer, *Oncogene*, 24 (2005) 7465–7474.
- [176] G.L. Semenza, Targeting HIF-1 for cancer therapy, *Nature reviews. Cancer*, 3 (2003) 721–732.
- [177] A. Sundqvist, M.T. Bengoechea-Alonso, X. Ye, V. Lukiyanchuk, J. Jin, J.W. Harper, J. Ericsson, Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7), *Cell metabolism*, 1 (2005) 379–391.
- [178] D.C. Berwick, I. Hers, K.J. Heesom, S.K. Moule, J.M. Tavaré, The identification of ATP-citrate lyase as a protein kinase B (Akt) substrate in primary adipocytes, *The Journal of biological chemistry*, 277 (2002) 33895–33900.
- [179] A.Z. Zhao, M.M. Shinohara, D. Huang, M. Shimizu, H. Eldar-Finkelman, E.G. Krebs, J.A. Beavo, K.E. Bornfeldt, Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes, *The Journal of biological chemistry*, 275 (2000) 11348–11354.
- [180] S. Wullschleger, R. Loewith, M.N. Hall, TOR signaling in growth and metabolism, *Cell*, 124 (2006) 471–484.
- [181] E.M. Beauchamp, L.C. Plataniotis, The evolution of the TOR pathway and its role in cancer, *Oncogene*, 32 (2013) 3923–3932.
- [182] Y. Sancak, C.C. Thoreen, T.R. Peterson, R.A. Lindquist, S.A. Kang, E. Spooner, S.A. Carr, D.M. Sabatini, PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase, *Molecular cell*, 25 (2007) 903–915.
- [183] A. Garami, F.J. Zwartkruis, T. Nobukuni, M. Joaquin, M. Rocco, H. Stocker, S.C. Kozma, E. Hafen, J.L. Bos, G. Thomas, Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2, *Molecular cell*, 11 (2003) 1457–1466.
- [184] K. Inoki, Y. Li, T. Xu, K.L. Guan, Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling, *Genes & development*, 17 (2003) 1829–1834.
- [185] E. Vander Haar, S.I. Lee, S. Bandhakavi, T.J. Griffin, D.H. Kim, Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40, *Nature cell biology*, 9 (2007) 316–323.
- [186] I. Shiojima, K. Walsh, Role of Akt signaling in vascular homeostasis and angiogenesis, *Circ Res*, 90 (2002) 1243–1250.
- [187] A.K. Olsson, A. Dimberg, J. Kreuger, L. Claesson-Welsh, VEGF receptor signalling – in control of vascular function, *Nature reviews. Molecular cell biology*, 7 (2006) 359–371.
- [188] P.J. Ratcliffe, C.W. Pugh, P.H. Maxwell, Targeting tumors through the HIF system, *Nat Med*, 6 (2000) 1315–1316.
- [189] J.A. Forsythe, B.H. Jiang, N.V. Iyer, F. Agani, S.W. Leung, R.D. Koos, G.L. Semenza, Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1, *Molecular and cellular biology*, 16 (1996) 4604–4613.

- [190] N. Pore, S. Liu, D.A. Haas-Kogan, D.M. O'Rourke, A. Maity, PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter, *Cancer research*, 63 (2003) 236–241.
- [191] S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, A.M. Zeiher, Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation, *Nature*, 399 (1999) 601–605.
- [192] J. Fontana, D. Fulton, Y. Chen, T.A. Fairchild, T.J. McCabe, N. Fujita, T. Tsuruo, W.C. Sessa, Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release, *Circ Res*, 90 (2002) 866–873.
- [193] J. Karar, A. Maity, PI3K/AKT/mTOR Pathway in Angiogenesis, *Frontiers in molecular neuroscience*, 4 (2011) 51.
- [194] Z. Luo, Y. Fujio, Y. Kureishi, R.D. Rudic, G. Daumerie, D. Fulton, W.C. Sessa, K. Walsh, Acute modulation of endothelial Akt/PKB activity alters nitric oxide-dependent vasomotor activity in vivo, *J Clin Invest*, 106 (2000) 493–499.
- [195] C. Skurk, Y. Izumiya, H. Maatz, P. Razeghi, I. Shiojima, M. Sandri, K. Sato, L. Zeng, S. Schiekofer, D. Pimentel, S. Lecker, H. Taegtmeyer, A.L. Goldberg, K. Walsh, The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling, *The Journal of biological chemistry*, 280 (2005) 20814–20823.
- [196] J. Shao, H. Yamashita, L. Qiao, J.E. Friedman, Decreased Akt kinase activity and insulin resistance in C57BL/KsJ-Lepr<sup>db/db</sup> mice, *The Journal of endocrinology*, 167 (2000) 107–115.
- [197] R.S. Garofalo, S.J. Orena, K. Rafidi, A.J. Torchia, J.L. Stock, A.L. Hildebrandt, T. Coskran, S.C. Black, D.J. Brees, J.R. Wicks, J.D. McNeish, K.G. Coleman, Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta, *J Clin Invest*, 112 (2003) 197–208.
- [198] Y. Piao, H.G. Kim, M.S. Oh, Y.K. Pak, Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP(+)-induced mitochondrial dysfunctions in neuronal cells, *Biochimica et biophysica acta*, 1820 (2012) 577–585.
- [199] S. Jimenez, M. Torres, M. Vizuete, R. Sanchez-Varo, E. Sanchez-Mejias, L. Trujillo-Estrada, I. Carmona-Cuenca, C. Caballero, D. Ruano, A. Gutierrez, J. Vitorica, Age-dependent accumulation of soluble amyloid beta (A $\beta$ ) oligomers reverses the neuroprotective effect of soluble amyloid precursor protein-alpha (sAPP(alpha)) by modulating phosphatidylinositol 3-kinase (PI3K)/Akt-GSK-3beta pathway in Alzheimer mouse model, *The Journal of biological chemistry*, 286 (2011) 18414–18425.
- [200] B. Jie, X. Zhang, X. Wu, Y. Xin, Y. Liu, Y. Guo, Neuregulin-1 suppresses cardiomyocyte apoptosis by activating PI3K/Akt and inhibiting mitochondrial permeability transition pore, *Molecular and cellular biochemistry*, 370 (2012) 35–43.
- [201] D.A. Altomare, J.R. Testa, Perturbations of the AKT signaling pathway in human cancer, *Oncogene*, 24 (2005) 7455–7464.
- [202] E. Tokunaga, E. Oki, A. Egashira, N. Sadanaga, M. Morita, Y. Kakeji, Y. Maehara, Deregulation of the Akt pathway in human cancer, *Current cancer drug targets*, 8 (2008) 27–36.

- [203] E. Castellano, J. Downward, Role of RAS in the regulation of PI 3-kinase, *Current topics in microbiology and immunology*, 346 (2010) 143–169.
- [204] J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, S.I. Wang, J. Puc, C. Miliareis, L. Rodgers, R. McCombie, S.H. Bigner, B.C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M.H. Wigler, R. Parsons, PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer, *Science (New York, N.Y.)*, 275 (1997) 1943–1947.
- [205] D.H. Teng, R. Hu, H. Lin, T. Davis, D. Iliev, C. Frye, B. Swedlund, K.L. Hansen, V.L. Vinson, K.L. Gumpfer, L. Ellis, A. El-Naggar, M. Frazier, S. Jasser, L.A. Langford, J. Lee, G.B. Mills, M.A. Pershouse, R.E. Pollack, C. Tornos, P. Troncoso, W.K. Yung, G. Fujii, A. Berson, P.A. Steck, et al., MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines, *Cancer research*, 57 (1997) 5221–5225.
- [206] J.Q. Cheng, A.K. Godwin, A. Bellacosa, T. Taguchi, T.F. Franke, T.C. Hamilton, P.N. Tsichlis, J.R. Testa, AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas, *Proc Natl Acad Sci U S A*, 89 (1992) 9267–9271.
- [207] A. Bellacosa, D. de Feo, A.K. Godwin, D.W. Bell, J.Q. Cheng, D.A. Altomare, M. Wan, L. Dubeau, G. Scambia, V. Masciullo, Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas, *Int J Cancer*, 64 (1995).
- [208] J.R. Graff, B.W. Konicek, A.M. McNulty, Z. Wang, K. Houck, S. Allen, J.D. Paul, A. Hbailu, R.G. Goode, G.E. Sandusky, R.L. Vessella, B.L. Neubauer, Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression, *The Journal of biological chemistry*, 275 (2000) 24500–24505.
- [209] K. Nakayama, N. Nakayama, R.J. Kurman, L. Cope, G. Pohl, Y. Samuels, V.E. Velculescu, T.L. Wang, M. Shih Ie, Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms, *Cancer biology & therapy*, 5 (2006) 779–785.
- [210] J.Q. Cheng, B. Ruggeri, W.M. Klein, G. Sonoda, D.A. Altomare, D.K. Watson, J.R. Testa, Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA, *Proc Natl Acad Sci USA*, 93 (1996).
- [211] K.M. Turner, Y. Sun, P. Ji, K.J. Granberg, B. Bernard, L. Hu, D.E. Cogdell, X. Zhou, O. Yli-Harja, M. Nykter, I. Shmulevich, W.K. Yung, G.N. Fuller, W. Zhang, Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression, *Proc Natl Acad Sci U S A*, 112 (2015) 3421–3426.
- [212] J.D. Carpten, A.L. Faber, C. Horn, G.P. Donoho, S.L. Briggs, C.M. Robbins, G. Hostetter, S. Boguslawski, T.Y. Moses, S. Savage, M. Uhlik, A. Lin, J. Du, Y.W. Qian, D.J. Zeckner, G. Tucker-Kellogg, J. Touchman, K. Patel, S. Mousses, M. Bittner, R. Schevitz, M.H. Lai, K.L. Blanchard, J.E. Thomas, A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, *Nature*, 448 (2007) 439–444.
- [213] M.A. Davies, K. Stemke-Hale, C. Tellez, T.L. Calderone, W. Deng, V.G. Prieto, A.J. Lazar, J.E. Gershenwald, G.B. Mills, A novel AKT3 mutation in melanoma tumours and cell lines, *Br J Cancer*, 99 (2008) 1265–1268.
- [214] J. LoPiccolo, G.M. Blumenthal, W.B. Bernstein, P.A. Dennis, Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations,

- Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 11 (2008) 32–50.
- [215] M.C. Mendoza, E.E. Er, J. Blenis, The Ras-ERK and PI3K-mTOR Pathways: Cross-talk and Compensation, *Trends in biochemical sciences*, 36 (2011) 320–328.
- [216] H.C. Dan, M.J. Cooper, P.C. Cogswell, J.A. Duncan, J.P. Ting, A.S. Baldwin, Akt-dependent regulation of NF- $\kappa$ B is controlled by mTOR and Raptor in association with IKK, *Genes & development*, 22 (2008) 1490–1500.
- [217] C.A. Grimes, R.S. Jope, The multifaceted roles of glycogen synthase kinase 3 $\beta$  in cellular signaling, *Progress in neurobiology*, 65 (2001) 391–426.
- [218] E.C. Hales, S.M. Orr, A. Larson Gedman, J.W. Taub, L.H. Matherly, Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells, *The Journal of biological chemistry*, 288 (2013) 22836–22848.
- [219] A.H. Kim, G. Khursigara, X. Sun, T.F. Franke, M.V. Chao, Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1, *Molecular and cellular biology*, 21 (2001) 893–901.
- [220] K. Polyak, W.C. Hahn, Roots and stems: stem cells in cancer, *Nat Med*, 12 (2006) 296–300.
- [221] H. Lage, An overview of cancer multidrug resistance: a still unsolved problem, *Cellular and molecular life sciences : CMLS*, 65 (2008) 3145–3167.
- [222] H. Korkaya, M.S. Wicha, Selective targeting of cancer stem cells: a new concept in cancer therapeutics, *BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy*, 21 (2007) 299–310.
- [223] Y. Saito, H. Kitamura, A. Hijikata, M. Tomizawa-Murasawa, S. Tanaka, S. Takagi, N. Uchida, N. Suzuki, A. Sone, Y. Najima, H. Ozawa, A. Wake, S. Taniguchi, L.D. Shultz, O. Ohara, F. Ishikawa, Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells, *Science translational medicine*, 2 (2010) 17ra19.
- [224] P. Chu, D.J. Clanton, T.S. Snipas, J. Lee, E. Mitchell, M.L. Nguyen, E. Hare, R.J. Peach, Characterization of a subpopulation of colon cancer cells with stem cell-like properties, *Int J Cancer*, 124 (2009) 1312–1321.
- [225] R. Marhaba, M. Zoller, CD44 in cancer progression: adhesion, migration and growth regulation, *Journal of molecular histology*, 35 (2004) 211–231.
- [226] Y.K. Wang, Y.L. Zhu, F.M. Qiu, T. Zhang, Z.G. Chen, S. Zheng, J. Huang, Activation of Akt and MAPK pathways enhances the tumorigenicity of CD133+ primary colon cancer cells, *Carcinogenesis*, 31 (2010) 1376–1380.
- [227] L.S. Zhang, H.W. Ma, H.J. Greyner, W. Zuo, M.E. Mummert, Inhibition of cell proliferation by CD44: Akt is inactivated and EGR-1 is down-regulated, *Cell proliferation*, 43 (2010) 385–395.
- [228] V. Subramaniam, I.R. Vincent, H. Gardner, E. Chan, H. Dhamko, S. Jothy, CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation, *Experimental and molecular pathology*, 83 (2007) 207–215.
- [229] A. Kawamoto, K. Tanaka, S. Saigusa, Y. Toiyama, Y. Morimoto, H. Fujikawa, T. Iwata, K. Matsushita, T. Yokoe, H. Yasuda, Y. Inoue, C. Miki, M. Kusunoki, Clinical significance of radiation-induced CD133 expression in residual rectal



- cancer cells after chemoradiotherapy, *Experimental and therapeutic medicine*, 3 (2012) 403–409.
- [230] S.H. Sahlberg, D. Spiegelberg, B. Glimelius, B. Stenerlow, M. Nestor, Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells, *PLoS One*, 9 (2014) e94621.
- [231] R. Gargini, J.P. Cerliani, M. Escoll, I.M. Anton, F. Wandosell, Cancer stem cell-like phenotype and survival are coordinately regulated by Akt/FoxO/Bim pathway, *Stem cells (Dayton, Ohio)*, 33 (2015) 646–660.
- [232] C. Segrelles, R. Garcia-Escudero, M.I. Garin, J.F. Aranda, P. Hernandez, J.M. Ariza, M. Santos, J.M. Paramio, C. Lorz, Akt signaling leads to stem cell activation and promotes tumor development in epidermis, *Stem cells (Dayton, Ohio)*, 32 (2014) 1917–1928.
- [233] J. Li, B.P. Zhou, Activation of beta-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters, *BMC cancer*, 11 (2011) 49.
- [234] D. Iliopoulos, C. Polytarchou, M. Hatzia Apostolou, F. Kottakis, I.G. Maroulakou, K. Struhl, P.N. Tschlis, MicroRNAs differentially regulated by Akt isoforms control EMT and stem cell renewal in cancer cells, *Science signaling*, 2 (2009) ra62.
- [235] B. Zheng, J. Zhou, Q. Geng, Q. Dong, [A preliminary study on the origin of human lung adenocarcinoma stem cells from lung bronchioalveolar stem cells.], *Zhongguo fei ai za zhi = Chinese journal of lung cancer*, 11 (2008) 759–764.
- [236] C.B. Rountree, W. Ding, L. He, B. Stiles, Expansion of CD133-expressing liver cancer stem cells in liver-specific phosphatase and tensin homolog deleted on chromosome 10-deleted mice, *Stem cells (Dayton, Ohio)*, 27 (2009) 290–299.
- [237] H. Korsten, A. Ziel-van der Made, X. Ma, T. van der Kwast, J. Trapman, Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model, *PLoS One*, 4 (2009) e5662.
- [238] A. Dubrovskaya, S. Kim, R.J. Salomone, J.R. Walker, S.M. Maira, C. Garcia-Echeverria, P.G. Schultz, V.A. Reddy, The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations, *Proc Natl Acad Sci U S A*, 106 (2009) 268–273.
- [239] Y. Yang, K. Iwanaga, M.G. Raso, M. Wislez, A.E. Hanna, E.D. Wieder, J.J. Molldrem, Wistuba, II, G. Powis, F.J. Demayo, C.F. Kim, J.M. Kurie, Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer, *PLoS One*, 3 (2008) e2220.
- [240] J. Zhou, J. Wulfschlegel, H. Zhang, P. Gu, Y. Yang, J. Deng, J.B. Margolick, L.A. Liotta, E. Petricoin, 3rd, Y. Zhang, Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance, *Proc Natl Acad Sci U S A*, 104 (2007) 16158–16163.
- [241] J.R. Molina, Y. Hayashi, C. Stephens, M.M. Georgescu, Invasive glioblastoma cells acquire stemness and increased Akt activation, *Neoplasia (New York, N.Y.)*, 12 (2010) 453–463.
- [242] I. Bruns, A. Czibere, J.C. Fischer, F. Roels, R.P. Caddeu, S. Buest, D. Bruennert, A.N. Huenerlituerkoglu, N.H. Stoecklein, R. Singh, L.F. Zerbini, M. Jager, G. Kobbe, N. Gattermann, R. Kronenwett, B. Brors, R. Haas, The

- hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence, *Leukemia*, 23 (2009) 892–899.
- [243] I. Petta, S. Lievens, C. Libert, J. Tavernier, K. De Bosscher, Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics, *Molecular therapy : the journal of the American Society of Gene Therapy*, (2015).
- [244] B. Margolis, E.Y. Skolnik, Activation of Ras by receptor tyrosine kinases, *Journal of the American Society of Nephrology : JASN*, 5 (1994) 1288–1299.
- [245] Y. Shi, A. Sharma, H. Wu, A. Lichtenstein, J. Gera, Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway, *The Journal of biological chemistry*, 280 (2005) 10964–10973.
- [246] A.A. Ivanov, F.R. Khuri, H. Fu, Targeting protein-protein interactions as an anticancer strategy, *Trends in pharmacological sciences*, 34 (2013) 393–400.
- [247] P. Vanhee, A.M. van der Sloot, E. Verschueren, L. Serrano, F. Rousseau, J. Schymkowitz, Computational design of peptide ligands, *Trends in biotechnology*, 29 (2011) 231–239.
- [248] C.G. Cummings, A.D. Hamilton, Disrupting protein-protein interactions with non-peptidic, small molecule alpha-helix mimetics, *Current opinion in chemical biology*, 14 (2010) 341–346.
- [249] L.K. Henchey, A.L. Jochim, P.S. Arora, Contemporary strategies for the stabilization of peptides in the alpha-helical conformation, *Current opinion in chemical biology*, 12 (2008) 692–697.
- [250] Y. Du, Z. Nikolovska-Coleska, M. Qui, L. Li, I. Lewis, R. Dingleline, J.A. Stuckey, K. Krajewski, P.P. Roller, S. Wang, H. Fu, A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions, *Assay and drug development technologies*, 9 (2011) 382–393.
- [251] M.R. Arkin, M.A. Glicksman, H. Fu, J.J. Havel, Y. Du, Inhibition of Protein-Protein Interactions: Non-Cellular Assay Formats, in: G.S. Sittampalam, N.P. Coussens, H. Nelson, M. Arkin, D. Auld, C. Austin, B. Bejcek, M. Glicksman, J. Inglese, P.W. Iversen, Z. Li, J. McGee, O. McManus, L. Minor, A. Napper, J.M. Peltier, T. Riss, O.J. Trask, Jr., J. Weidner (Eds.) *Assay Guidance Manual*, Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD), 2004.
- [252] M. Morell, S. Ventura, F.X. Avilés, Protein complementation assays: Approaches for the in vivo analysis of protein interactions, *FEBS Letters*, 583 (2009) 1684–1691.
- [253] E. Valkov, T. Sharpe, M. Marsh, S. Greive, M. Hyvonen, Targeting protein-protein interactions and fragment-based drug discovery, *Topics in current chemistry*, 317 (2012) 145–179.
- [254] P.H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A.J. Levine, N.P. Pavletich, Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain, *Science (New York, N.Y.)*, 274 (1996) 948–953.
- [255] L. Dubrez, J. Berthelet, V. Glorian, IAP proteins as targets for drug development in oncology, *OncoTargets and therapy*, 9 (2013) 1285–1304.

- [256] H. Sun, Z. Nikolovska-Coleska, C.Y. Yang, D. Qian, J. Lu, S. Qiu, L. Bai, Y. Peng, Q. Cai, S. Wang, Design of small-molecule peptidic and nonpeptidic Smac mimetics, *Accounts of chemical research*, 41 (2008) 1264–1277.
- [257] J.R. Porter, C.C. Fritz, K.M. Depew, Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy, *Current opinion in chemical biology*, 14 (2010) 412–420.
- [258] K. Sidera, E. Patsavoudi, HSP90 inhibitors: current development and potential in cancer therapy, *Recent patents on anti-cancer drug discovery*, 9 (2014) 1–20.
- [259] J. Bhutani, A. Sheikh, A.K. Niazi, Akt inhibitors: mechanism of action and implications for anticancer therapeutics, *Infect Agent Cancer*, 8 (2013) 49.
- [260] T.A. Yap, M.I. Walton, L.J. Hunter, M. Valenti, A. de Haven Brandon, P.D. Eve, R. Ruddle, S.P. Heaton, A. Henley, L. Pickard, G. Vijayaraghavan, J.J. Caldwell, N.T. Thompson, W. Aherne, F.I. Raynaud, S.A. Eccles, P. Workman, I. Collins, M.D. Garrett, Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930, *Mol Cancer Ther*, 10 (2011) 360–371.
- [261] J.F. Blake, R. Xu, J.R. Bencsik, D. Xiao, N.C. Kallan, S. Schlachter, I.S. Mitchell, K.L. Spencer, A.L. Banka, E.M. Wallace, S.L. Gloor, M. Martinson, R.D. Woessner, G.P. Vigers, B.J. Brandhuber, J. Liang, B.S. Safina, J. Li, B. Zhang, C. Chabot, S. Do, L. Lee, J. Oeh, D. Sampath, B.B. Lee, K. Lin, B.M. Liederer, N.J. Skelton, Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors, *J Med Chem*, 55 (2012) 8110–8127.
- [262] ClinicalTrials.gov | An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL). [<http://clinicaltrials.gov/ct2/show/NCT01532700>].
- [263] K.M. Grimshaw, L.J. Hunter, T.A. Yap, S.P. Heaton, M.I. Walton, S.J. Woodhead, L. Fazal, M. Reule, T.G. Davies, L.C. Seavers, V. Lock, J.F. Lyons, N.T. Thompson, P. Workman, M.D. Garrett, AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth, *Mol Cancer Ther*, 9 (2010) 1100–1110.
- [264] Y. Hu, L. Qiao, S. Wang, S.B. Rong, E.J. Meillet, M. Berggren, A. Gallegos, G. Powis, A.P. Kozikowski, 3-(Hydroxymethyl)-bearing phosphatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth, *J Med Chem*, 43 (2000) 3045–3051.
- [265] N.T. Ihle, R. Williams, S. Chow, W. Chew, M.I. Berggren, G. Paine-Murrieta, zD.J. Minion, R.J. Halter, P. Wipf, R. Abraham, L. Kirkpatrick, G. Powis, Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling, *Mol Cancer Ther*, 3 (2004) 763–772.
- [266] S.B. Kondapaka, S.S. Singh, G.P. Dasmahapatra, E.A. Sausville, K.K. Roy, Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation, *Mol Cancer Ther*, 2 (2003) 1093–1103.
- [267] Y. Luo, R.A. Smith, R. Guan, X. Liu, V. Klinghofer, J. Shen, C. Hutchins, P. Richardson, T. Holzman, S.H. Rosenberg, V.L. Giranda, Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition, *Biochemistry*, 43 (2004) 1254–1263.
- [268] H. Hirai, H. Sootome, Y. Nakatsuru, K. Miyama, S. Taguchi, K. Tsujioka, Y. Ueno, H. Hatch, P.K. Majumder, B.S. Pan, H. Kotani, MK-2206, an allosteric

- Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo, *Mol Cancer Ther*, 9 (2010) 1956–1967.
- [269] I. Shin, J. Edl, S. Biswas, P.C. Lin, R. Mernaugh, C.L. Arteaga, Proapoptotic activity of cell-permeable anti-Akt single-chain antibodies, *Cancer research*, 65 (2005) 2815–2824.
- [270] E.J. Meuillet, N. Ihle, A.F. Baker, J.M. Gard, C. Stamper, R. Williams, A. Coon, D. Mahadevan, B.L. George, L. Kirkpatrick, G. Powis, In vivo molecular pharmacology and antitumor activity of the targeted Akt inhibitor PX-316, *Oncology research*, 14 (2004) 513–527.
- [271] L. Yang, H.C. Dan, M. Sun, Q. Liu, X.M. Sun, R.I. Feldman, A.D. Hamilton, M. Polokoff, S.V. Nicosia, M. Herlyn, S.M. Sebt, J.Q. Cheng, Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt, *Cancer research*, 64 (2004) 4394–4399.
- [272] S. Kumar Pal, K. Reckamp, H. Yu, R.A. Figlin, Akt inhibitors in clinical development for the treatment of cancer, *Expert opinion on investigational drugs*, 19 (2010) 1355–1366.
- [273] A. Bononi, C. Agnoletto, E. De Marchi, S. Marchi, S. Patergnani, M. Bonora, C. Giorgi, S. Missiroli, F. Poletti, A. Rimessi, P. Pinton, Protein Kinases and Phosphatases in the Control of Cell Fate, *Enzyme Research*, 2011 (2011) 329098.
- [274] M. Cheung, J.R. Testa, Diverse mechanisms of AKT pathway activation in human malignancy, *Current cancer drug targets*, 13 (2013) 234–244.
- [275] E. Stefan, S. Aquin, N. Berger, C.R. Landry, B. Nyfeler, M. Bouvier, S.W. Michnick, Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities in vivo, *Proc Natl Acad Sci U S A*, 104 (2007) 16916–16921.
- [276] N. Grabinski, K. Bartkowiak, K. Grupp, B. Brandt, K. Pantel, M. Jucker, Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells, *Cellular signalling*, 23 (2011) 1952–1960.
- [277] R. Meier, D.R. Alessi, P. Cron, M. Andjelkovic, B.A. Hemmings, Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase B $\beta$ , *The Journal of biological chemistry*, 272 (1997) 30491–30497.
- [278] A. Gajadhar, A. Guha, A proximity ligation assay using transiently transfected, epitope-tagged proteins: application for in situ detection of dimerized receptor tyrosine kinases, *BioTechniques*, 48 (2010) 145–152.
- [279] K.J. Won, B.K. Kim, G. Han, K. Lee, Y.J. Jung, H.M. Kim, K.B. Song, K.S. Chung, M. Won, NSC126188 induces apoptosis of prostate cancer PC-3 cells through inhibition of Akt membrane translocation, FoxO3a activation, and RhoB transcription, *Apoptosis : an international journal on programmed cell death*, 19 (2014) 179–190.
- [280] W.H. Biggs, 3rd, J. Meisenhelder, T. Hunter, W.K. Cavenee, K.C. Arden, Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1, *Proc Natl Acad Sci U S A*, 96 (1999) 7421–7426.

- [281] D.A. Cross, D.R. Alessi, P. Cohen, M. Andjelkovich, B.A. Hemmings, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B, *Nature*, 378 (1995) 785–789.
- [282] G. Rena, S. Guo, S.C. Cichy, T.G. Unterman, P. Cohen, Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B, *The Journal of biological chemistry*, 274 (1999) 17179–17183.
- [283] G. Kulik, M.J. Weber, Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I, *Molecular and cellular biology*, 18 (1998) 6711–6718.
- [284] D.L. Hudson, A.T. Guy, P. Fry, M.J. O’Hare, F.M. Watt, J.R. Masters, Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression, *The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society*, 49 (2001) 271–278.
- [285] M.E. Kaighn, K.S. Narayan, Y. Ohnuki, J.F. Lechner, L.W. Jones, Establishment and characterization of a human prostatic carcinoma cell line (PC-3), *Investigative urology*, 17 (1979) 16–23.
- [286] R.M. Biondi, D. Komander, C.C. Thomas, J.M. Lizcano, M. Deak, D.R. Alessi, D.M. van Aalten, High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site, *The EMBO journal*, 21 (2002) 4219–4228.
- [287] R.M. Biondi, A.R. Nebreda, Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions, *The Biochemical journal*, 372 (2003) 1–13.
- [288] K.J. Schmitz, H. Lang, J. Wohlschlaeger, G.C. Sotiropoulos, H. Reis, K.W. Schmid, H.A. Baba, AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma, *World journal of gastroenterology*, 13 (2007) 6470–6477.
- [289] K.J. Schmitz, J. Wohlschlaeger, H. Lang, G.C. Sotiropoulos, M. Malago, K. Steveling, H. Reis, V.R. Cicinnati, K.W. Schmid, H.A. Baba, Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection, *Journal of hepatology*, 48 (2008) 83–90.
- [290] K. Nakanishi, M. Sakamoto, S. Yamasaki, S. Todo, S. Hirohashi, Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma, *Cancer*, 103 (2005) 307–312.
- [291] M. Kumar, X. Zhao, X.W. Wang, Molecular carcinogenesis of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: one step closer to personalized medicine?, *Cell & bioscience*, 1 (2011) 5.
- [292] P.A. Farazi, R.A. DePinho, Hepatocellular carcinoma pathogenesis: from genes to environment, *Nature reviews. Cancer*, 6 (2006) 674–687.
- [293] A. Brunet, J. Park, H. Tran, L.S. Hu, B.A. Hemmings, M.E. Greenberg, Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHL1 (FOXO3a), *Molecular and cellular biology*, 21 (2001) 952–965.
- [294] S. Shangary, S. Wang, Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy, *Annual review of pharmacology and toxicology*, 49 (2009) 223–241.
- [295] J.Y. Trosset, C. Dalvit, S. Knapp, M. Fasolini, M. Veronesi, S. Mantegani, L.M. Gianellini, C. Catana, M. Sundstrom, P.F. Stouten, J.K. Moll, Inhibition of

- protein-protein interactions: the discovery of druglike beta-catenin inhibitors by combining virtual and biophysical screening, *Proteins*, 64 (2006) 60–67.
- [296] A. Najafov, E.M. Sommer, J.M. Axten, M.P. Deyoung, D.R. Alessi, Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1, *The Biochemical journal*, 433 (2011) 357–369.
- [297] S. Pant, S.F. Jones, C.D. Kurkjian, J.R. Infante, K.N. Moore, H.A. Burris, D.S. McMeekin, K.A. Benhadji, B.K. Patel, M.J. Frenzel, A first-in-human phase I study of the oral Notch inhibitor, LY900009, in patients with advanced cancer, *European Journal of Cancer*, 56 (2016) 1–9.
- [298] K. Maemets-Allas, J. Viil, V. Jaks, A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo, *Mol Cancer Ther*, 14 (2015) 2486–2496.
- [299] R.B. Shaw, Jr., A.K. Chong, A. Zhang, V.R. Hentz, J. Chang, Dupuytren’s disease: history, diagnosis, and treatment, *Plastic and reconstructive surgery*, 120 (2007) 44e–54e.
- [300] A. Cordova, M. Tripoli, B. Corradino, P. Napoli, F. Moschella, Dupuytren’s contracture: an update of biomolecular aspects and therapeutic perspectives, *Journal of hand surgery (Edinburgh, Scotland)*, 30 (2005) 557–562.
- [301] S. Rehman, R. Goodacre, P.J. Day, A. Bayat, H.V. Westerhoff, Dupuytren’s: a systems biology disease, *Arthritis research & therapy*, 13 (2011) 238.
- [302] F. Nassiri, M.D. Cusimano, B.W. Scheithauer, F. Rotondo, A. Fazio, G.M. Yousef, L.V. Syro, K. Kovacs, R.V. Lloyd, Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy, *Anticancer research*, 31 (2011) 2283–2290.
- [303] K. Schubert, T. Polte, U. Bonisch, S. Schader, R. Holtappels, G. Hildebrandt, J. Lehmann, J.C. Simon, U. Anderegg, A. Saalbach, Thy-1 (CD90) regulates the extravasation of leukocytes during inflammation, *European journal of immunology*, 41 (2011) 645–656.
- [304] S. Kraljevic Pavelic, M. Sedic, K. Hock, S. Vucinic, D. Jurisic, P. Gehrig, M. Scott, R. Schlapbach, T. Cacev, S. Kapitanovic, K. Pavelic, An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren’s disease, *The Journal of pathology*, 217 (2009) 524–533.
- [305] C. Krause, P. Kloen, P. Ten Dijke, Elevated transforming growth factor beta and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren’s disease fibroblasts, *Fibrogenesis & tissue repair*, 4 (2011) 14.
- [306] A.M. Gonzalez, M. Buscaglia, R. Fox, A. Isacchi, P. Sarmientos, J. Farris, M. Ong, D. Martineau, D.A. Lappi, A. Baird, Basic fibroblast growth factor in Dupuytren’s contracture, *The American journal of pathology*, 141 (1992) 661–671.
- [307] C. Raykha, J. Crawford, B.S. Gan, P. Fu, L.A. Bach, D.B. O’Gorman, IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren’s disease, *Biochimica et biophysica acta*, 1832 (2013) 1511–1519.
- [308] F.D. Cruz, I. Matushansky, Solid tumor differentiation therapy – is it possible?, *Oncotarget*, 3 (2012) 559–567.
- [309] M. Leszczyniecka, T. Roberts, P. Dent, S. Grant, P.B. Fisher, Differentiation therapy of human cancer: basic science and clinical applications, *Pharmacology & therapeutics*, 90 (2001) 105–156.

- [310] S. Faivre, S. Djelloul, E. Raymond, New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors, *Seminars in oncology*, 33 (2006) 407–420.
- [311] I. Bozic, J.G. Reiter, B. Allen, T. Antal, K. Chatterjee, P. Shah, Y.S. Moon, A. Yaquibie, N. Kelly, D.T. Le, E.J. Lipson, P.B. Chapman, L.A. Diaz, Jr., B. Vogelstein, M.A. Nowak, Evolutionary dynamics of cancer in response to targeted combination therapy, *eLife*, 2 (2013) e00747.
- [312] N.C. Institute, Developmental therapeutics program NCI/NIH., (1955).
- [313] R.V. Guest, L. Boulter, T.J. Kendall, S.E. Minnis-Lyons, R. Walker, S.J. Wigmore, O.J. Sansom, S.J. Forbes, Cell lineage tracing reveals a biliary origin of intrahepatic cholangiocarcinoma, *Cancer research*, 74 (2014) 1005–1010.
- [314] B. Fan, Y. Malato, D.F. Calvisi, S. Naqvi, N. Razumilava, S. Ribback, G.J. Gores, F. Dombrowski, M. Evert, X. Chen, H. Willenbring, Cholangiocarcinomas can originate from hepatocytes in mice, *J Clin Invest*, 122 (2012) 2911–2915.
- [315] S. Zhao, J. Fu, X. Liu, T. Wang, J. Zhang, Y. Zhao, Activation of Akt/GSK-3beta/beta-catenin signaling pathway is involved in survival of neurons after traumatic brain injury in rats, *Neurological research*, 34 (2012) 400–407.
- [316] N. Rivlin, R. Brosh, M. Oren, V. Rotter, Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis, *Genes & cancer*, 2 (2011) 466–474.
- [317] B. Shih, A. Bayat, Scientific understanding and clinical management of Dupuytren disease, *Nature reviews. Rheumatology*, 6 (2010) 715–726.
- [318] C. Calabrese, H. Poppleton, M. Kocak, T.L. Hogg, C. Fuller, B. Hamner, E.Y. Oh, M.W. Gaber, D. Finklestein, M. Allen, A. Frank, I.T. Bayazitov, S.S. Zakharenko, A. Gajjar, A. Davidoff, R.J. Gilbertson, A perivascular niche for brain tumor stem cells, *Cancer cell*, 11 (2007) 69–82.
- [319] X. Li, U. Talts, J.F. Talts, E. Arman, P. Ekblom, P. Lonai, Akt/PKB regulates laminin and collagen IV isotypes of the basement membrane, *Proc Natl Acad Sci U S A*, 98 (2001) 14416–14421.

## ACKNOWLEDGEMENTS

The present study was mainly carried out at the Institute of Molecular and Cell Biology of the University of Tartu. I highly appreciate the help of all people I have worked with during this time.

I am grateful to my supervisor Viljar Jaks for offering me the opportunity to work in his research team, providing interesting research objectives and inspiring ideas.

I would like to thank Prof. Maido Remm, Lilian Kadaja-Saarepuu and Prof. Arnold Kristjuhan for reviewing this dissertation and suggesting corrections.

I am very grateful to the people of our research group for offering good company, advice and skills for experimental work whenever needed. My special thanks goes to Janeli Viil, Annika Trei and Mariliis Klaas for their friendliness and support.

I am grateful to all my colleagues from neighbouring labs throughout the years for always providing help and advice whenever needed, especially Dimtry Lubenets, Martin Pook, Arnold and Kersti Kristjuhan, Sulev Ingerpuu, Anneli Kukk, Sulev Kuuse and the people of the animal facility.

Within the framework of my PhD studies, I had an opportunity to work with very kind and helpful people outside IMCB. I am very grateful to Marianna Školnaja, Illar and Pille Pata, who helped to perform the animal experiments, and to Heide Marie Resch, Katharina Gegenschatz and Piotr Wardega from Nanotemper, who guided me in the world of Microscale Thermophoresis.

For the last but not least, I am deeply grateful to my family and closest friends who have always supported me in everything and anything. Thank you for being there and guiding me towards to being a better person, better mother and better friend.



## **PUBLICATIONS**

## CURRICULUM VITAE

Name: Kristina Mäemets-Allas  
Date of birth: January 31<sup>th</sup>, 1977 in Tartu, Estonia  
Family status: married, three children  
Contact: University of Tartu, Institute of Molecular and Cell Biology,  
23 Riia Street, 51010 Tartu, Estonia  
E-mail: kristina902@gmail.com

### Education and professional employment

2012 – ... University of Tartu, doctoral studies in Molecular and Cell Biology (specialty cell biology)  
2011 – 2015 The Competence Centre for Cancer Research, researcher  
2005 – 2007 University of Tartu, Department of Pharmacology, researcher  
2004 – 2005 Tartu University Hospital, technician  
2003 – 2005 University of Tartu, Master's degree in Molecular and Cell Biology (specialty molecular biology)  
1999 – 2003 University of Tartu, Bachelor's degree in Biology (specialty molecular biology and genetics)  
1992 – 1995 Hugo Treffner Gymnasium

### Special Courses

2005 Course: “Good Laboratory Practice for Study Directors, Principal Investigators, Study Staff and Management”; Turku, Finland  
2007 Course: “Laboratory Animal Science: C-category competence course”; University of Tartu, Estonia  
2013 Course: “In vivo Imaging”; Tallinn, Estonia  
2014 Course: “Microscale Thermophoresis User Training”, Munich, Germany  
2015 Conference: “The International Liver Congress 2015”, Vienna, Austria

### List of Publications

**Mäemets-Allas, K.**, Belitškin, D., Jaks, V. (2016) The inhibition of AKT-PDPK1 interaction efficiently suppresses the growth of murine primary liver tumor cells. *Biochem Biophys Res Commun.* 474(1):118–125  
**Mäemets-Allas, K.**, Viil, J., Jaks, V. (2015) A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth *In Vivo.* *Mol Cancer Ther.* 14(11):2486–96  
Viil, J., Maasalu, K., **Mäemets-Allas, K.**, Tamming, L., Lõhmussaar, K., Tooming, M., Ingerpuu, S., Märtson, A., Jaks, V. Laminin-rich blood vessels display activated growth factor signaling and act as the proliferation centers in Dupuytren's contracture. (2015) *Arthritis Res Ther.* 17(1):144–153

- Klaas, M., Kangur, T., Viil, J., **Mäemets-Allas, K.**, Minajeva, A., Vadi, K., Antsov, M., Lapidus, N., Järvekülg, M., Jaks, V. (2016) The alterations in the extracellular matrix composition guide the repair of damaged liver tissue. *Scientific Reports*. 6:27398
- Maron, E., Tõru, I., **Mäemets, K.**, Sepp, S., Vasar, V., Shlik, J., Zharkovsky, A. (2009) CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects. *J Psychopharmacol*. 23(4):460–4
- Ilves, I., **Mäemets, K.**, Silla, T., Janikson, K., Ustav, M. (2006) Brd4 is involved in multiple processes of the bovine papillomavirus type 1 life cycle. *J Virol*. 80(7):3660–5

## ELULOOKIRJELDUS

Nimi: Kristina Mäemets-Allas  
Sünniaeg: 31. jaanuar, 1977, Tartu, Eesti  
Perekonnaseis: abielus, kolm last  
Kontaktandmed: Tartu Ülikool, Molekulaar- ja Rakubioloogia Instituut, Raku-  
bioloogia õppetool, Riia 23, 51010 Tartu, Eesti  
E-mail: kristina902@gmail.com

### Haridus- ja erialane teenistuskäik

2012 – ... Tartu Ülikool, doktoriõpe, molekulaar- ja rakubioloogia õppe-  
kava (rakubioloogia eriala)  
2011 – 2015 Vähiuuringute Tehnoloogia Arenduskeskus, teadur  
2005 – 2007 Tartu Ülikool, Farmakoloogia Instituut, erakorraline teadur  
2004 – 2005 Tartu Ülikooli Kliinikum, laborant  
2003 – 2005 Tartu Ülikool, magistrikraad, molekulaar- ja rakubioloogia  
õppekava (molekulaarbioloogia eriala)  
1999 – 2003 Tartu Ülikool, bakalaureusekraad, bioloogia õppekava (mole-  
kulaarbioloogia ja geneetika eriala)  
1992 – 1995 Hugo Treffneri Gümnaasium

### Erialane enesetäiendus

2005 Koolitus “Good Laboratory Practice for Study Directors,  
Principal Investigators, Study Staff and Management”; Turu,  
Soome  
2007 Kursus “Laboratory Animal Science: C-category competence  
course”; Tartu, Eesti  
2013 “Eluskuvamine”; Tallinn, Eesti  
2014 Koolitus “Microscale Thermophoresis User Training”,  
München, Saksamaa  
2015 Konverents “The International Liver Congress 2015”, Viin,  
Austria

### Teaduspublikatsioonid

**Mäemets-Allas, K.**, Belitškin, D., Jaks, V. (2016) The inhibition of AKT-  
PDPK1 interaction efficiently suppresses the growth of murine primary liver  
tumor cells. *Biochem Biophys Res Commun.* 474(1):118–125  
**Mäemets-Allas, K.**, Viil, J., Jaks, V. (2015) A Novel Inhibitor of AKT1-PDPK1  
Interaction Efficiently Suppresses the Activity of AKT Pathway and  
Restricts Tumor Growth *In Vivo*. *Mol Cancer Ther.* 14(11):2486–96  
Viil, J., Maasalu, K., **Mäemets-Allas, K.**, Tamming, L., Lõhmussaar, K.,  
Tooming, M., Ingerpuu, S., Märtson, A., Jaks, V. Laminin-rich blood vessels  
display activated growth factor signaling and act as the proliferation centers  
in Dupuytren’s contracture. (2015) *Arthritis Res Ther.* 17(1):144–153

- Klaas, M., Kangur, T., Viil, J., **Mäemets-Allas, K.**, Minajeva, A., Vadi, K., Antsov, M., Lapidus, N., Järvekülg, M., Jaks, V. (2016) The alterations in the extracellular matrix composition guide the repair of damaged liver tissue. *Scientific Reports*. 6:27398
- Maron, E., Tõru, I., **Mäemets, K.**, Sepp, S., Vasar, V., Shlik, J., Zharkovsky, A. (2009) CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects. *J Psychopharmacol*. 23(4):460–4
- Ilves, I., **Mäemets, K.**, Silla, T., Janikson, K., Ustav, M. (2006) Brd4 is involved in multiple processes of the bovine papillomavirus type 1 life cycle. *J Virol*. 80(7):3660–5

## DISSERTATIONES BIOLOGICAE UNIVERSITATIS TARTUENSIS

1. **Toivo Maimets.** Studies of human oncoprotein p53. Tartu, 1991, 96 p.
2. **Enn K. Seppet.** Thyroid state control over energy metabolism, ion transport and contractile functions in rat heart. Tartu, 1991, 135 p.
3. **Kristjan Zobel.** Epifüütsete makrosamblike väärtus õhu saastuse indikaatoritena Hamar-Dobani boreaalsetes mägimetsades. Tartu, 1992, 131 lk.
4. **Andres Mäe.** Conjugal mobilization of catabolic plasmids by transposable elements in helper plasmids. Tartu, 1992, 91 p.
5. **Maia Kivisaar.** Studies on phenol degradation genes of *Pseudomonas* sp. strain EST 1001. Tartu, 1992, 61 p.
6. **Allan Nurk.** Nucleotide sequences of phenol degradative genes from *Pseudomonas* sp. strain EST 1001 and their transcriptional activation in *Pseudomonas putida*. Tartu, 1992, 72 p.
7. **Ülo Tamm.** The genus *Populus* L. in Estonia: variation of the species biology and introduction. Tartu, 1993, 91 p.
8. **Jaanus Remme.** Studies on the peptidyltransferase centre of the *E.coli* ribosome. Tartu, 1993, 68 p.
9. **Ülo Langel.** Galanin and galanin antagonists. Tartu, 1993, 97 p.
10. **Arvo Käär.** The development of an automatic online dynamic fluorescence-based pH-dependent fiber optic penicillin flowthrough biosensor for the control of the benzylpenicillin hydrolysis. Tartu, 1993, 117 p.
11. **Lilian Järvekülg.** Antigenic analysis and development of sensitive immunoassay for potato viruses. Tartu, 1993, 147 p.
12. **Jaak Palumets.** Analysis of phytomass partition in Norway spruce. Tartu, 1993, 47 p.
13. **Arne Sellin.** Variation in hydraulic architecture of *Picea abies* (L.) Karst. trees grown under different environmental conditions. Tartu, 1994, 119 p.
13. **Mati Reeben.** Regulation of light neurofilament gene expression. Tartu, 1994, 108 p.
14. **Urmas Tartes.** Respiration rhythms in insects. Tartu, 1995, 109 p.
15. **Ülo Puurand.** The complete nucleotide sequence and infections *in vitro* transcripts from cloned cDNA of a potato A potyvirus. Tartu, 1995, 96 p.
16. **Peeter Hõrak.** Pathways of selection in avian reproduction: a functional framework and its application in the population study of the great tit (*Parus major*). Tartu, 1995, 118 p.
17. **Erkki Truve.** Studies on specific and broad spectrum virus resistance in transgenic plants. Tartu, 1996, 158 p.
18. **Illar Pata.** Cloning and characterization of human and mouse ribosomal protein S6-encoding genes. Tartu, 1996, 60 p.
19. **Ülo Niinemets.** Importance of structural features of leaves and canopy in determining species shade-tolerance in temperature deciduous woody taxa. Tartu, 1996, 150 p.

20. **Ants Kurg.** Bovine leukemia virus: molecular studies on the packaging region and DNA diagnostics in cattle. Tartu, 1996, 104 p.
21. **Ene Ustav.** E2 as the modulator of the BPV1 DNA replication. Tartu, 1996, 100 p.
22. **Aksel Soosaar.** Role of helix-loop-helix and nuclear hormone receptor transcription factors in neurogenesis. Tartu, 1996, 109 p.
23. **Maido Remm.** Human papillomavirus type 18: replication, transformation and gene expression. Tartu, 1997, 117 p.
24. **Tiiu Kull.** Population dynamics in *Cypripedium calceolus* L. Tartu, 1997, 124 p.
25. **Kalle Olli.** Evolutionary life-strategies of autotrophic planktonic microorganisms in the Baltic Sea. Tartu, 1997, 180 p.
26. **Meelis Pärtel.** Species diversity and community dynamics in calcareous grassland communities in Western Estonia. Tartu, 1997, 124 p.
27. **Malle Leht.** The Genus *Potentilla* L. in Estonia, Latvia and Lithuania: distribution, morphology and taxonomy. Tartu, 1997, 186 p.
28. **Tanel Tenson.** Ribosomes, peptides and antibiotic resistance. Tartu, 1997, 80 p.
29. **Arvo Tuvikene.** Assessment of inland water pollution using biomarker responses in fish *in vivo* and *in vitro*. Tartu, 1997, 160 p.
30. **Urmas Saarma.** Tuning ribosomal elongation cycle by mutagenesis of 23S rRNA. Tartu, 1997, 134 p.
31. **Henn Ojaveer.** Composition and dynamics of fish stocks in the gulf of Riga ecosystem. Tartu, 1997, 138 p.
32. **Lembi Lõugas.** Post-glacial development of vertebrate fauna in Estonian water bodies. Tartu, 1997, 138 p.
33. **Margus Pooga.** Cell penetrating peptide, transportin, and its predecessors, galanin-based chimeric peptides. Tartu, 1998, 110 p.
34. **Andres Saag.** Evolutionary relationships in some cetrarioid genera (Lichenized Ascomycota). Tartu, 1998, 196 p.
35. **Aivar Liiv.** Ribosomal large subunit assembly *in vivo*. Tartu, 1998, 158 p.
36. **Tatjana Oja.** Isoenzyme diversity and phylogenetic affinities among the eurasian annual bromes (*Bromus* L., Poaceae). Tartu, 1998, 92 p.
37. **Mari Moora.** The influence of arbuscular mycorrhizal (AM) symbiosis on the competition and coexistence of calcareous grassland plant species. Tartu, 1998, 78 p.
38. **Olavi Kurina.** Fungus gnats in Estonia (*Diptera: Bolitophilidae, Keroplattidae, Macroceridae, Ditomyiidae, Diadocidiidae, Mycetophilidae*). Tartu, 1998, 200 p.
39. **Andrus Tasa.** Biological leaching of shales: black shale and oil shale. Tartu, 1998, 98 p.
40. **Arnold Kristjuhan.** Studies on transcriptional activator properties of tumor suppressor protein p53. Tartu, 1998, 86 p.
41. **Sulev Ingerpuu.** Characterization of some human myeloid cell surface and nuclear differentiation antigens. Tartu, 1998, 163 p.

42. **Veljo Kisand**. Responses of planktonic bacteria to the abiotic and biotic factors in the shallow lake Võrtsjärv. Tartu, 1998, 118 p.
43. **Kadri Põldmaa**. Studies in the systematics of hypomyces and allied genera (Hypocreales, Ascomycota). Tartu, 1998, 178 p.
44. **Markus Vetemaa**. Reproduction parameters of fish as indicators in environmental monitoring. Tartu, 1998, 117 p.
45. **Heli Talvik**. Prepatent periods and species composition of different *Oesophagostomum* spp. populations in Estonia and Denmark. Tartu, 1998, 104 p.
46. **Katrin Heinsoo**. Cuticular and stomatal antechamber conductance to water vapour diffusion in *Picea abies* (L.) karst. Tartu, 1999, 133 p.
47. **Tarmo Annilo**. Studies on mammalian ribosomal protein S7. Tartu, 1998, 77 p.
48. **Indrek Ots**. Health state indices of reproducing great tits (*Parus major*): sources of variation and connections with life-history traits. Tartu, 1999, 117 p.
49. **Juan Jose Cantero**. Plant community diversity and habitat relationships in central Argentina grasslands. Tartu, 1999, 161 p.
50. **Rein Kalamees**. Seed bank, seed rain and community regeneration in Estonian calcareous grasslands. Tartu, 1999, 107 p.
51. **Sulev Kõks**. Cholecystokinin (CCK) – induced anxiety in rats: influence of environmental stimuli and involvement of endopioid mechanisms and serotonin. Tartu, 1999, 123 p.
52. **Ebe Sild**. Impact of increasing concentrations of O<sub>3</sub> and CO<sub>2</sub> on wheat, clover and pasture. Tartu, 1999, 123 p.
53. **Ljudmilla Timofejeva**. Electron microscopical analysis of the synaptosomal complex formation in cereals. Tartu, 1999, 99 p.
54. **Andres Valkna**. Interactions of galanin receptor with ligands and G-proteins: studies with synthetic peptides. Tartu, 1999, 103 p.
55. **Taavi Virro**. Life cycles of planktonic rotifers in lake Peipsi. Tartu, 1999, 101 p.
56. **Ana Rebane**. Mammalian ribosomal protein S3a genes and intron-encoded small nucleolar RNAs U73 and U82. Tartu, 1999, 85 p.
57. **Tiina Tamm**. Cocksfoot mottle virus: the genome organisation and translational strategies. Tartu, 2000, 101 p.
58. **Reet Kurg**. Structure-function relationship of the bovine papilloma virus E2 protein. Tartu, 2000, 89 p.
59. **Toomas Kivisild**. The origins of Southern and Western Eurasian populations: an mtDNA study. Tartu, 2000, 121 p.
60. **Niilo Kaldalu**. Studies of the TOL plasmid transcription factor XylS. Tartu, 2000, 88 p.
61. **Dina Lepik**. Modulation of viral DNA replication by tumor suppressor protein p53. Tartu, 2000, 106 p.



62. **Kai Vellak**. Influence of different factors on the diversity of the bryophyte vegetation in forest and wooded meadow communities. Tartu, 2000, 122 p.
63. **Jonne Kotta**. Impact of eutrophication and biological invasions on the structure and functions of benthic macrofauna. Tartu, 2000, 160 p.
64. **Georg Martin**. Phytobenthic communities of the Gulf of Riga and the inner sea the West-Estonian archipelago. Tartu, 2000, 139 p.
65. **Silvia Sepp**. Morphological and genetical variation of *Alchemilla L.* in Estonia. Tartu, 2000. 124 p.
66. **Jaan Liira**. On the determinants of structure and diversity in herbaceous plant communities. Tartu, 2000, 96 p.
67. **Priit Zingel**. The role of planktonic ciliates in lake ecosystems. Tartu, 2001, 111 p.
68. **Tiit Teder**. Direct and indirect effects in Host-parasitoid interactions: ecological and evolutionary consequences. Tartu, 2001, 122 p.
69. **Hannes Kollist**. Leaf apoplastic ascorbate as ozone scavenger and its transport across the plasma membrane. Tartu, 2001, 80 p.
70. **Reet Marits**. Role of two-component regulator system PehR-PehS and extracellular protease PrtW in virulence of *Erwinia Carotovora* subsp. *Carotovora*. Tartu, 2001, 112 p.
71. **Vallo Tilgar**. Effect of calcium supplementation on reproductive performance of the pied flycatcher *Ficedula hypoleuca* and the great tit *Parus major*, breeding in Northern temperate forests. Tartu, 2002, 126 p.
72. **Rita Hõrak**. Regulation of transposition of transposon Tn4652 in *Pseudomonas putida*. Tartu, 2002, 108 p.
73. **Liina Eek-Piirsoo**. The effect of fertilization, mowing and additional illumination on the structure of a species-rich grassland community. Tartu, 2002, 74 p.
74. **Krõõt Aasamaa**. Shoot hydraulic conductance and stomatal conductance of six temperate deciduous tree species. Tartu, 2002, 110 p.
75. **Nele Ingerpuu**. Bryophyte diversity and vascular plants. Tartu, 2002, 112 p.
76. **Neeme Tõnisson**. Mutation detection by primer extension on oligonucleotide microarrays. Tartu, 2002, 124 p.
77. **Margus Pensa**. Variation in needle retention of Scots pine in relation to leaf morphology, nitrogen conservation and tree age. Tartu, 2003, 110 p.
78. **Asko Lõhmus**. Habitat preferences and quality for birds of prey: from principles to applications. Tartu, 2003, 168 p.
79. **Viljar Jaks**. p53 – a switch in cellular circuit. Tartu, 2003, 160 p.
80. **Jaana Männik**. Characterization and genetic studies of four ATP-binding cassette (ABC) transporters. Tartu, 2003, 140 p.
81. **Marek Sammul**. Competition and coexistence of clonal plants in relation to productivity. Tartu, 2003, 159 p.
82. **Ivar Ilves**. Virus-cell interactions in the replication cycle of bovine papillomavirus type 1. Tartu, 2003, 89 p.

83. **Andres Männik.** Design and characterization of a novel vector system based on the stable replicator of bovine papillomavirus type 1. Tartu, 2003, 109 p.
84. **Ivika Ostonen.** Fine root structure, dynamics and proportion in net primary production of Norway spruce forest ecosystem in relation to site conditions. Tartu, 2003, 158 p.
85. **Godrun Veldre.** Somatic status of 12–15-year-old Tartu schoolchildren. Tartu, 2003, 199 p.
86. **Ülo Väli.** The greater spotted eagle *Aquila clanga* and the lesser spotted eagle *A. pomarina*: taxonomy, phylogeography and ecology. Tartu, 2004, 159 p.
87. **Aare Abroi.** The determinants for the native activities of the bovine papillomavirus type 1 E2 protein are separable. Tartu, 2004, 135 p.
88. **Tiina Kahre.** Cystic fibrosis in Estonia. Tartu, 2004, 116 p.
89. **Helen Orav-Kotta.** Habitat choice and feeding activity of benthic suspension feeders and mesograzers in the northern Baltic Sea. Tartu, 2004, 117 p.
90. **Maarja Õpik.** Diversity of arbuscular mycorrhizal fungi in the roots of perennial plants and their effect on plant performance. Tartu, 2004, 175 p.
91. **Kadri Tali.** Species structure of *Neotinea ustulata*. Tartu, 2004, 109 p.
92. **Kristiina Tambets.** Towards the understanding of post-glacial spread of human mitochondrial DNA haplogroups in Europe and beyond: a phylogeographic approach. Tartu, 2004, 163 p.
93. **Arvi Jõers.** Regulation of p53-dependent transcription. Tartu, 2004, 103 p.
94. **Lilian Kadaja.** Studies on modulation of the activity of tumor suppressor protein p53. Tartu, 2004, 103 p.
95. **Jaak Truu.** Oil shale industry wastewater: impact on river microbial community and possibilities for bioremediation. Tartu, 2004, 128 p.
96. **Maire Peters.** Natural horizontal transfer of the *pheBA* operon. Tartu, 2004, 105 p.
97. **Ülo Maiväli.** Studies on the structure-function relationship of the bacterial ribosome. Tartu, 2004, 130 p.
98. **Merit Otsus.** Plant community regeneration and species diversity in dry calcareous grasslands. Tartu, 2004, 103 p.
99. **Mikk Heidemaa.** Systematic studies on sawflies of the genera *Dolerus*, *Empria*, and *Caliroa* (Hymenoptera: Tenthredinidae). Tartu, 2004, 167 p.
100. **Ilmar Tõnno.** The impact of nitrogen and phosphorus concentration and N/P ratio on cyanobacterial dominance and N<sub>2</sub> fixation in some Estonian lakes. Tartu, 2004, 111 p.
101. **Lauri Saks.** Immune function, parasites, and carotenoid-based ornaments in greenfinches. Tartu, 2004, 144 p.
102. **Siiri Roots.** Human Y-chromosomal variation in European populations. Tartu, 2004, 142 p.
103. **Eve Vedler.** Structure of the 2,4-dichloro-phenoxyacetic acid-degradative plasmid pEST4011. Tartu, 2005. 106 p.

104. **Andres Tover.** Regulation of transcription of the phenol degradation *pheBA* operon in *Pseudomonas putida*. Tartu, 2005, 126 p.
105. **Helen Udras.** Hexose kinases and glucose transport in the yeast *Hansenula polymorpha*. Tartu, 2005, 100 p.
106. **Ave Suija.** Lichens and lichenicolous fungi in Estonia: diversity, distribution patterns, taxonomy. Tartu, 2005, 162 p.
107. **Piret Lõhmus.** Forest lichens and their substrata in Estonia. Tartu, 2005, 162 p.
108. **Inga Lips.** Abiotic factors controlling the cyanobacterial bloom occurrence in the Gulf of Finland. Tartu, 2005, 156 p.
109. **Kaasik, Krista.** Circadian clock genes in mammalian clockwork, metabolism and behaviour. Tartu, 2005, 121 p.
110. **Juhan Javoš.** The effects of experience on host acceptance in ovipositing moths. Tartu, 2005, 112 p.
111. **Tiina Sedman.** Characterization of the yeast *Saccharomyces cerevisiae* mitochondrial DNA helicase Hmi1. Tartu, 2005, 103 p.
112. **Ruth Agurauja.** Hawaiian endemic fern lineage *Diellia* (Aspleniaceae): distribution, population structure and ecology. Tartu, 2005, 112 p.
113. **Riho Teras.** Regulation of transcription from the fusion promoters generated by transposition of Tn4652 into the upstream region of *pheBA* operon in *Pseudomonas putida*. Tartu, 2005, 106 p.
114. **Mait Metspalu.** Through the course of prehistory in india: tracing the mtDNA trail. Tartu, 2005, 138 p.
115. **Elin Lõhmussaar.** The comparative patterns of linkage disequilibrium in European populations and its implication for genetic association studies. Tartu, 2006, 124 p.
116. **Priit Kupper.** Hydraulic and environmental limitations to leaf water relations in trees with respect to canopy position. Tartu, 2006, 126 p.
117. **Heili Ilves.** Stress-induced transposition of Tn4652 in *Pseudomonas Putida*. Tartu, 2006, 120 p.
118. **Silja Kuusk.** Biochemical properties of Hmi1p, a DNA helicase from *Saccharomyces cerevisiae* mitochondria. Tartu, 2006, 126 p.
119. **Kersti Püssa.** Forest edges on medium resolution landsat thematic mapper satellite images. Tartu, 2006, 90 p.
120. **Lea Tummeleht.** Physiological condition and immune function in great tits (*Parus major* l.): Sources of variation and trade-offs in relation to growth. Tartu, 2006, 94 p.
121. **Toomas Esperk.** Larval instar as a key element of insect growth schedules. Tartu, 2006, 186 p.
122. **Harri Valdmann.** Lynx (*Lynx lynx*) and wolf (*Canis lupus*) in the Baltic region: Diets, helminth parasites and genetic variation. Tartu, 2006. 102 p.
123. **Priit Jõers.** Studies of the mitochondrial helicase Hmi1p in *Candida albicans* and *Saccharomyces cerevisia*. Tartu, 2006. 113 p.
124. **Kersti Lilleväli.** Gata3 and Gata2 in inner ear development. Tartu, 2007, 123 p.

125. **Kai Rünk.** Comparative ecology of three fern species: *Dryopteris carthusiana* (Vill.) H.P. Fuchs, *D. expansa* (C. Presl) Fraser-Jenkins & Jermy and *D. dilatata* (Hoffm.) A. Gray (Dryopteridaceae). Tartu, 2007, 143 p.
126. **Aveliina Helm.** Formation and persistence of dry grassland diversity: role of human history and landscape structure. Tartu, 2007, 89 p.
127. **Leho Tedersoo.** Ectomycorrhizal fungi: diversity and community structure in Estonia, Seychelles and Australia. Tartu, 2007, 233 p.
128. **Marko Mägi.** The habitat-related variation of reproductive performance of great tits in a deciduous-coniferous forest mosaic: looking for causes and consequences. Tartu, 2007, 135 p.
129. **Valeria Lulla.** Replication strategies and applications of Semliki Forest virus. Tartu, 2007, 109 p.
130. **Ülle Reier.** Estonian threatened vascular plant species: causes of rarity and conservation. Tartu, 2007, 79 p.
131. **Inga Jüriado.** Diversity of lichen species in Estonia: influence of regional and local factors. Tartu, 2007, 171 p.
132. **Tatjana Krama.** Mobbing behaviour in birds: costs and reciprocity based cooperation. Tartu, 2007, 112 p.
133. **Signe Saumaa.** The role of DNA mismatch repair and oxidative DNA damage defense systems in avoidance of stationary phase mutations in *Pseudomonas putida*. Tartu, 2007, 172 p.
134. **Reedik Mägi.** The linkage disequilibrium and the selection of genetic markers for association studies in european populations. Tartu, 2007, 96 p.
135. **Priit Kilgas.** Blood parameters as indicators of physiological condition and skeletal development in great tits (*Parus major*): natural variation and application in the reproductive ecology of birds. Tartu, 2007, 129 p.
136. **Anu Albert.** The role of water salinity in structuring eastern Baltic coastal fish communities. Tartu, 2007, 95 p.
137. **Kärt Padari.** Protein transduction mechanisms of transportans. Tartu, 2008, 128 p.
138. **Siiri-Lii Sandre.** Selective forces on larval colouration in a moth. Tartu, 2008, 125 p.
139. **Ülle Jõgar.** Conservation and restoration of semi-natural floodplain meadows and their rare plant species. Tartu, 2008, 99 p.
140. **Lauri Laanisto.** Macroecological approach in vegetation science: generality of ecological relationships at the global scale. Tartu, 2008, 133 p.
141. **Reidar Andreson.** Methods and software for predicting PCR failure rate in large genomes. Tartu, 2008, 105 p.
142. **Birgot Paavel.** Bio-optical properties of turbid lakes. Tartu, 2008, 175 p.
143. **Kaire Torn.** Distribution and ecology of charophytes in the Baltic Sea. Tartu, 2008, 98 p.
144. **Vladimir Vimberg.** Peptide mediated macrolide resistance. Tartu, 2008, 190 p.
145. **Daima Örd.** Studies on the stress-inducible pseudokinase TRB3, a novel inhibitor of transcription factor ATF4. Tartu, 2008, 108 p.

146. **Lauri Saag.** Taxonomic and ecologic problems in the genus *Lepraria* (*Stereocaulaceae*, lichenised *Ascomycota*). Tartu, 2008, 175 p.
147. **Ulvi Karu.** Antioxidant protection, carotenoids and coccidians in greenfinches – assessment of the costs of immune activation and mechanisms of parasite resistance in a passerine with carotenoid-based ornaments. Tartu, 2008, 124 p.
148. **Jaanus Remm.** Tree-cavities in forests: density, characteristics and occupancy by animals. Tartu, 2008, 128 p.
149. **Epp Moks.** Tapeworm parasites *Echinococcus multilocularis* and *E. granulosus* in Estonia: phylogenetic relationships and occurrence in wild carnivores and ungulates. Tartu, 2008, 82 p.
150. **Eve Eensalu.** Acclimation of stomatal structure and function in tree canopy: effect of light and CO<sub>2</sub> concentration. Tartu, 2008, 108 p.
151. **Janne Pullat.** Design, functionlization and application of an *in situ* synthesized oligonucleotide microarray. Tartu, 2008, 108 p.
152. **Marta Putrinš.** Responses of *Pseudomonas putida* to phenol-induced metabolic and stress signals. Tartu, 2008, 142 p.
153. **Marina Semtšenko.** Plant root behaviour: responses to neighbours and physical obstructions. Tartu, 2008, 106 p.
154. **Marge Starast.** Influence of cultivation techniques on productivity and fruit quality of some *Vaccinium* and *Rubus* taxa. Tartu, 2008, 154 p.
155. **Age Tats.** Sequence motifs influencing the efficiency of translation. Tartu, 2009, 104 p.
156. **Radi Tegova.** The role of specialized DNA polymerases in mutagenesis in *Pseudomonas putida*. Tartu, 2009, 124 p.
157. **Tsipe Aavik.** Plant species richness, composition and functional trait pattern in agricultural landscapes – the role of land use intensity and landscape structure. Tartu, 2009, 112 p.
158. **Kaja Kiiver.** Semliki forest virus based vectors and cell lines for studying the replication and interactions of alphaviruses and hepaciviruses. Tartu, 2009, 104 p.
159. **Meelis Kadaja.** Papillomavirus Replication Machinery Induces Genomic Instability in its Host Cell. Tartu, 2009, 126 p.
160. **Pille Hallast.** Human and chimpanzee Luteinizing hormone/Chorionic Gonadotropin beta (*LHB/CGB*) gene clusters: diversity and divergence of young duplicated genes. Tartu, 2009, 168 p.
161. **Ain Vellak.** Spatial and temporal aspects of plant species conservation. Tartu, 2009, 86 p.
162. **Triinu Remmel.** Body size evolution in insects with different colouration strategies: the role of predation risk. Tartu, 2009, 168 p.
163. **Jaana Salujõe.** Zooplankton as the indicator of ecological quality and fish predation in lake ecosystems. Tartu, 2009, 129 p.
164. **Ele Vahtmäe.** Mapping benthic habitat with remote sensing in optically complex coastal environments. Tartu, 2009, 109 p.

165. **Liisa Metsamaa**. Model-based assessment to improve the use of remote sensing in recognition and quantitative mapping of cyanobacteria. Tartu, 2009, 114 p.
166. **Pille Säälük**. The role of endocytosis in the protein transduction by cell-penetrating peptides. Tartu, 2009, 155 p.
167. **Lauri Peil**. Ribosome assembly factors in *Escherichia coli*. Tartu, 2009, 147 p.
168. **Lea Hallik**. Generality and specificity in light harvesting, carbon gain capacity and shade tolerance among plant functional groups. Tartu, 2009, 99 p.
169. **Mariliis Tark**. Mutagenic potential of DNA damage repair and tolerance mechanisms under starvation stress. Tartu, 2009, 191 p.
170. **Riinu Rannap**. Impacts of habitat loss and restoration on amphibian populations. Tartu, 2009, 117 p.
171. **Maarja Adojaan**. Molecular variation of HIV-1 and the use of this knowledge in vaccine development. Tartu, 2009, 95 p.
172. **Signe Altmäe**. Genomics and transcriptomics of human induced ovarian folliculogenesis. Tartu, 2010, 179 p.
173. **Triin Suvi**. Mycorrhizal fungi of native and introduced trees in the Seychelles Islands. Tartu, 2010, 107 p.
174. **Velda Lauringson**. Role of suspension feeding in a brackish-water coastal sea. Tartu, 2010, 123 p.
175. **Eero Talts**. Photosynthetic cyclic electron transport – measurement and variably proton-coupled mechanism. Tartu, 2010, 121 p.
176. **Mari Nelis**. Genetic structure of the Estonian population and genetic distance from other populations of European descent. Tartu, 2010, 97 p.
177. **Kaarel Krjutškov**. Arrayed Primer Extension-2 as a multiplex PCR-based method for nucleic acid variation analysis: method and applications. Tartu, 2010, 129 p.
178. **Egle Köster**. Morphological and genetical variation within species complexes: *Anthyllis vulneraria* s. l. and *Alchemilla vulgaris* (coll.). Tartu, 2010, 101 p.
179. **Erki Õunap**. Systematic studies on the subfamily Sterrhinae (Lepidoptera: Geometridae). Tartu, 2010, 111 p.
180. **Merike Jõesaar**. Diversity of key catabolic genes at degradation of phenol and *p*-cresol in pseudomonads. Tartu, 2010, 125 p.
181. **Kristjan Herkül**. Effects of physical disturbance and habitat-modifying species on sediment properties and benthic communities in the northern Baltic Sea. Tartu, 2010, 123 p.
182. **Arto Pulk**. Studies on bacterial ribosomes by chemical modification approaches. Tartu, 2010, 161 p.
183. **Maria Põllupüü**. Ecological relations of cladocerans in a brackish-water ecosystem. Tartu, 2010, 126 p.
184. **Toomas Silla**. Study of the segregation mechanism of the Bovine Papillomavirus Type 1. Tartu, 2010, 188 p.

185. **Gyaneshwer Chaubey**. The demographic history of India: A perspective based on genetic evidence. Tartu, 2010, 184 p.
186. **Katrin Kepp**. Genes involved in cardiovascular traits: detection of genetic variation in Estonian and Czech populations. Tartu, 2010, 164 p.
187. **Virve Sõber**. The role of biotic interactions in plant reproductive performance. Tartu, 2010, 92 p.
188. **Kersti Kangro**. The response of phytoplankton community to the changes in nutrient loading. Tartu, 2010, 144 p.
189. **Joachim M. Gerhold**. Replication and Recombination of mitochondrial DNA in Yeast. Tartu, 2010, 120 p.
190. **Helen Tammert**. Ecological role of physiological and phylogenetic diversity in aquatic bacterial communities. Tartu, 2010, 140 p.
191. **Elle Rajandu**. Factors determining plant and lichen species diversity and composition in Estonian *Calamagrostis* and *Hepatica* site type forests. Tartu, 2010, 123 p.
192. **Paula Ann Kivistik**. ColR-ColS signalling system and transposition of Tn4652 in the adaptation of *Pseudomonas putida*. Tartu, 2010, 118 p.
193. **Siim Sõber**. Blood pressure genetics: from candidate genes to genome-wide association studies. Tartu, 2011, 120 p.
194. **Kalle Kipper**. Studies on the role of helix 69 of 23S rRNA in the factor-dependent stages of translation initiation, elongation, and termination. Tartu, 2011, 178 p.
195. **Triinu Siibak**. Effect of antibiotics on ribosome assembly is indirect. Tartu, 2011, 134 p.
196. **Tambet Tõnissoo**. Identification and molecular analysis of the role of guanine nucleotide exchange factor RIC-8 in mouse development and neural function. Tartu, 2011, 110 p.
197. **Helin Räägel**. Multiple faces of cell-penetrating peptides – their intracellular trafficking, stability and endosomal escape during protein transduction. Tartu, 2011, 161 p.
198. **Andres Jaanus**. Phytoplankton in Estonian coastal waters – variability, trends and response to environmental pressures. Tartu, 2011, 157 p.
199. **Tiit Nikopensius**. Genetic predisposition to nonsyndromic orofacial clefts. Tartu, 2011, 152 p.
200. **Signe Värvi**. Studies on the mechanisms of RNA polymerase II-dependent transcription elongation. Tartu, 2011, 108 p.
201. **Kristjan Välik**. Gene expression profiling and genome-wide association studies of non-small cell lung cancer. Tartu, 2011, 98 p.
202. **Arno Põllumäe**. Spatio-temporal patterns of native and invasive zooplankton species under changing climate and eutrophication conditions. Tartu, 2011, 153 p.
203. **Egle Tammeleht**. Brown bear (*Ursus arctos*) population structure, demographic processes and variations in diet in northern Eurasia. Tartu, 2011, 143 p.

205. **Teele Jairus**. Species composition and host preference among ectomycorrhizal fungi in Australian and African ecosystems. Tartu, 2011, 106 p.
206. **Kessy Abarenkov**. PlutoF – cloud database and computing services supporting biological research. Tartu, 2011, 125 p.
207. **Marina Grigorova**. Fine-scale genetic variation of follicle-stimulating hormone beta-subunit coding gene (*FSHB*) and its association with reproductive health. Tartu, 2011, 184 p.
208. **Anu Tiitsaar**. The effects of predation risk and habitat history on butterfly communities. Tartu, 2011, 97 p.
209. **Elin Sild**. Oxidative defences in immunoeological context: validation and application of assays for nitric oxide production and oxidative burst in a wild passerine. Tartu, 2011, 105 p.
210. **Irja Saar**. The taxonomy and phylogeny of the genera *Cystoderma* and *Cystodermella* (Agaricales, Fungi). Tartu, 2012, 167 p.
211. **Pauli Saag**. Natural variation in plumage bacterial assemblages in two wild breeding passerines. Tartu, 2012, 113 p.
212. **Aleksei Lulla**. Alphaviral nonstructural protease and its polyprotein substrate: arrangements for the perfect marriage. Tartu, 2012, 143 p.
213. **Mari Järve**. Different genetic perspectives on human history in Europe and the Caucasus: the stories told by uniparental and autosomal markers. Tartu, 2012, 119 p.
214. **Ott Scheler**. The application of tmRNA as a marker molecule in bacterial diagnostics using microarray and biosensor technology. Tartu, 2012, 93 p.
215. **Anna Balikova**. Studies on the functions of tumor-associated mucin-like leukosialin (CD43) in human cancer cells. Tartu, 2012, 129 p.
216. **Triinu Kõressaar**. Improvement of PCR primer design for detection of prokaryotic species. Tartu, 2012, 83 p.
217. **Tuul Sepp**. Hematological health state indices of greenfinches: sources of individual variation and responses to immune system manipulation. Tartu, 2012, 117 p.
218. **Rya Ero**. Modifier view of the bacterial ribosome. Tartu, 2012, 146 p.
219. **Mohammad Bahram**. Biogeography of ectomycorrhizal fungi across different spatial scales. Tartu, 2012, 165 p.
220. **Annely Lorents**. Overcoming the plasma membrane barrier: uptake of amphipathic cell-penetrating peptides induces influx of calcium ions and downstream responses. Tartu, 2012, 113 p.
221. **Katrin Männik**. Exploring the genomics of cognitive impairment: whole-genome SNP genotyping experience in Estonian patients and general population. Tartu, 2012, 171 p.
222. **Marko Prous**. Taxonomy and phylogeny of the sawfly genus *Empria* (Hymenoptera, Tenthredinidae). Tartu, 2012, 192 p.
223. **Triinu Visnapuu**. Levansucrases encoded in the genome of *Pseudomonas syringae* pv. tomato DC3000: heterologous expression, biochemical characterization, mutational analysis and spectrum of polymerization products. Tartu, 2012, 160 p.



224. **Nele Tamberg.** Studies on Semliki Forest virus replication and pathogenesis. Tartu, 2012, 109 p.
225. **Tõnu Esko.** Novel applications of SNP array data in the analysis of the genetic structure of Europeans and in genetic association studies. Tartu, 2012, 149 p.
226. **Timo Arula.** Ecology of early life-history stages of herring *Clupea harengus membras* in the northeastern Baltic Sea. Tartu, 2012, 143 p.
227. **Inga Hiiesalu.** Belowground plant diversity and coexistence patterns in grassland ecosystems. Tartu, 2012, 130 p.
228. **Kadri Koorem.** The influence of abiotic and biotic factors on small-scale plant community patterns and regeneration in boreonemoral forest. Tartu, 2012, 114 p.
229. **Liis Andresen.** Regulation of virulence in plant-pathogenic pectobacteria. Tartu, 2012, 122 p.
230. **Kaupo Kohv.** The direct and indirect effects of management on boreal forest structure and field layer vegetation. Tartu, 2012, 124 p.
231. **Mart Jüssi.** Living on an edge: landlocked seals in changing climate. Tartu, 2012, 114 p.
232. **Riina Klais.** Phytoplankton trends in the Baltic Sea. Tartu, 2012, 136 p.
233. **Rauno Veeroja.** Effects of winter weather, population density and timing of reproduction on life-history traits and population dynamics of moose (*Alces alces*) in Estonia. Tartu, 2012, 92 p.
234. **Marju Keis.** Brown bear (*Ursus arctos*) phylogeography in northern Eurasia. Tartu, 2013, 142 p.
235. **Sergei Põlme.** Biogeography and ecology of *alnus*- associated ectomycorrhizal fungi – from regional to global scale. Tartu, 2013, 90 p.
236. **Liis Uusküla.** Placental gene expression in normal and complicated pregnancy. Tartu, 2013, 173 p.
237. **Marko Lõoke.** Studies on DNA replication initiation in *Saccharomyces cerevisiae*. Tartu, 2013, 112 p.
238. **Anne Aan.** Light- and nitrogen-use and biomass allocation along productivity gradients in multilayer plant communities. Tartu, 2013, 127 p.
239. **Heidi Tamm.** Comprehending phylogenetic diversity – case studies in three groups of ascomycetes. Tartu, 2013, 136 p.
240. **Liina Kangur.** High-Pressure Spectroscopy Study of Chromophore-Binding Hydrogen Bonds in Light-Harvesting Complexes of Photosynthetic Bacteria. Tartu, 2013, 150 p.
241. **Margus Leppik.** Substrate specificity of the multisite specific pseudouridine synthase RluD. Tartu, 2013, 111 p.
242. **Lauris Kaplinski.** The application of oligonucleotide hybridization model for PCR and microarray optimization. Tartu, 2013, 103 p.
243. **Merli Pärnoja.** Patterns of macrophyte distribution and productivity in coastal ecosystems: effect of abiotic and biotic forcing. Tartu, 2013, 155 p.
244. **Tõnu Margus.** Distribution and phylogeny of the bacterial translational GTPases and the Mqsr/YgiT regulatory system. Tartu, 2013, 126 p.

245. **Pille Mänd.** Light use capacity and carbon and nitrogen budget of plants: remote assessment and physiological determinants. Tartu, 2013, 128 p.
246. **Mario Plaas.** Animal model of Wolfram Syndrome in mice: behavioural, biochemical and psychopharmacological characterization. Tartu, 2013, 144 p.
247. **Georgi Hudjašov.** Maps of mitochondrial DNA, Y-chromosome and tyrosinase variation in Eurasian and Oceanian populations. Tartu, 2013, 115 p.
248. **Mari Lepik.** Plasticity to light in herbaceous plants and its importance for community structure and diversity. Tartu, 2013, 102 p.
249. **Ede Leppik.** Diversity of lichens in semi-natural habitats of Estonia. Tartu, 2013, 151 p.
250. **Ülle Saks.** Arbuscular mycorrhizal fungal diversity patterns in boreo-nemoral forest ecosystems. Tartu, 2013, 151 p.
251. **Eneli Oitmaa.** Development of arrayed primer extension microarray assays for molecular diagnostic applications. Tartu, 2013, 147 p.
252. **Jekaterina Jutkina.** The horizontal gene pool for aromatics degradation: bacterial catabolic plasmids of the Baltic Sea aquatic system. Tartu, 2013, 121 p.
253. **Helen Vellau.** Reaction norms for size and age at maturity in insects: rules and exceptions. Tartu, 2014, 132 p.
254. **Randel Kreitsberg.** Using biomarkers in assessment of environmental contamination in fish – new perspectives. Tartu, 2014, 107 p.
255. **Krista Takkis.** Changes in plant species richness and population performance in response to habitat loss and fragmentation. Tartu, 2014, 141 p.
256. **Liina Nagirnaja.** Global and fine-scale genetic determinants of recurrent pregnancy loss. Tartu, 2014, 211 p.
257. **Triin Triisberg.** Factors influencing the re-vegetation of abandoned extracted peatlands in Estonia. Tartu, 2014, 133 p.
258. **Villu Soon.** A phylogenetic revision of the *Chrysis ignita* species group (Hymenoptera: Chrysididae) with emphasis on the northern European fauna. Tartu, 2014, 211 p.
259. **Andrei Nikonov.** RNA-Dependent RNA Polymerase Activity as a Basis for the Detection of Positive-Strand RNA Viruses by Vertebrate Host Cells. Tartu, 2014, 207 p.
260. **Eele Õunapuu-Pikas.** Spatio-temporal variability of leaf hydraulic conductance in woody plants: ecophysiological consequences. Tartu, 2014, 135 p.
261. **Marju Männiste.** Physiological ecology of greenfinches: information content of feathers in relation to immune function and behavior. Tartu, 2014, 121 p.
262. **Katre Kets.** Effects of elevated concentrations of CO<sub>2</sub> and O<sub>3</sub> on leaf photosynthetic parameters in *Populus tremuloides*: diurnal, seasonal and interannual patterns. Tartu, 2014, 115 p.

263. **Küllli Lokko**. Seasonal and spatial variability of zoopsammon communities in relation to environmental parameters. Tartu, 2014, 129 p.
264. **Olga Žilina**. Chromosomal microarray analysis as diagnostic tool: Estonian experience. Tartu, 2014, 152 p.
265. **Kertu Lõhmus**. Colonisation ecology of forest-dwelling vascular plants and the conservation value of rural manor parks. Tartu, 2014, 111 p.
266. **Anu Aun**. Mitochondria as integral modulators of cellular signaling. Tartu, 2014, 167 p.
267. **Chandana Basu Mallick**. Genetics of adaptive traits and gender-specific demographic processes in South Asian populations. Tartu, 2014, 160 p.
268. **Riin Tamme**. The relationship between small-scale environmental heterogeneity and plant species diversity. Tartu, 2014, 130 p.
269. **Liina Remm**. Impacts of forest drainage on biodiversity and habitat quality: implications for sustainable management and conservation. Tartu, 2015, 126 p.
270. **Tiina Talve**. Genetic diversity and taxonomy within the genus *Rhinanthus*. Tartu, 2015, 106 p.
271. **Mehis Rohtla**. Otolith sclerochronological studies on migrations, spawning habitat preferences and age of freshwater fishes inhabiting the Baltic Sea. Tartu, 2015, 137 p.
272. **Alexey Reshchikov**. The world fauna of the genus *Lathrolestes* (Hymenoptera, Ichneumonidae). Tartu, 2015, 247 p.
273. **Martin Pook**. Studies on artificial and extracellular matrix protein-rich surfaces as regulators of cell growth and differentiation. Tartu, 2015, 142 p.
274. **Mai Kukumägi**. Factors affecting soil respiration and its components in silver birch and Norway spruce stands. Tartu, 2015, 155 p.
275. **Helen Karu**. Development of ecosystems under human activity in the North-East Estonian industrial region: forests on post-mining sites and bogs. Tartu, 2015, 152 p.
276. **Hedi Peterson**. Exploiting high-throughput data for establishing relationships between genes. Tartu, 2015, 186 p.
277. **Priit Adler**. Analysis and visualisation of large scale microarray data, Tartu, 2015, 126 p.
278. **Aigar Niglas**. Effects of environmental factors on gas exchange in deciduous trees: focus on photosynthetic water-use efficiency. Tartu, 2015, 152 p.
279. **Silja Laht**. Classification and identification of conopeptides using profile hidden Markov models and position-specific scoring matrices. Tartu, 2015, 100 p.
280. **Martin Kesler**. Biological characteristics and restoration of Atlantic salmon *Salmo salar* populations in the Rivers of Northern Estonia. Tartu, 2015, 97 p.
281. **Pratyush Kumar Das**. Biochemical perspective on alphaviral nonstructural protein 2: a tale from multiple domains to enzymatic profiling. Tartu, 2015, 205 p.

282. **Priit Palta**. Computational methods for DNA copy number detection. Tartu, 2015, 130 p.
283. **Julia Sidorenko**. Combating DNA damage and maintenance of genome integrity in pseudomonads. Tartu, 2015, 174 p.
284. **Anastasiia Kovtun-Kante**. Charophytes of Estonian inland and coastal waters: distribution and environmental preferences. Tartu, 2015, 97 p.
285. **Ly Lindman**. The ecology of protected butterfly species in Estonia. Tartu, 2015, 171 p.
286. **Jaanis Lodjak**. Association of Insulin-like Growth Factor I and Corticosterone with Nestling Growth and Fledging Success in Wild Passerines. Tartu, 2016, 113 p.
287. **Ann Kraut**. Conservation of Wood-Inhabiting Biodiversity – Semi-Natural Forests as an Opportunity. Tartu, 2016, 141 p.
288. **Tiit Örd**. Functions and regulation of the mammalian pseudokinase TRIB3. Tartu, 2016, 182. p.
289. **Kairi Käiro**. Biological Quality According to Macroinvertebrates in Streams of Estonia (Baltic Ecoregion of Europe): Effects of Human-induced Hydromorphological Changes. Tartu, 2016, 126 p.
290. **Leidi Laurimaa**. *Echinococcus multilocularis* and other zoonotic parasites in Estonian canids. Tartu, 2016, 144 p.
291. **Helerin Margus**. Characterization of cell-penetrating peptide/nucleic acid nanocomplexes and their cell-entry mechanisms. Tartu, 2016, 173 p.
292. **Kadri Runnel**. Fungal targets and tools for forest conservation. Tartu, 2016, 157 p.
293. **Urmo Võsa**. MicroRNAs in disease and health: aberrant regulation in lung cancer and association with genomic variation. Tartu, 2016, 163 p.